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Abstract of thesis entitled: Immunomodulatory Activities of Cordyceps 
sinensis Used as a Single Herb and in Concoction 
Submitted by Lee Ka-wai Sharon 
for the degree of Master of Philosophy in Chemical Pathology 
at the Chinese University of Hong Kong in July 2004 
Escalating prevalence of cancer and allergy such as asthma has prompted 
the search of an effective immunomodulatory agent. According to concepts of 
Traditional Chinese medicine (TCM), Cordyceps sinensis (Dong Cong Xia 
Cao) is the only Yin-yang double invigorated herb which m a y possess both 
suppressive and enhancement effect on the human immune system. Recent 
evidence has shown that C. sinensis contains immunologically active 
ingredients. Advances in plant Technology have also escalated usage of 
cultivated C. sinensis. The rationale of this study therefore divides into two 
parts. The first part focuses at elucidating immune regulatory and anti-cancer 
activities of the cultivated fruiting bodies of C. sinensis, namely 
H E R B S n S E N S E S ™ Cordyceps, with the wild form C. sinensis as the 
comparison. The second aims at demonstrating the anti-asthmatic potential 
of a C. sinensis Wheeze-Relief Formula comprising Radix astragali {Huang 
qi), Radix Stemonae {Bai Bu), Bulbus Fritillariae Cirrhosae (Chuan Bei) and 
Radix Scutellariae (Huang qin). 
Hot water extracts of C. sinensis, H E R B S n S E N S E S ™ Cordyceps, and 
Wheeze-Relief Formula were investigated in the present study. To ensure 
safety, Limulus Amebocyte lysate test, trypan blue exclusion assay and the 
Colorimetric 5-bromo-2'-deoxyuridine (BrdU) cell proliferation enzyme linked 
immunosorbent assay (ELISA) were first performed for the quantification of 
endotoxin level, cytotoxicity and cytostaticity of the three T C M preparations. 
To study the in vitro efficacy of C. sinensis and H E R B S n S E N S E S ™ 
Cordyceps, w e examined their (1) mitogenic activities on unstimulated and 
mitogen-activated peripheral blood mononuclear cells 
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(PBMC), (2) macrophage functions in terms of phagocytosis and release of 
reactive oxygen species (ROS) by intracellular fluorescence staining, (3) 
cytokine induction from lymphocytes and monocytes by cytometric bead 
array (CBA) method, (4) surface expression of IL-2 receptor a (CD25) by 
immunoflorescence staining, (5) gene expression of cytokine and cytokine 
receptors by c D N A expression array, and (6) anti-tumor and apoptotic 
activities on seven selected cancer cell lines by BrdU proliferation ELISA and 
A N N E X I N V apoptosis assay, respectively. In vivo anti-tumor activities of C. 
sinensis and H E R B S n S E N S E S ™ Cordyceps were manifested by the survival 
model using Erhlich ascites tumor (EAT)-bearing female ICR mice. Similarly, 
in vivo immunomodulatory and anti-tumor activities of H E R B S n S E N S E S ™ 
Cordyceps w a s substantiated by respectively using healthy and sarcoma 180 
(SC-180)-inoculated female BALB/c mice. Parameters including spleen and 
tumor weight, spleen cell proliferation, induction of cytokines and surface 
expression of CD3+，CD4+，and CD8+ on spleen cells were investigated in the 
in vivo BALB/c model. The proliferation of unstimulated or mitogen-activated 
spleen cells w a s measured by BrdU proliferation ELISA. Cytokines generated 
from unstimulated or mitogen-activated spleen cells were quantitated by 
cytometric bead array (CBA), while the CD3+，CD4+，and CD8+ T cells were 
identified by immunophenotying. O n the other hand, the efficacy of Wheeze-
Relief Formula w a s demonstrated in both in vitro and human system. The in 
vitro assay investigated effects of Wheeze-Relief Formula on (1) survival of 
unstimulated or IL-5 activated eosinophils by BrdU proliferation ELISA, (2) 
degranulation of eosinophil cationic protein (ECP) from eosinophils using 
fluorescence enzyme immunoassay (FEIA), (3) expression of adhesion 
molecules C D 4 9 d and chemokine receptor C C R 3 on eosinophils, and 
surface expression of low affinity IgE receptor (FCsRII, C D 2 3 ) on P B M C by 
immunoflorescence staining, (4) cytokine release from P B M C using C B A , 
and (5) gene expression of cytokines and cytokine receptors using c D N A 
expression array. In the randomized, double-blinded, placebo-control clinical 
trial with good clinical practice (GCP) of Wheeze-Relief Formula, a total of 90 
paediatric patients with a diagnosis of asthma and on regular steroid 
inhalation therapy were recruited. Serological inflammatory markers including 
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tumor necrosis factor (TNF) a, interleukin (IL)-18, cysteinyl leukotrienes(LTs) 
C4，D4 and E4, LT B4, thymus and activation-regulated chemokine (TARC), 
and eosinophil derived neurotoxin (EDN) were measured using ELISA. 
Specific house dust mite IgE and total IgE of the patients were quantitated by 
using FEIA and microparticle enzyme immunoassay, respectively. 
Results showed that the endotoxin level of C. sinensis, H E R B S n S E N S E S ™ 
Cordyceps, and Wheeze-Relief Formula was found to be less than 0.02，0.6 
and 1.0 EU/mg, respectively. Optimal concentration of C. sinensis, 
H E R B S n S E N S E S ™ Cordyceps and Wheeze-Relief Formula on P B M C were 
3，1，1 mg/mL, respectively. All the three T C M preparations (< 5 mg/mL) 
retained P B M C viability above 70 % . The optimal concentration of Wheeze-
Relief Formula on eosinophils was 1 mg/mL with viability above 90 % . 
In the in vitro efficacy experiments elucidating immunomodulatory and anti-
tumor activities of C. sinensis and H E R B S n S E N S E S ™ Cordyceps, low 
concentrations of the T C M preparations exerted mitogenic activities on 
P B M C . Secretion of proinflammatory cytokines TNFa, IL-6, IL-10 and IL-ip 
were induced The cytokine induction potency of C. sinensis was higher than 
H E R B S n S E N S E S ™ Cordyceps. The surface expression of IL-2 receptor a 
and gene expression of IL-1a, IL-ip，IL-6, IL-12p40, IL-15，and cytokine 
receptors of IL-12p，IL-1, IL-2a，and IL-2(3 were upregulated by both C. 
sinensis and H E R B S n S E N S E S ™ Cordyceps, although the gene expression 
level induced by H E R B S n S E N S E S ™ Cordyceps was less prominent. Results 
also demonstrated that both C. sinensis and H E R B S n S E N S E S ™ Cordyceps 
induced phagocytosis and release R〇S from monocytes/macrophages. Yet 
w e found that H E R B S n S E N S E S ™ Cordyceps m a y be more efficient in 
inducing macrophage phagocytosis than the natural form. A m o n g the seven 
tumor cell lines tested, the human eosinophilic leukemic cancer cell line 
(EoL-1) and murine monocytes and macrophages cancer cell line (PU5-1.8) 
were apoptosed in the presence of the two T C M preparations, in which the 
apoptotic inducing potency of H E R B S n S E N S E S ™ Cordyceps is generally 
higher. 
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The in vivo anti-tumor experiments showed that C. sinensis did not prolong 
m e a n survival days of female Erhlich ascites tumor (EAT) bearing ICR mice. 
H E R B S n S E N S E S ™ Cordyceps, however, lengthened the m e a n survival 
days of EAT-inoculated ICR mice by 64 % . In the healthy BALB/c mice model, 
H E R B S n S E N S E S ™ Cordyceps did not profoundly increase spleen cell size, 
spleen cell proliferation and cytokine release from either unstimulated or 
mitogen-activated spleen cells. Yet the expression of CD3+ and CD4+ spleen 
cells, though not CD8+ were elevated. In the sarcoma 180 (SC-180) bearing 
B A L B / C mice model, w e found that H E R B S n S E N S E S ™ Cordyceps 
remarkably reduced spleen and tumor size when compared to the placebo-
fed group. The expression of CD3+ and CD4+ spleen cells, though not CD8+， 
w a s analogously heightened by H E R B S n S E N S E S ™ Cordyceps. The 
secretion of cytokines, including IFNy，TNFoc，IL-2, IL-6, IL-10, IL-12p70, and 
M C P - 1 from mitogen-activated spleen cells were profoundly decreased in the 
H E R B S n S E N S E S ™ Cordyceps fed mice when compared to the placebo 
control. 
The second study aimed at elucidating the anti-asthmatic activity of the 
Wheeze-Relief Formula. Based on the in vitro experiments, w e found that 
Wheeze-Relief Formula inhibited proliferation of both unstimulated and IL-5 
activated eosinophils. The addition of Wheeze-Relief Formula (1 mg/mL) also 
significantly suppressed E C P release from the platelet-activating factor (PAF) 
and granulocyte macrophage-colony stimulating factor (GM-CSF) activated 
eosinophils and significantly inhibited the expression of C D 4 9 d and C C R 3 on 
eosinophils (p < 0.05). Wheeze-Relief Formula exhibited observable 
inhibition on the surface expression of low affinity IgE receptor C D 2 3 , 
secretion of cytokines TNFoc, IL-5 and IL-10，and the gene expression of 
cytokine receptor IL-2a, and chemokine MCP-1, M D C , and M C P - 2 in house-
dust-mite activated P B M C . In the clinical trial, prescription of Wheeze-Relief 
Formula significantly suppressed plasma concentration of TNFoc in asthmatic 
children (p < 0.05). 
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The above results provide a biochemical basis for better understanding the 
immunomodulatory efficacy of the singly apply C. sinensis and 
H E R B S n S E N S E S ™ Cordyceps, and the concocted C. sinensis, Wheeze-
Relief Formula. W e demonstrated that the H E R B S n S E N S E S ™ Cordyceps 
possessed immunomodulatory and anti-tumor activities as efficient as that 
exerted by natural C. sinensis, while H E R B S n S E N S E S ™ Cordyceps m a y be 
even more efficient in suppressing tumor proliferation than C. sinensis. The 
immunomodulatory activities possessed by C. sinensis and 
H E R B S n S E N S E S ™ Cordyceps m a y involve the activation of cell-mediated 
immunity via the enhancement of macrophage functions, elevated 
proliferation of lymphocytes, induction of cytokines release and heightened 
expression of IL-2 receptor a. The anti-tumor activity of H E R B S n S E N S E S ™ 
Cordyceps m a y also be mediated by the increased cell-mediated immunity 
and macrophage phagocytosis. O n the other hand, the Wheeze-Relief 
Formula m a y possess anti-asthmatic activities as suggested from the in vitro 
inhibition on the activity of eosinophil and house-dust-mite stimulated P B M C . 
However, further experiments on the clinical trial must be performed to 






















陣列（Cytometric Bead Array，CBA)檢查對淋巴細胞和巨唾細胞 
釋放細胞因子的影響。（4)免疫螢光測定分析對介白質素 -2a受體 
(CD25)表達的影響。(5) cDNA膜片研究對細胞因子及其受體的基因 
表達的影響。（6) BrdU細胞增殖ELISA測試及Annexin V/PI染色 
法分別檢測對腫瘤生長及誘導細胞调亡能力的影響。我們以載瘤 























毒素（EDN)。至於病人的總 IgE及特異性 IgE (屋塵喊）計量則以 
• M X ®總 I g E測試及F E I A作分析。 
結果展示草答香^冬蟲夏草、天然冬蟲夏草及補培納氣湯的内毒素 
水平分別是不多於 0 . 6 � 1� 2 E U / m g �草荅香谓冬蟲夏草、天然冬 
蟲夏草及補培納氣湯在 P B M C 的適合測量濃度則分別為 3 � 1 � 1 
mg/mL ；於濃度5 mg/mL或以上，細胞存活性保留於70 %以上。 
補培納氣湯在嗜酸性白血球的適合測量濃度為1 mg/mL，細胞存活 




夠增加TNFa、細胞介白素 -6、細胞介白素 -1p、細胞介白素 -10從 
淋巴細胞及巨嗟細胞的分泌，但天然冬蟲夏草的激化性則較草荅香 
™冬蟲夏草為高。於草答香 T M冬蟲夏草及天然冬蟲夏草的影響下， 
細胞介白素-2a受體的細胞面表達’及細胞介白素-1a、細胞介白素 











而草荅香谓冬蟲夏草則能延長載瘤（E A T )小鼠的壽命達6 4 % �於 













氣湯（1 m g / m L )能有效地抑制人粒細胞巨嗟細胞集落刺激因子 
(GM-CSF)及血小板活躍因子（PAF)激化的嗜酸性白血球以釋放 
ECP (P < 0.05)。此外’嗜酸性白血球附著分子CD49d和趨化因子 
受體CCR3的表達亦有效地減少（P < 0.05)。實驗亦証明補培納氣 
湯能降低屋塵絲激化後PBMC的CD23表達、細胞因子TNFa、細 
胞介白素-5、細胞介白素-10的分泌，以及細胞介白素-2a受體、趙 
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1.1. The Search of Immunomodulatory Agents 
Prevalence of age-related diseases such as cancer and chronic ailments like 
asthma are escalating in industrialized nations especially in the past decade 
(World Health Organization, 2004). In Hong Kong, cancer has been the 
leading cause of death since the 1960's, claiming one in every three deaths 
in 1999 (Department of Health Annual Report, Hong Kong, 2000-2001). The 
prevalence of asthma, allergic diseases and atopy in Hong Kong's 
schoolchildren has been comparatively higher than those in m a n y 
industrialized Western countries. In 2001，the Phase II International Study of 
Asthma and Allergies in Childhood (ISAAC) found that the atopic rate of 
adolescent schoolchildren in Hong Kong w a s 41.2 % , representing a 2-fold 
elevation over the preceding six years (Wong et al, 2001 )• 
Modern treatments of these chronic conditions are Western based which 
alleviate symptoms rather than provide complete cure. Surgery, 
chemotherapy and radiotherapy are conventional but rather invasive 
treatments of cancer. Corticosteroids are drugs used for ameliorating asthma 
symptoms but associated with growth retardation in children. Besides, there 
are no preventive measures for cancer and asthma in modern medicine. 
Cancer and asthma are immune-related diseases which are respectively 
caused by over-suppression and over-activation of the immunity. 
Immunomodulatory agents m a y shed lights on both prevention and treatment 
of these chronic detrimental conditions, in which Traditional Chinese 
medicine ( T C M ) is a powerful new trend in such pharmaceutical development 
(Yuan and Lin, 2000). The therapeutic strategy of T C M focuses on holistic 
management which is especially appealing in modulating chronic and age-
related diseases. A typical caseload might include asthma, eczema, 
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rheumatoid arthritis, fatigue and cancer (Ho and Lisowski, 1997; Vickers and 
Zollman, 1999; Yuan and Lin, 2000). Compared to the single chemical-
entities used in modern medicine, T C M typically uses herbal medicine as 
treatment agent, which is thought to associate with fewer side effects and 
m a y therefore compensate the limitation of modern medicine (Ho and 
Lisowski, 1997). 
1.2. Cordyceps sinensis (Dong Cong Xia Cad) as an 
Immunomodulatory Agent 
1.2.1. General Aspects 
Cordyceps sinensis (Berk) Sacc {Dong Cong Xia Cao^) is an insect-parasitic 
fungus of the ascomycetes family growing on the larvae of Lepidoptera, 
usually Hepialus varians (Figure 1.1). It is found at high altitude on the 
Qinghai-Tibetan plateau. The normal range of this fungus is above 2 k m 
elevation with occasional discovery at 6 k m above sea level (Kuo et al, 1996; 
Bensky et al, 1993). C. sinensis has been widely used as a tonic for longevity, 
endurance and vitality (Yamaguchi et al, 2000). Chinese has long used it as 
a nutritional additive to be cooked with meat (Huang et al, 1999). There has 
also been no report regarding its potential or known hazards (McGuffin et al, 
1997). 
1.2.2. Evidence from the Traditional Chinese Medicine Concepts 
Cordyceps sinensis is the only T C M which possesses both Yin and Yang 
double i n v i g o r a t i o n 2 ’ 4 . The doctrine of Yin and Yang is a T C M concept which 
was established under the influence of Confucius in about 500 BC. In this 
doctrine, Yin and Yang is the symbolic way of designing opposing forces that 
work in everything from the cells of the body to the stars in the universe 
(Chan, 1995). In the human immune system, Yin and Yang respectively refer 
to the suppressed and enhanced status. Therefore, the Yin-yang double 
invigorated C. sinensis exerts both immuno-suppressive and immuno-
：2-
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enhancing activities, depending on the body's condition to accomplish 
immunomodulation in general (Figure 1.2). 
Figure 1.1. The (a) natural morphology and (b) dried-form of Cordyceps 
sinensis. Zhang Clinic: http://www.dr-zhang.com/formulas/cordyc4.jpg. 
Accessed on 18 June 2004. 
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Figure 1.2. Possible immunomodulatory activities derived from the 
double Yin-yang invigoration of C. sinensis, 
— 
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1.2.3. Evidence from the Traditional Chinese Medicine Classics 
The immunomodulatory activities of C. sinensis have been well-documented 
in historical literature. In Ben Cao Bei Yao written by Wang On in the Qing 
Dynasty, C. sinensis w a s suggested as a tonic for the lung and kidney, a 
mucolytic and anti-tussive agent, and a blood coagulant〗. Ben Cao Gan Wu 
Xu Wei stated that 'C. sinensis has the s a m e function as Ginseng，, and ‘is 
able to nourish the sperm and spinal fluids'"^ . Yao Zin Kao claimed that 'it 
tastes bitterly but acts mildly. It can enhance sperm production and exercise 
tolerance. It is essential for life maintainance.^' Ben Cao Zhen \7 documented 
its ability to remove fatigue®. Zhong Yao Zhi suggested that C. sinensis is 
able to alleviate fatigue and cure hemoptysis, erectile dysfunction and 
premature ejaculation, low back pain and joint pain^. Wen Fong Si Kao even 
recorded a clinical case, in which a terminal patient recovered after taking C. 
sinensis as a daily supplement^. These literatures all positively supported 
that C. sinensis can improve the general well being, which m a y be largely 
contributed to the enhancement or modulation of immunity. 
1.2.4. Evidence from the Modern Research Literature 
A thorough review on Cordyceps sinensis was carried out in August 2002 
and updated in July 2004 by using PubMed, the literature database of 
National Centre for Biotechnology Information (NCBI). T w o hundred and nine 
papers were displayed when typing the keyword 'Cordyceps'. Approximately 
50 % of these journals were written in English and published in international 
peer-reviewed journals. A variety of immunomodulatory effects of the single 
C. sinensis have been reported based on in vitro, in vivo and clinical studies. 
1.2.4.1. Immunomodulation 
Immunosuppressive functions of Cordyceps sinensis have been previously 
reported. Kuo et a/found that a low-molecular-weight fraction (CS-36-39 and 
CS-48-51) isolated from C. sinensis by methanol could inhibit blastogenesis 
response, natural killer (NK) cell activity, and production of interleukin(IL)-2 
：4. 
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and tumor necrosis factor(TNF)a from phytohemagglutinin(PHA)-stimulated 
h u m a n peripheral mononuclear cells ( P B M C ) (Kuo et al, 1996). Zhang et al 
demonstrated that C. sinensis dose-dependently inhibited phagocytic 
function of peripheral blood leukocytes，mitogenic response of spleen 
lymphocytes to concanavalin A, and lipopolysaccharide(LPS)-induced IL-1 
release of macrophages in vitro. Furthermore, an in vivo study showed that 
immunosuppressive activity of C. sinensis was estimated to be close to that 
of cyclosporine A on skin allograft (Zhu and Yu, 1990). Zhang also reviewed 
the potential of C. sinensis as an immunosuppressive agent in prolonging 
survival of murine performed with skin allograft (Zhang, 1990) and 
heterotropic heart allograft (Zhang and Xia, 1990). In addition, effect of C. 
sinensis preparation in rat with heterotropic heart allograft was similar to 
those of cyclosporine A and glucocorticoid. The study thereby suggested C. 
sinensis as a promising immunosuppressant in clinical organ transplantation 
(Wang and Shiao, 2000). 
Auto-immune disease is a type of immune dysregulation caused by 
uncontrolled immune responses against self tissue antigens. Oral therapy of 
methanol extract (H1-A) of C. sinensis has significantly reduced proteinuria, 
serum creatinine levels, and renal mesangial proliferation in the mice with 
autoimmune disease (Yang et al, 1999; Lin et al, 1999). The 
immunosuppressant effects m a y be due to the apoptosis of IL-1 and platelet-
derived growth factor (PDGF)-activated human mesangial cells via the 
modulation of signal transduction proteins Bcl-2 and Bcl-XL (Yang et al, 
1999). Water extracts of C. sinensis improves defective IL-2 production in 
patients with systemic lupus erythematosus (SLE). In vivo experiments 
showed that water extracts of C. sinensis m a y inhibit anti-double strand D N A 
production in a lupus mice model (NZB/NZW F1) (Chen et al, 1993). 
Immunoenhancing potential of C. sinensis has also been widely reported. It 
was demonstrated that a crystallized preparation of C. sinensis (Cs-Cr) 
increases the number of T helper cells and Lyt-1/Lyt-2 (T helper to T 
suppressor cell) ratio in peripheral blood and spleen. The spleen weight, 
phagocyte counts, and phagocytic activity were elevated. Cs-Cr protected T 
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helper cells from the immunosuppressive effects of prednisolone acetate and 
cyclophosphamide. Therefore, Cs-Cr m a y be an immuno-regulator of cellular 
immunity and m a y be useful in immune-deficient or immuno-suppressed 
patients (Chen et al, 1991). Koh et al reported that orally administered hot-
water extract of C. sinensis to mice stimulated the activation of macrophage, 
enhanced hematopoietic growth factor such as IL-6 production, and 
promoted bone marrow cell proliferation (Koh et al, 2002). Yamaguchi et al 
showed that oral administration of the water extract of C. sinensis in tumor-
inoculated mice m a y augment the antibody responses, chemotaxis of 
peritoneal macrophages, and phagocytic activity of macrophages. Protective 
activity against systemic infection by Salmonella enteritides w a s also 
enhanced (Yamaguchi et al, 1990). In addition, methanolic extracts of C. 
sinensis suppressed proliferation of lipopolysaccharide(LPS)-activated 
bronchoalveolar lavage fluids (BALF) cells, reduced the production of Th2 
inflammatory cytokine IL-ip, IL-6, IL-8, IL-10 and TNFa but enhanced the 
secretion of Th1 cytokines IL-12 and IFNy (Kuo et al, 2001), therefore 
suggesting the therapeutic value of C. sinensis in treating asthma. Additional 
studies supported that the pharmacological action of C. sinensis on murine 
immune organs were mainly mediated through the host immune system 
(Yamaguchi et al, 1990; Bao et al, 1988; Liu, 1988). 
Several clinical studies have been carried out to investigate the potential of C. 
sinensis on declined immune function. The effects of C. sinensis on 
peripheral N K cells from healthy persons and leukemia patients have been 
studied (Liu et al, 1992). C. sinensis treatment augmented N K cell activity 
and increased C D 1 6 expression in lymphocytes and the binding capacity to 
K562 cells. C. sinensis as an adjunct therapy in the treatment of leukemia 
has been suggested. The modulating effects of C. sinensis on T-lymphocyte 
subsets in chronic renal failure also deserve attention (Guan et al, 1992). In a 
clinical study, synchronous measurement of renal function and T-cell subsets 
were taken in patients of chronic renal failure (CRF) (n=51). Patients (n=28) 
taking C. sinensis were considered as a study group. C. sinensis treatment 
improves renal function and simultaneously enhances the cellular immune 
function in C R F . 
IQ. 
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1.2.4.2. Anti-tumor Effects 
Early in 1989，Yoshida et al demonstrated that oral administration of warm-
water extracted C. sinensis increased the median survival time of mice 
inoculated with Ehrlich ascites tumors (Yoshida et al, 1989). In the following 
next year, Yamaguchi et al showed that oral administration of the water 
extract of C. sinensis in mice might reduce tumor size and might prolong host 
survival time (Yamaguchi et al, 1990). Later, ethanol extracts of C. sinensis 
w a s shown to elevate in vivo and in vitro activities of murine and human 
natural killer cells. Colony formation of B16 melanoma in mouse lungs w a s 
reduced significantly by intraperitoneal pretreatment of the mice with the C. 
sinensis extracts (Xu et al, 1992). Analogously, extracts of C. sinensis 
induced apoptosis of B16 melanoma cells in vitro, and buffered toxicity and 
synergized anti-tumor effects of methotrexate in mice (Nakamura et al, 2003). 
Polysaccharide fraction of C. sinensis stimulated the activity of peripheral 
blood mononuclear cells but inhibited proliferation of human leukemic U937 
cell line in vitro (Chen et al, 1997). Kuo et al suggested that methanol 
extracts of C. sinensis contained inhibitory substances against tumor cell 
lines (Kuo et al, 1994). Water extract of C. sinensis might relieve liver 
metastasis of tumor bearing mice (Nakamura et al, 1999). Other reports 
showed that down-regulation of the major histocompatibility complex ( M H C ) 
antigens on the cell surface of certain tumors resulted in an escape of 
immunosurveillance and thus cancer formation (Perreault et al, 1994; Rimsza 
et al, 2004). Evidence has demonstrated augmentation of M H C class II 
antigen expression on tumor cells HA22TA/GH by the action of warm water 
extracts of C. sinensis (Chiu et al, 1998). Shin et al showed that ethanol 
extracts of C. sinensis not only enhanced phagocytosis and lysosomal 
enzymatic activity in vitro, but also increased life span and decreased tumor 
size in mice inoculated with Sarcoma-180 tumor cells. Various in vitro 
experiments have reported the anti-oxidant activities of C. sinensis 
(Yamaguchi et al, 2000; Li et al, 2001，2002， 2003)， suggesting it as a 
potential anti-tumor agent (Shklar, 1998). 
/ 
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1.2.4.3. Other Activities Related to the Immune System 
There is evidence that hot-water extract of mycelia from C. sinensis m a y 
substitute avilamycin as an antibiotic growth promoter in broiler chicks when 
orally administered (Koh et al, 2003). Reports have also shown the 
endurance enhancement activity exerted by C. sinensis (Earnest et al, 2004)， 
which probably acts through the induction of steroidogenesis (Wang et al, 
1998; Huang et al, 2000，2001a, 2001b，2004; Hsu et al, 2003) and the relief 
of fatigue and stress (Koh et al, 2003). 
1.2.4.4. Potential Active Ingredients: Cordycepin and Polysaccharides 
The immunomodulatory activities of C. sinensis are probably due to two 
substances — the cordycepin (Figure 1.3) and polysaccharides. A n early 
report has documented that Cordyceps sp. contains cordycepin, a nucleoside 
derivative (Cunningham et al, 1950). In vitro and in vivo studies have 
suggested that cordycepin possesses a wide range of biological activities 
related to immunomodulation on different extent, including upregulatory 
effects of anti-inflammatory interleukin-10 production and interleukin-10 
m R N A expression (Zhou et al, 2002)，anti-bacterial and anti-fungal activity 
(Ahn et al, 2000; Sugar et al, 1998), inhibition of D N A and R N A synthesis 
(Plagemann, 1971; Glazer et al, 1976; loannidis et al, 1999; Montreau et al, 
2003)，enhancement of cell differentiation (Mathew and Ellis, 1989), change 
in the distribution of cytoskeleton in cells (Zieve and Roemer, 1988; Deitch 
and Sawicki, 1979)，in vitro anti-tumor activity on bladder, colon and lung 
carcinoma, fibrosarcoma and leukemic cells (Hubbell et al, 1985; K o d a m a et 
al, 2000; Koc et al, 1996)，in vitro inhibition of the infection and reverse 
transcriptase activity of human immunodeficiency virus type 1 (Montefiori et 
al, 1989; Muller et al, 1991)，and in vitro inhibition of methylation of nucleic 
acid (Kuo et al, 1994). 
Polysaccharides, the second substance, are macromolecules consisting of 
hundreds or thousands of simple sugars joined by strong glycosidic bonds 
(Cooper, 2000). Its special ring structure has probably contributed to its 
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immuno-modulatory activities. C. sinensis is m a d e up by three sugar 
components - glucose, mannose and galactose (Li et al, 1989). The fruiting 
body of C. sinensis contains the amino acid adenosine and two 
polysaccharides: ergosteryl-3-O-p-D-glucopyranoside and 22-
dihydroergostery丨-3-0-p-D-glucopyranoside. The latter two have been 
subsequently identified as tumor inhibitors (Kuo et al, 1994). 
Besides, recent finding has shown that substances other than cordycepin 
and polysaccharides m a y also possess immunomodulatory activities (Kuo et 
a/，1994). Kuo et al have demonstrated that low molecular weight substances 
in C. sinensis m a y have anti-tumor property. T w o anti-tumor sterols, namely 
5a,8a-epidioxy-24(R)-methylcholesta-6,22-dien-3p-D-glucopyranoside and 
5,6-epoxy-24(R)-methylcholesta-7,22-dien-3p-ol, have been isolated from the 
methanolic extract of cultured mycelia of C. sinensis. The glycosylated form 
of ergosterol peroxide inhibits the proliferation of human leukemic cell lines 
(Bok et al, 1999). 
i 
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Figure 1.3. Cordycepin as a potential immunological ingredients 
contained in C. sinensis. 
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1-2.5. Prescription and Usage: Single vs Concocted 
1.2.5.1 • Apply Singly: Cultured Cordyceps sinensis 
The difficulty in accessing wild form C. sinensis makes them rare and 
expensive. Advances in plant technology have prompted cultivation 
researches of C. sinensis. The first commercial strain of C. sinensis w a s 
isolated in 1982 at the Institute of Materia Medica, Chinese A c a d a m y of 
Medical Sciences. This strain is known as CS-4 with a Latin n a m e 
Paecilomyces hepiali Chen. The aseptically fermented mycelium of this strain 
underwent extensive clinical trials in human during the 1980's and a 
commercial product named JinShuiBao capsules was developed accordingly. 
Research has showed that the Jinshuibao capsule is able to accelerate the 
repair of damaged deoxyribonucleic acid (DNA) (Zhang et al, 1997). In a 
clinical trial, Jinshuibao can restore cellular immunologic functions and 
improve the quality of life of thirty-six cancer patients (Zhou et al, 1995). The 
clinical trials of CS-4 in human have involved more than 2000 patients and 
the chemical composition, therapeutic activity and toxicity have also been 
elucidated (Bau, 1995). Evidence has also shown that C o r d y M a x ™ Cs-4 is 
effective in improving glucose metabolism and insulin sensitivity (Balon et al, 
2002; Dai et al, 2001; Zhao et al, 2002). Other strains isolated from C. 
sinensis are listed in Table 1.1. 
i 
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Latin Name Isolated by Commercial products 
^ Qing Hai Institute of 
Cephalosporium 
. Livestock and Vetrinary Nina Xin Bao 
sinensis 
Sciences 
Paecilomyces sinensis Fu Jian Qing Liu 
A A — Various 
Cn80-2 County Hospital 
Sanming Mycological 
Soydalilum sp, S M 1 H 8 8 1 9 
Institute 
Chinese Navy Institute 
Scydalilum sp. 832 
of Medicine 
Hirsutella sinensis :; Various 
Mortierella hepialld ： 
Various 
Chen Lu 




Table 1.1. Commercial strains isolated from C. sinensis. 
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1.2.5.2. In concoction: As an Anti-asthmatic Agent 
T C M herbs are traditionally prescribed in combination for synergistic and 
toxic-buffering effects. A typical T C M formula composes of master, advisor(s) 
and soldier(s) drugs. The master drug is non-toxic and can be used long term, 
while adviser and soldier drugs m a y be rather toxic but usually more effective 
(Chan, 1995). Researches have shown that concocted T C M perhaps exerts 
more effective immunomodulatory activities (Table 1.2). A typical study 
demonstrating the medicinal values of T C M concoction was carried out by 
Sheehan et al in 1992. They showed that a ten-herbs T C M formula 
significantly reduced eczema scores in 87 patients with severe, wide-spread 
atopic eczema. Analogously, several reports have also demonstrated the 
potential pharmaceutical activities of concocted C. sinensis. Liu et al in 1996 
reported Fuzheng Huayu Recipe, a C. sinensis contained formula, had 
beneficial effects in treating hepatic cirrhosis. 
As previously mentioned, anti-asthmatic drug such as corticosteroid, though 
effective in treatment, m a y be associated with adverse side effects. The 
search of alternative anti-asthmatic agents is therefore necessary. The 
aforementioned evidence has shown that C. sinensis possesses 
immunomodulatory and anti-tussive activities, implying that it m a y be an 
effective anti-asthmatic agent. Yet, much scientific evidence of C. sinensis 
lies on its immune regulatory effects while the anti-tussive reports are scarce 
(Kuo et al, 2002). Wheeze-Relief Formula using C. sinensis as the master 
T C M plus 4 other anti-tussive agents as the synergizer was subsequently 
developed. This formula is designed by a Chinese Medicine practitioner and 
it consists of five herbal components, including, Dong Chong Xia Cao 
{Cordyceps sinensis), Huang qi ^ {Radix astragali), Bai Bu i�{Radix 
Stemonae)，Chuan Bei ” {Bulbus Fritillariae Cirrhosae), and Huang qin ^^ 
{Radix Scutellariae). These herbs have been commonly used for various 
diseases and are known to be safe. Huang Qi is believed to possess 
immunomodulatory (Jin et al, 1996; Kajimura et al, 1997; Lee et al, 2003) and 
lung nourishing effects (He and Zou, 1998). Bai Bu and Chuan Bei are well 
known for their anti-tussive and mucolytic effects. They are c o m m o n 
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ingredients in m a n y patent Chinese cough mixtures used for chronic 
bronchitis treatment. Whereas Huang Qin has antimicrobial, anti-
inflammatory and sedative effects and is often used in bronchilitis and 
chronic bronchitis (Huang et al, 1983). 
1.3. Our Hypothesis and Rationale 
The limitation of modern medicine on health maintenance, cancer and 
asthma led us to the search of immunomodulatory agents from T C M , in 
which the Yin-yang double invigorated C. sinensis is perhaps the most 
equivalent candidate. Recently developed cultured fruiting bodies of C. 
sinensis, or the H E R B S n S E N S E S ™ Cordyceps, m a y possess 
immunomodulatory activities for cancer prevention and maintaining general 
well beings. However, there have been no scientific supports on this 
speculation. In the present study, w e investigated the in vitro and in vivo 
immunomodulatory and anti-tumor activities of commercial 
H E R B S n S E N S E S ™ Cordyceps, with natural C. sinensis as a comparison 
(Figure 1.2). W e have also investigated the potential anti-asthmatic efficacy 
of the newly developed Wheeze-Relief Formula in treating allergic conditions 
by an in vitro system. The integration of T C M with conventional modern 
medicine continues across practice settings and modalities. In the present 
study, w e have also introduced a double-blind placebo-control clinical trial 
with good clinical practice (GCP) of Wheeze-Relief Formula on the 
symptomatic improvement of asthmatic children, with the ultimate goal of 
reducing their requirement for corticosteroid dosage (Figure 1.4). 
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Figure 1.4. The general study scheme of the immunomodulatory effects 
of Cordyceps sinensis. Three different forms of C. sinensis were studied, 
including the naturally grown, commercially cultured fruiting bodies and the 
concocted form. They were associated with different hypotheses which will 
be tested in chapters 4-11. 
Table 1.2. Immunomodulatory activities of various TCM formulae. 
TCM Formulae 
Ba- Wei-Di-Huang- Wan 
Bu-Zhong- Yi- Qi- Tang 
Study Model Immunomodulatory Activities 
Possess immunomodulation toward Th1 predominance by 








Suppress IL-4 secretion and proliferation of splenic lymphocytes 
1. Therapeutic agent against candidiasis in patients with 
glucocorticoid-induced immunosuppression. 
Restore the antitumor T cell responses in stress-burdened 
tumor-bearing mice by normalizing the serum 
corticosterone, interleukin-12 and the expression of 
costimulatory molecules. 
Inhibit influenza virus infection via enhancement of the host 
immune responses. 
Restore impaired immune functions in aged mice by 
enhancing number of T cells and NK cells. 
Suppress the elevation of anti-ovalbumin lgGi in serum and 
IL-2 secretion from splenic lymphocytes 
Suppresses IgE antibody production and histamine release 
Contributor 
Furuya et al, 
2 0 0 1 ， 2 0 0 2 
Suzuki et a/， 
1999 
Abe et al, 
1999; 
Li et al, 1999; 











In vivo guinea pig 
model 
In vitro 
In vivo mice model 
In vivo mice model 
In vivo guinea pig 
model 
in type I allergic reaction in mice immunized with ovalbumin 
plus aluminum hydroxide adjuvant. 
7. Reduce eosinophilia, serum levels of ovalbumin-specific IgE 
and lgG1, and Th2-type cytokine production (IL-4) in the 
airway in ovalbumin-sensitized mice following ovalbumin 
inhalation. 
8. Increase the level of ovalbumin-specific lgG2a and IFNy 
production. 
1. Inhibit the antigen induced immediate asthmatic responses 
(lAR) and late asthmatic responses (LAR). 
2. Suppress the eosinophil infiltration into airways. 
Anti-inflammatory and immuno-regulatory effects through the 
cytokine modulation for the treatment of Adamantiades-Behcet's 
disease. 
1. Modulate intestinal immune system. 
2. Inhibit liver metastasis possibly through a mechanism 
mediated by the activation of macrophages and/or T-cells in 
the host immune system. 
Inhibit pulmonary metastasis in mice bearing B16F10 melanoma 
cells through the stimulation of CD8+ T cells. 
1 • Significantly inhibited the neutrophil increase and infiltration 
in the airway at 1, 6 and 24 hr after antigen challenge. 
Ishimitsu et a/, 
2001 
Kao et al, 
2004 
Kim et al, 
2002 
Kiyohara et al, 
2002; 
Ohnishi et al, 
1998 
Suzuki et al, 
1997 







In vivo mice model 
2. Stimulate P2-adrenoceptors on bronchial smooth muscle 
Therapeutic potential in the treatment of HIV positive patients. 




Reduce number of sneezes after a topical antigen challenge 
Inhibite an increase in vascular permeability induced by 
histamine and serotonin. 
Suppress 丨eukotrienes release from polymorphonuclear 
leukocytes 
Act on hepatic sinusoidal endothelial cells to increase the 
level of estradiol receptors, thereby affecting the immune 
reactions in the liver. 
Modulate both cellular and humoral immune responses 
specific for hepatitis B virus (MBV)-associated antigens. 
Suppress type IV allergic reaction by the flavonoids and 
lignans contained. 
Inhibit IL-3, IL-5 and granulocyte macrophage colony 
stimulating factor (GM-CSF) activated eosinophils survival. 




H o m m a et al, 
2000; 
Mizoguchim 
et al, 1991; 










In vivo mice model 
H u m a n Clinical 
Trial 
4 - 3 5 weeks 
Children 
In vivo mice model 
In vivo guinea pig 
model 
In vivo rat model 
3. Decrease number of eosinophils in bronchoalveolar lavage 
fluid 4 hours after antigen challenge 
4. Inhibit infiltration of eosinophils and T-Iymphocytes into the 
lung parenchyma. 
5. Inhibit calcium ionophore-stimulated synthesis of cysteinyl 
leukotrienes and LT B4 
6. Decrease in the number of eosinophils in the 
bronchoalveolar lavage fluid during late asthmatic response. 
Suppress the release of leukotrienes (LT) B4 and LT C 4 from 
polymorphonuclear leukocytes of asthmatic patients. 
Resolve the inflammation and immune response associated with 
secretory otitis media. 
As an adjuvant in the treatment of rheumatoid arthritis by 
regulating interferon(IFN)-y production. 
Inhibit neutrophil increase and infiltration in the airway at 1, 2, 4， 
6，8 hr after antigen challenge 
1 • Inhibit IgE-mediated synthesis of LT C 4 and LT B4. 
2. Inhibit phospholipase A 2 and 5-5-lipoxygenase activities 
without affecting the mobilization of [Ca2' 


















In vivo mice model 
ShhQuan-Da-Bu- Tang 




In vivo mice model 
1. Inhibits IgE receptor-associated protein phosphorylation in 
the histamine release pathway 
2. Augment nonspecific resistance to bacteria Pseudomonas 
aeruginosa, Klebsiella pneumoneae. 
3. Enhance the immune response by eliminating the inhibitory, 
functions of prostaglandin E2 on lymphocyte functions and 
by enhancing antigen presentation. 
4. A polyclonal B-cell activator which induces IgA production in 
the mucosal immune system. 
5. Anti-atherosclerotic by improving the reduced lymphocyte 
and macrophage functions. 
6. Modulate lung inflammation by regulating local immune 
response. 
7. Different effects on lung immunity in hosts with different 
genetic backgrounds. 
1. Suppress HIV indirectly via the inhibition of prostaglandin E2 
(PGE2) or superoxide production. 
2. Upregulate the suppressed immunity by enhancing 
leukotrienes (LT) B4 secretion. 






Nagatsu et al, 
1989; 
Tauchi et al, 
1993; 
Shen et al, 
1996; 
Inoue et al, 
1996; 











In vivo mice model 
Modulate hematopoiesis and immune response via regulating 
G M - C S F secretion. 
Improve the memory related behavior and the abnormalities in 
lymphocytes in the climacteric disorder. 
In vivo rat mode! Act against idiopathic membranous nephropathy. 
In vivo mice model 
In vivo mice and rat 
model 
Relieve Behcet's syndrome by inhibiting the early phases of the 
cellular immune response. 
1. Inhibit the homologous passive cutaneous anaphylaxis in 
rats and the heterologous P C A in mice 
2. Decrease mast cell degranulation of calvarial periosteum in 
rats 
3. Inhibit the release of anaphylactic mediators from sensitized 
lung tissues of guinea pigs and the contraction of isolated 
guinea pigs ileum induced by histamine. 




Hattori et al, 
1990 
Koda et al, 
1987 
Dai et a/, 1997 
Xiao-Chai'HU'Tang 
In vivo mice model 
1. Induce apoptosis on h u m a n lung fibroblasts. 
2. As an adjuvant to nasally inoculated influenza H A vaccine. 
3. A s a treatment of influenza virus infection on patients with 
allergic pulmonary inflammation. 
4. Administration before allergen challenge m a y reduce 
bronchial inflammation, by decreasing the number of total 
cells and eosinophil infiltration in the BALF, and 
downregulated the allergen- or mitogen-induced 
intrapulmonary lymphocyte response. 
5. Inhibited the antigen-induced immediate asthmatic response 
(lAR) and late asthmatic response (LAR) in actively 
sensitized guinea pigs. 
6. Attenuated the eosinophil increase and infiltration at 1, 6, 24， 
48, and 72 h after antigen challenge w h e n it w a s 
administered once daily from the day of sensitization to the 
day of challenge. 
Y a m a d a and 
Nagai，1998 
Nagai and 
Y a m a d a , 
1998; 
Liu et a/， 
2002; 
Kao et al, 
2000; 
Kao et al, 
2001 






















2.1 • General Aspects of the Human Immune System 
The present study has focused on the regulatory mechanism of C. sinensis 
on h u m a n immunity. A series of scientific and systematic experiments based 
on h u m a n immunology were designed to investigate the hypothesis. This 
chapter briefly introduces immunological principles and the experiments 
thereby developed. 
The h u man immune system comprises organs and vessels in the body that 
are involved in producing and delivering the cells and molecules to protect us 
from infections and cancer. This defensive ability is called immunity, which 
occurs either non-specifically as innate immunity, or specifically as acquired 
immunity. Innate immunity defends against invaders by mechanical barriers, 
s o m e secreted products and inflammatory cells such as macrophages and 
dentritic cells. Innate immunity is unable to distinguish pathogens and 
specifically kill them. As pathogens are rapidly replicating and is of huge 
diversity, immunity more powerful in killing the pathogens specifically and 
quickly was developed, especially when the innate defense barriers are 
breached. This explains the importance of acquired immunity. In brief, this 
adaptive immune system is capable of exquisitely distinguishing among 
different invaders, and significantly alters its intensity and response time 
upon re-exposure. (Alberts et al, 1994; Goldsby et a/，2000; Sell et al, 2001; 
Janeway et al, 2001) 
2.2. Designing the In vitro Study on Cell-mediated Immunity 
The major participants of the immune system are immunological cells and 
their products. Cells such as lymphocytes are particularly important in 
directing the role of acquired immunity. There are two types of lymphocytes, 
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namely，the bone-marrow derived lymphocytes, or B cells, and the thymus-
derived lymphocytes, or T cells. They are respectively attributed to the 
antibody or humoral immune responses, and the cell-mediated or cellular 
immune responses. 
The humoral immune responses involve the production of antibodies from 
plasma cells, which are virtually the mature B cells. As there is a vast number 
of antibodies being produced, modulation of this immune response is difficult 
to be quantified. However, the cell-mediated immune responses involve the 
generation of specialized T cells that react with foreign antigens on the 
surface of other host cells, such as macrophages. Such specialized T cells 
are of few types and most of the mediators that they secrets are functionally 
known. Therefore, it is possible to measure the changes in cell-mediated 
immunity experimentally. Moreover, specialized T cells and their mediators 
enhance the humoral immunity. T cells in other words orchestrate the 
immune system. Modulation of the cell mediated immunity provides a direct 
effect on the human immune system. (Alberts et a/’ 1994; Goldsby et a/，2000; 
Sell et al, 2001; Janeway et al, 2001) In order to investigate the effects of 
H E R B S n S E N S E S ™ Cordyceps and C. sinensis on our immune system, w e 
selected two important players of the cellular branch of immune responses, 
namely the T cells and macrophages. 
2.2.1. T Cells 
丁 cells are morphologically s a m e as B cells. T cells are small, round cells 
found in the peripheral blood, lymph nodes, spleen, thymus, tonsils, and 
appendix and scattered throughout the connective tissue in many other 
organs (Sell et al, 2001). They are responsible for the primary recognition of 
the foreigner of our immune system named antigen, and also functions as 
immunologically specific effector cells. T cells m a y be divided into 
subpopulations on the basis of function and phenotypic markers. Those help 
in antibody formation are named T-helper [TH] cells, those kill target cells by 
lysis are T-cytotoxic [Tc] cells, and T-suppressor [Ts] cells inhibit certain 
immune responses. A m o n g these three major subpopulations, the TH cells 
— 
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can be further classified into two major subsets, Th1 and Th2. Th1 cells are 
crucial for activating macrophages, whereas Th2 cells are the most effective 
activators of B cells. The mediators, or cytokines in specific, that Th1 and 
Th2 produced contribute to these subsets' functions and the regulation of 
subsets themselves. Th1 produces cytokines called interleukin(IL)-2 and 
interferon g a m m a (IFNy). Th2 produces IL-4, IL-5, IL-6, and IL-10. A m o n g 
these, IL-10 inhibits the development of Th1 cells and IFNy prevents the 
activation of Th2 cells. Therefore, any dominance of a single subset 
eventually shifts the immune response to that respective side. In addition, IL-
2 specifically binds to its receptor to initiate 丁 cells proliferation, IL-4 is a B 
cell stimulatory factor, IL-5 is an activator for eosinophils, and IL-6 is a 
multifunctional inflammatory cytokine. (Alberts et al, 1994; Goldsby et al, 
2000; Sell et al, 2001; Janeway et al, 2001) 
In other words, the proliferation of T cells, their cytokine production, and their 
cytokine receptor expression are the key markers for immunomodu丨ation. 
Part of our experiments will be based on these parameters to elucidate the 
immunomodulatory efficacy of H E R B S n S E N S E S ™ Cordyceps and C. 
sinensis (Figure 2.1). 
2.2.2. Macrophages 
Macrophages are large mononuclear phagocytic cells important in immunity. 
They are migratory cells deriving from bone marrow precursors and are 
found in most tissues of the body (Janeway et al, 2001). Macrophages 
located in blood are termed monocytes, and those in tissues are called 
histiocytes (Sell etal, 2001). 
Macrophages usually act as a front line of host defense and contribute to the 
innate immunity. Pathogens are destroyed by macrophages once they are 
recognized by the macrophage receptors. However, a number of pathogens 
have evolved protective features from immediate macrophage killing. O n e 
such device is the development of a thick polysaccharide coat which 
prevents recognition by phagocyte receptors. In this way, the pathogens 
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invade the host in sufficient numbers which overwhelm the immediate innate 
immunity. Acquired immune responses are therefore triggered. The 
production of IFNy and other mediators by T cells activate macrophages, 
which subsequently enhances phagocytosis, the process of engulfing and 
digesting microbes. Several mechanisms exist for this purpose, including the 
development of reactive forms of oxygen, induction of cytokine production, 
the development of nitric oxide, as well as the induction of a series of 
proteolytic enzymes. These mechanisms are basically the parameters for 
immunomodulation and w e have selected s o m e for the investigation of 
H E R B S n S E N S E S ™ Cordyceps and C. sinensis (Figure 2.1). In addition, T 
cells are further activated by the stimulated macrophages to proliferate and 
produce cytokines. Both macrophages and T cells are coordinated in such a 
w a y to enhance immunity and prevent infections, and that is the reason w h y 
both cells are included in the present study. (Alberts et al, 1994; Goldsby et 
al, 2000; Sell et al, 2001 ； Janeway et al, 2001) 
— 
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Figure 2.1. The experimental design elucidating the in vitro activities of 
C. sinensis on cell mediated immunity. 
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2.3. Designing the In vitro and In vivo Study of Anti-tumor Activities 
Majority of cancers occur in patients over 65 years of age, it has been 
suggested that this is due to the age-associated decline in immune function. 
S o m e cancer patients have decreased cell-mediated immune responses to a 
variety of antigens, and these patients appear to have more rapid tumor 
growth than cancer patients whose cell-mediated immunity is not decreased 
(Janeway et al, 2001). These suggested possible relation of tumor to 
immunity. In our present study, w e focused on (1) the effects of 
H E R B S n S E N S E S ™ Cordyceps and C. sinensis on the biology of tumor and 
(2) the possible role of H E R B S n S E N S E S ™ Cordyceps and C. sinensis on 
the immunity involved in tumor regression and engulfment. 
2.3.1. Tumor Biology 
The biology of cell division, differentiation, and apoptosis is exceedingly 
similar in both normal and cancer cells. The cancer cell differs from its normal 
counterpart in that it is aberrantly regulated. Four cellular functions tend to be 
inappropriately regulated in a neoplasm. First, the normal constraints on 
cellular proliferation are ineffective. Second, the differentiation program is 
distorted. Third, chromosomal and genetic organization m a y be destabilized 
such that variant cells arise with high frequency. Finally, the tightly regulated 
programmed cell death (apoptosis) m a y be dysregulated (Bast et a/，2002). 
The in vitro system in studying the anti-tumorigenecity of 
H E R B S n S E N S E S ™ Cordyceps and C. sinensis will be based on the above 
mentioned cellular defects. W e hypothesize that H E R B S n S E N S E S ™ 
Cordyceps and C. sinensis exerts its anti-tumor activity mainly through the 
inhibition of tumor proliferation and restoration of apoptosis. (Figure 2.2) 
2.3.2. Tumor and Immunity 
The relationship of tumor and the immune system was first proposed by Sir 
Macfarlane Burnet in 1957, who postulated that lymphocytes acted as 
sentinels in recognizing and eliminating continuously arising, nascent 
— 
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transformed cells. This hypothesis is known as immunosurveillance. Recent 
researches on immunity and tumor have prompted the development of the 
theory 'cancer immunoediting', which more appropriately describes the dual 
host-protecting and tumor-sculpting actions of the immune system that 
prevent and shape neoplastic diseases (Dunn et al, 2002). Major cell types 
involved in tumor immunity are described in the following paragraph and are 
summarized in Table 2.1. 
2.3.2.1 • T-Cell-Mediated Cytolysis (Tc Cells) 
Tc cells directly recognize cell surface antigens of the target cell via the T-cell 
receptor. O n e effector T cell can react with and lyse m a n y target cells. The 
reaction of specific T cells with the target cell causes membrane alterations in 
the target cells and results in swelling of the target cell and eventual osmotic 
lysis. Tc cells have Fas ligand (FasL) on their cell surface and react with Fas 
on tumor cells, activating the Fas-dependent cell-killing mechanism. There 
m a y also be exocytosis of granules containing perforin or granzymes from 
the T-killer cell that form complement like lesions in the cell membrane of the 
target eel! (Janeway et al, 2001). 
2.3.2.2. Delayed-Type Hypersensitivity (TDTH Cells) 
T cells responsible for delayed-type hypersensitivity reaction (TDTH Cells) 
specifically recognize antigens in tissues and are activated to release 
mediators that attract and activate macrophages. The activated 
macrophages are able to phagocytose cells and destroy them. In s o m e 
animal models, this mechanism is highly effective in killing tumors in vivo, but 
the mechanism cannot be duplicated in vitro (Janeway et al, 2001). 
2.3.2.3. Natural Killer (NK) Cells 
N K cells are lymphocytes do not have detectable surface immunoglobulin or 
T-cell markers and are active in certain types of lymphocyte-mediated target 
cell killing. They are part of the innate immunity. N K cells share some 
— 
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properties of T cells and macrophages and of B cells and granulocytes. N K 
cells are believed to arise from a c o m m o n T-cell-NK-cell progenitor before 
the migration of prothymocytes to the thymus. N K cells have receptors 
belongs belonging to three receptor families, which recognize major 
histocompatibility complex ( M H C ) class I molecules. N K activation is inhibited 
w h e n N K cells react with class I M H C molecules on the surface of a cell. 
Thus, cell normally expressing class I M H C are protected against N K killing, 
whereas cells that lack class I M H C , such as tumor cells, are not protected 
(Janeway et al, 2001 ； Long, 2002). 
2.3.2.4. Lymphokine-Activated Killer (LAK) Cells 
In 1980, Elizabeth Grimm demonstrated that incubation of 'normal' mouse 
spleen cells or human peripheral blood lymphocytes for 3 to 4 days in vitro 
with IL-2 resulted in the generation of L A K cells that did not bear T cell 
markers, were not M H C restricted, lysed cell lines resistant to N K killing, and 
were effective in reducing large tumor cell masses in mice (Janeway et al, 
2001). 
2.3.2.5. Antibody-Dependent Cell-Mediated Cytotoxic (ADCC) Cells 
A D C C are effector cells that m a y react with antibody bound to target cells 
and cause lysis. The effector cell types are heterogeneous and include 
polymorphonuclear leukocytes, macrophages and lymphocytes. The 
lymphocytes involved usually have no distinguishing T or B cells surface 
markers. They have been called null cells or Killer (K) cells. The Fc receptor 
for IgG is a c o m m o n feature of A D C C . Killing requires effecter-target cell 
interaction accomplished by the antibody binding by its antigen recognition 
sites to the target cells and by its Fc to the effecter eels. Lysis of the target 
cells by A D C C follows interaction with the killer cells (Janeway et al, 2001). 
2.3.2.6. Activated Macrophages (AM^) 
Macrophages are activated as a result of a delayed-type hypersensitivity 
— 
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reaction initiated by TDTH cells or by nonspecific macrophage activators such 
as polynucleotides. Macrophages scavenge injured and garbage cells. 
Mechanism of this type of killing involves the phagocytic activity of 
macrophage, through formation of reactive oxygen species (ROS) and 
activation of proteolytic enzymes (Janeway et al, 2001). 
Cells Marker Specificity Mechanism(s) Function MHC 
restriction 
Tc C D S Specific Lysis Tumor rejection Class II 
TDTH C D 4 Specific Macrophage Tumor rejection Class I 
activation 
- , .：• • 
丨鼓级欲丨園欲胃舞丨耗胃箱發舞丨is•丨丨资& 
N K N K Nonspecific Lysis Tumor NR^ 
surveillance? 
L A K L A K Nonspecific Lysis Immunotherapy? N R 
,力：IL-2R 
A D G G FcR Nonspecific Lysis Uncertain N R 
||||i|i|||^|||i||||i 
TIL ； ； ' Mixed Both? Lysis and Uncertain Both 
. m a c r o p h a g e 
|l;llllllill;||iiill;| 
activation 
AM(|) Monocyte Nonspecific Lysis and Tumor rejection N R 
,, phagocytosis 
Table 2.1. Properties of cell mediating tumor immunity. ^NR, not 
restricted. (Janeway et al, 2001). 
2.3.3. Mechanism of Tumor Engulfment 
Immunosurveillance occurs during the elimination process of immunoediting. 
In the first phase of elimination, once solid tumors reach a certain size, they 
begin to grow invasively and require an enhanced blood supply that arises as 
a consequence of the production of stromagenic and angiogenic proteins 
(Hanahan and Folkman, 1996). Invasive growth causes minor disruptions 
within the surrounding tissue that induce inflammatory signals leading to 
recruitment of cells of the innate immune system (NKT, NK, macrophages 
— 
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and dendritic cells) into the site. Structures on the transformed cells (either 
expressed as a result of the transformation process itself or induced by the 
ongoing but limited inflammatory response) are recognized by infiltrating 
lymphocytes such as N K T and N K cells, which are then stimulated to 
produce IFNy. In the second phase, the IFNy that w a s initially produced m a y 
induce a limited amount of tumor death by m e a n s of antiproliferative and 
apopotic mechanisms. However, it also induces the production of the 
chemokines C X C L 1 0 (interferon-inducible protein-10, IP-10), C X C L 9 
(monokine induced by IFNy, MIG) and C X C L 1 1 (interferon-inducible T cell 
chemoattractant, I-TAG) from the tumor cells themselves as well as from 
surrounding normal host tissues. At least s o m e of these chemokines have 
potent angiostatic capacities and thus block the formation of n e w blood 
vessels within the tumor, which leads to even more tumor cell death. T u m o r 
cell debris formed as either a direct or indirect consequence of IFNy 
production at the tumor is then ingested by local dendritic cells, which h o m e 
to draining lymph nodes. Chemokines produced during the escalating 
inflammatory process recruit more N K cells and macrophages to the site. In 
the third phase, the tumor-infiltrating N K cells and macrophages transactivate 
one another by reciprocal production of IFNy and 丨L-12, and kill more of the 
tumor by mechanisms involving tumor necrosis factor-related apoptosis-
inducing ligand, perforin and reactive oxygen and nitrogen intermediates. In 
the draining lymph node, the newly immigrated dendritic cells induce tumor-
specific CD4+ T helper cells expressing IFNy (TH1 cells) that in turn facilitate 
the development of tumor-specific CD8+ T cells. In the fourth phase, tumor-
specific CD4+ and CD8+ T cells h o m e to the tumor site, where the cytolytic T 
lymphocytes destroy the remaining antigen-bearing tumor cells whose 
immunogenicities have been enhanced by exposure to locally produced IFNy. 
2.3.4. The Experimental Plan 
Because of the intimacy between tumor engulfment and immunity (Burnet, 
1957; Dunn et al, 2002), and the evidence that s o m e tumors m a y produce 
immunosuppressive products (Janeway et al, 2001)，immunomodulatory 
agents m a y shed lights on both cancer prevention and treatment. Previous 
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evidence has demonstrated that C. sinensis exerts possible 
immunomodulatory activities, it is likely that H E R B S n S E N S E S ™ Cordyceps, 
the fruiting bodies of C. sinensis m a y also possess similar 
immunomodulatory and perhaps anti-tumorigenic functions. T w o in vivo 
animal models were thereby devised to investigate the postulation that 
H E R B S n S E N S E S ™ Cordyceps and C. sinensis is anti-tumorigenic through 
immunomodulation. The first animal model m a d e use of the Ehrlich ascites 
tumor (EAT) bearing ICR mice to test for any life-prolongation effects exerted 
by H E R B S n S E N S E S ™ Cordyceps and C. sinensis. BALB/c mice contributed 
to the second model, which enabled the examination of H E R B S n S E N S E S ™ 
Cordyceps and C. sinensis on the immunity of healthy BALB/c mice and 
sarcoma 180 (SC-180) bearing BALB/c mice. The parameters evaluated in 
the second mice model are derived by the concepts that cell mediated 
immunity and especially T cells are largely contributed to the 
immunomodulation and tumor removal. In the human body, spleen is the 
largest reservoir organ of T cells, and T cells are basically the major 
constituent of spleen cells. Therefore, the spleen cells m a y provide evidence 
for any increase in (1) expression of Th (CD4+) cell, Tc (CD8+) cell and T cell 
in general (CD3+)，（2) T cell proliferation, and (3) cytokine production, e.g. 
！FNy from Th1 cells. Moreover, the tumor size and the spleen weight would 
also be measured to give evidence of our hypothesis. The experimental plan 
is illustrated below in Figure 2.2. 
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Figure 2.2. Experimental plan depicting the anti-tumor activities of 
Cordyceps sinensis in both in vitro and in vivo system. 
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2.4. Designing the In vitro Study and Clinical Trials on Anti-asthmatic 
Activities 
I m m u n e responses to antigens of either endogenous or exogenous sources 
can cause tissue-damaging reactions. Classically, these are called 
hypersensitivity reactions and the resultant tissue lesions hypersensitivity 
disease (Kumar et al, 1997). According to Gell and Coombs, allergy is type I 
hypersensitivity which is characterized by mast cells degranulation and the 
release of inflammatory mediators, all triggered and mediated by IgE 
antibodies upon exposure to specific substances called allergens, such as 
pollens, house-dust mite, cockroach, food, drugs and stings (Playfair and 
Chain, 2001). 
Allergic asthma is a type 丨 hypersensitivity reaction characterized by recurrent 
and reversible airway obstruction. Like all type I hypersensitivity reactions, 
allergic asthma is driven by cytokines released from Th2 cells. Cytokines IL-4 
and IL-5 favor the synthesis of IgE, while IL-4 individually sensitizes growth of 
mast cells and IL-5 activates eosinophils. IgE, mast cells and eosinophils are 
key participants in allergic asthma. Attacks of atopic asthma often 
demonstrate two phase: an early phase, beginning 30 to 60 minutes after 
inhalation of antigen and then remitting, followed 4 to 8 hours later by a more 
protracted late phase. The initial triggering of mast cells occurs on the 
mucosal surface; the resultant mediators release opens mucosal intercellular 
junctions, allowing penetration of the antigen to more numerous mucosal 
mast cells. Direct stimulation of subepithelial vagal (parasympathetic) 
receptors provokes reflex bronchoconstriction. Mast cell activation leads to 
the release of a variety of primary and secondary mediators. Those 
considered important in the pathogenesis of asthma include leukotrienes (LT) 
C4，D4, E4, eosinophilic and neutrophilic chemotatic factors and leukotrienes 
B4. These mediators induce bronchoconstriction edema and mucus secretion; 
these initial reactions are followed by late phase, which is dominated by 
additional recruitment of leukocytes: basophils, neutrophils, and eosinophils. 
Such recruitment is favored by release of cytokines, such as T N F a from mast 
cells, that up-regulate adhesion molecules on vascular endothelium and also 
— 
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on inflammatory cells. Epithelial cells themselves are sources of mediators, 
such as endothelin and nitric oxide (NO), that can cause smooth muscle 
contraction and relaxation, respectively. Loss of epithelial integrity，by 
reducing available N O , m a y thus contribute to airway hyperresponsiveness. 
Eosinophils are particularly important in the late phase. Eosinophils 
accumulated at sites of allergic inflammation are favored by mast-cell-derived 
chemotactic factors IL-5 and platelet-activating factor (PAF). Eosinophil 
chemotaxis is mediated by chemokines. The most potent of these appears to 
be eotaxin, produced in part by activated bronchial epithelial cells. The 
accumulated eosinophils exert a variety of effects. Their armamentarium of 
mediators is as extensive as that of mast cells and in addition they produce 
major basic protein ( M B P ) and eosinophil cationic protein (ECP), which are 
toxic to the epithelial cells. Activated eosinophils also produce LT C 4 and 
P A F and directly activate mast cells to release mediators. Thus eosinophils 
can amplify and sustain the inflammatory response without additional 
exposure to the triggering antigen (Kumar et al, 1997). 
O u r experiments are designed according to the asthma pathogenesis (Figure 
2.3). W e hypothesized that Wheeze-Relief Formula m a y reduce inflammatory 
mediators and decreased activity of eosinophils and activated T cells. 
Experiments elucidating the hypotheses were divided into two major 
sections - the in vitro study and clinical trial, in which the former would 
basically test on the activities of eosinophils and house-dite-mite stimulated 
lymphocytes (Figure 2.3). The clinical trial collected plasma from patients and 
subsequently measured the plasma concentration of inflammatory mediators, 
including chemokines, cytokines and IgE before and after treatment. 
_ 
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Figure 2.3. Experimental plan depicting the anti-allergic activities of 
Wheeze-relief Formula in both in vitro and human system. 
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Materials and Methods 
3.1. List of Materials and Their Origin 
3.1.1. Traditional Chinese Medicine 
H E R B S n S E N S E S ™ Cordyceps GreaterChina Technology Group, H K 
Natural Cordyceps sinensis Shanghai Lei Yuen Shan 
Pharmaceutical C o Limited 
Wheeze-Relief Formula Institute of Chinese Medicine, C U H K , 
H K 
3.1.2. Cells for In vitro Experiments 
H u m a n Buffy Coat Blood Transfusion Center, Hong Kong 
Red Cross, H K 
Murine Ehrlich Ascites Tumor (EAT) Kindly provided by Prof. K N Leung, 
Department of Biochemistry, C U H K , 
H K 
H u m a n Eosinophilic Leukemic Cell Riken Cell Bank, Tsukuba Science 
Line City, Japan 
(EoL-1) 
H u m a n Hep-3B American Type Culture Collection 
(ATCC), U S A 
H u m a n Leukemic Cell Line (HL-60) Kindly provided by Prof. K N Leung, 
Department of Biochemistry, C U H K , 
H K 
H u m a n Mast Cell Line (HMC-1) Kindly provided by Prof. JH 
Butterfield, Mayo Clinic, Rochester, 
Minn., U S A 
Murine Sarcoma 180 (SC-180) Kindly provided by Prof. K N Leung, 
Department of Biochemistry, C U H K , 
H K 
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Murine PU5-1.8 Kindly provided by Prof. K N Leung, 
Department of Biochemistry, C U H K , 
H K 
3.1.3. Mice for In vivo Experiments 
Female BALB/c mice Laboratory Animals Service Center, 
C U H K 
Female ICR mice Laboratory Animals Service Center, 
C U H K 
3.1.4. Medium, Buffer, Supplements and Reagents for Cell Culture 
Dulbecco's Modified Eagle medium: Gibco™ Invitrogen Corp, C A , U S A 
Nutrient Mixture F-12 ( D M E M ) 
Iscove's Modified Dulbecco's medium Gibco™ Invitrogen Corp, C A , U S A 
(IMDM) 
R P M I 1640 medium Gibco™ Invitrogen Corp, C A , U S A 
a-thioglycerol Sigma Chemicals Co, M O , U S A 
Fetal bovin serum (FBS) Hyclone Co, Logan, Boston, U S A 
Phosphate buffered saline (PBS) Gibco™ Invitrogen Corp, C A , U S A 
Sodium chloride (NaCI) Sigma Chemicals Co, M O , U S A 
Trypsin-EDTA Gibco™ Invitrogen Corp, C A , U S A 
Ficoll™-Paque Plus solution Amersham Pharmacia Biotech Ltd, 
Uppsala, Sweden 
Percoll™ solution Amersham Pharmacia Biotech Ltd, 
Uppsala, Sweden 
Anti-CD16 magnetic micro beads Miltenyi Biotec, Bergisch Gladbach, 
Germany 
Canada Balsam mounting solution Sigma Chemicals Co, M O , U S A 
3.1.5. Dyes for Cellular Staining 
Trypan Blue dye (0.4 % ) Sigma Chemicals Co, M O , U S A 
Hemacolor® for Microscopy E Merck Diagnostica, Darmstadt, 
Germany 
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3.1.6. Cell Mitogens and Activator 
Recombinant human granulocyte Pepro Tech E C Ltd, London, U K 
macrophage-colony stimulating factor 
( G M - C S F ) 
Lipopolysaccharide from Escherichia Sigma Chemical Co, M O , U S A 
CO//0127:B8 (LPS) 
Recombinant human tumor necrosis Pepro Tech E C Ltd, London, U K 
factor (TNF) a 
Recombinant house dust mite protein Indoor Biotechnologies, Cardiff, U K 
Der p 1 (Der p 1) 
Phytohemagglutinin-M (PHA) Sigma Chemical Co, M O , U S A 
H u m a n recombinant platelet Calbiochem Corp, CA，USA 
activating factor (PAF) 
3.1.7. Reagents for Flow Cytometric Analysis 
F A S C flow sheath fluid B D Biosciences Corp, C A , U S A 
Bovine serum albumin (BSA) Sigma Chemical Co, M O , U S A 
H u m a n pooled serum Kindly provided by the Department of 
Chemical Pathology，Prince of Wales 
Hospital, H K 
Sodium azide Sigma Chemical Co, M O , U S A 
Paraformaldehyde Sigma Chemicals Co, M O , U S A 
3.1.8. Reagent Kits 
Colorimetric 5-bromo-2'-deoxyuridine Roche Diagnostics G m b H , Roche 
(BrdU) cell proliferation enzyme Applied Science, Penzberg, Germany 
linked immunosorbent assay (ELISA) 
Eosinophilic cationic protein (ECP) Pharmacia and Upjohn Diagnostics 
fluorescence enzyme immunoassay A B , Uppsala, Sweden 
(FEIA) 
G E Array ampoLabelling kit SuperArray Bioscience Corp, 
Bethesda，MD, U S A 
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Non-radioactive GEArray Q-series SuperArray Bioscience Corp, 
h u m a n inflammatory Bethesda, M D , U S A 
cytokine/receptor gene array 
H u m a n chemokine cytometric bead B D Pharmingen Corp, C A , U S A 
array (CBA) Kit 
H u m a n inflammation C B A kit B D Pharmingen Corp, C A , U S A 
IMx® total IgE assay kit Abbott Laboratories, Diagnostics 
Division, IL, U S A 
Mouse Th1/Th2 C B A Kit B D Pharmingen Corp, C A , U S A 
Mouse inflammation C B A Kit B D Pharmingen Corp, C A , U S A 
QCL-1000® chromogenic Limulus BioWhittaker Inc, M D , U S A 
amebocyte lysate (LAL) test 
Pharmacia C A P S y s t e m ™ specific Pharmacia Diagnostics A B , Uppsala, 
IgE fluorescence Sweden 
enzymeimmunoassay (FEIA) kit 
T A G S ™ annexin V-FITC/propidium Trevigen Inc, M D , U S A 
iodide (PI) staining kit 
3.1.9. EUSA Kits 
Eosinophil derived neurotoxin (EDN) M B L , Nagoya, Japan 
E U S A 
Leukotriene B4 enzymeimmunoassay Amersham Pharmacia Biotech, NJ， 
(EIA) system U S A 
Leukotriene C4/D4/E4 Amersham Pharmacia Biotech, NJ, 
enzymeimmunoassay (EIA) system U S A 
Quantikine® human IFNy E U S A R & D System Inc, M N , U S A 
Quantikine® human thymus and R & D System Inc, M N , U S A 
activation regulated chemokine 
(TARC) E U S A 
H u m a n T N F a high sensitivity E U S A R & D System Inc, M N , U S A 
H u m a n IL-18 E U S A M B L , Nagoya, Japan 
3.1.10. Antibodies 
— 
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Rat lgG2a anti-human C C R 3 R & D Systems Inc, M N , U S A 
monoclonal antibody, 
C3rboxyfluoresc6ni 门-conjugated 
M o u s e lgG2a anti-human C D 1 1 b B D Biosciences Corp, C A , U S A 
monoclonal antibody 
M o u s e lgGi anti-human C D 1 8 B D Biosciences Corp, C A , U S A 
monoclonal antibody, fluorescence 
isothiocyanate(FITC)-conjugated 
Rat lgG2a anti-human C D 2 3 B D Biosciences Corp, C A , U S A 
monoclonal antibody，FITC-
conjugated 
M o u s e lgGi anti-human C D 2 5 B D Biosciences Corp, C A , U S A 
monoclonal antibody，FITC-
conjugated 
M o u s e lgGi anti-human C D 4 9 d B D Biosciences Corp, C A , U S A 
monoclonal antibody 
M o u s e lgGi anti-human ICAM-1 R & D Systems Inc, M N , U S A 
(CD54) monoclonal antibody, FITC-
conju gated 
Rat lgG2b anti-mouse C D S B D Biosciences Corp, C A , U S A 
monoclonal antibody, FITC-
conjugated 
Rat lgG2b anti-mouse C D 4 B D Biosciences Corp, C A , U S A 
monoclonal antibody, FITC-
conjugated 
Rat lgG2a anti-mouse C D 8 a B D Biosciences Corp, C A , U S A 
monoclonal antibody, FITC-
conjugated 
Rat lgG2a, K monoclonal B D Biosciences Corp, C A , U S A 
immunoglobulin, FITC-conjugated 
Rat lgG2b, K monoclonal B D Biosciences Corp, C A , U S A 
immunoglobulin, FITC-conjugated 
M o u s e lgGi monoclonal B D Biosciences Corp, C A , U S A 
immunoglobulin, FITC-conjugated 
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Purified m o u s e IgG (reagent grade) Sigma Chemicals Co, M O , U S A 
Goat anti-mouse IgG antibody, FITC- Z y m e d Laboratories Inc, South San 
conjugated Francisco, C A , U S A 
3.1.11. Reagents for RNA Extraction 
R N e a s y ® total R N A extraction kit Qiagen G m b H , Hilden, Germany 
P-Mercaptoethanol Sigma Chemicals Co, M O , U S A 
Diethyl pyrocarbonate (DEPC) Sigma Chemicals Co, M O , U S A 
3.1.12. Reagents for Gel Electrophoresis 
Agarose gel Invitrogen Corp, C A , U S A 
D N A ladder, 1 Kb Invitrogen Corp, C A , U S A 
Ethidium bromide Gibco Invitrogen Corp, C A , U S A 
Gel loading buffer Sigma Chemicals Co, M O , U S A 
Tris-acetate-EDTA (TAE) Invitrogen Corp, C A , U S A 
electrophoresis buffer 
3.1.13. Reagents for cDNA Expression Array 
RNasin® ribonudease inhibitor Promega Corp, Wl, U S A 
Deoxynucleotide triphosphates Promega Corp, Wl, U S A 
(dNTPs) 
Salmon sperm D N A solution Invitrogen Corp, C A , U S A 
Biotin-16-dUTP Roche Diagnostics Corp, IN, U S A 
M - M L V reverse transcriptase RNase Promega Corp, Wl, U S A 
H minus, point mutant 
S S C solution, 20X Invitrogen Corp, C A , U S A 
Sodium dodecyl sulfate (SDS) Sigma Chemicals Co. M O , U S A 
3.1.14. Other Reagents 
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N-Cetyl-N,N,N-trimethylammonium Calbiochem Corp, C A , U S A 
bromide (CTAB) 
Dihydrorhodamine 123 (DHR) Molecular Probe Europe BV, Leiden, 
The Netherlands 
Sodium pentobarbital Sigma Chemicals Co, M O , U S A 
Zymosan A from Saccharomyces Sigma Chemicals Co, M O , U S A 
cerevisiae，FITC-conjugated 
3.1.15. Special Equipment and Apparatus 
FASCalibur™ flow cytometry Beckton Dickinson, C A , U S A 
IMx System Abbott Laboratories, Diagnostics 
Division, U S A 
Nikon Eclipse E800 microscope Nikon Corp, Tokyo, Japan 
Magnetic Cell Sorting System Miltenyi Biotec, Bergisch Gladbach, 
Germany 
Pharmacia C A P S y s t e m ™ Pharmacia & Upjohn Diagnostics A B , 
Uppsala, Sweden 
Shandon Cytospin 3 Centrifuge Thermo Electronic Corp, PA, U S A 
3.2. Details of Materials 
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3.2.1. Traditional Chinese Medicine 
3.2.1.1. Natural Cordyceps sinensis 
The natural C. sinensis {Shanghai Lei Yun Shan Pharmaceutical C o Ltd) was 
purchased from a local Traditional Chinese Medicine shop. It was 
authentificated by the Institute of Chinese Medicine, the Chinese Univerisity 
of Hong Kong. 
3.2.1.2. HERBSnSENSES™ Cordyceps 
The commercially prepared C. sinensis was generously provided by the 
GreaterChina Technology Group with H E R B S n S E N S E S E S ™ as the brand 
name. This commercially available C. sinensis will be abbreviated below as 
H E R B S n S E N S E S ™ Corydceps. The capsules were manufactured with Good 
Manufacturing Practice ( G M P ) standard, each containing microcrystalline 
cellulose (12 % ) and fruiting bodies of C. sinensis (88 %). The nutritional 
content and active ingredients of H E R B S n S E N S E S ™ Corydceps have been 
verified by Michelson Laboratories Inc. in U S A . Certain microbial bacteria 
have also been tested but the level was too low to be detected. 
3.2.1.3. Wheeze-Relief Formula 
The Wheeze-Relief Formula was manufactured by the Hong Kong Institute of 
Biotechnology based on G M P standard. It is composed of Cordyceps 
sinensis, Radix astragali, Radix Stemonae, Bulbus Fritillariae Cirrhosae, and 
Radix Scutellariae, with 2 g for each ingredient. The powder was formulated 
into uniform dose tablets (300 mg/tablet) under the supervision of the Clinical 
Research Center on Chinese Medicine, the Chinese University of Hong Kong. 
Equivalent placebos tablets consisting of dark coloured corn starch was also 
prepared to exactly the same shape and colour. 
3.2.2. Media, Supplements and Reagents for Cell Culture 
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3.2.2.1. Cell Culture Media 
Both R P M I 1640 Medium (Gibco™ Invitrogen Corp) and I M D M medium 
(Gibco™ Invitrogen Corp) contained 25 m M N-2-hydroxy-ethyl-piperazine-N'-
2-ethane-sulfonic acid (HEPES) and 2 m M L-glutamine at pH 7.2. Dulbecco's 
Modified Eagle Medium: Nutrient Mixture F-12 (D-MEM/F12) (Gibco™ 
Invitrogen Corp) contained 15 m M H E P E S , 2 m M L-glutamine and pyridoxine 
HCI at pH 7.2. The detectable endotoxin was < 0.1 EU/ml as confirmed by 
Limulus amoebocyte lysate assay. The medium was stored at 4 
3.2.2.2. Serum Supplements 
Fetal Bovin Serum (FBS) (Hyclone Co) was used as serum supplements to 
the medium. The F B S was heat-inactivated at 56 for 30 mins (HIFBS). 
The serum had been tested with its endotoxin and hemoglobin level, which 
were respectively found to be <10 EU/ml and <10 mg/ml. The serum was 
stored in -20°C before use. 
3.2.2.3. Anti-CD16 Magnetic Microbeads 
The anti-CD16 magnetic micro beads (Miltenyi Biotec) were super-
paramagnetic microbeads conjugated to monoclonal mouse anti-human 
C D 1 6 antibodies. They were used for isolation of untouched eosinophils from 
peripheral blood by depletion of C D 1 6 positive neutrophils. 
3.2.2.4. FicoH™-Paque Plus Solution 
Each Ficoll丁M-Paque solution (Amersham Pharmacia Biotech Ltd) contained 
Ficoll 400, 5.7 g, diatrizoate sodium, 9.0 g, with edentate calcium disodium in 
water for injection. The density of Ficoll-Paque (1.077 g/ml 士 0.001 g/mL) is 
— 
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optimized for the isolation of peripheral blood mononuclear cells ( P B M C ) 
from h u m a n blood in vitro. The solution was stored at 4 after opened. 
3.2.2.5. PercoH™ Solution 
The PercoH™ solution (Amersham Pharmacia Biotech Ltd) consisted of silica 
particles (15-30 n m diameter) coated with non-dialysable polyvinylpyrrolidone 
(PVP). Free P V P w a s present at only 1-2%. Percoll™ is non-toxic, almost 
chemically inert and did not adhere to membranes. A density of 1.08 g/mL 
w a s prepared from the stock Percoir^ solution ( 1 . 1 3 土 0 . 0 0 5 g/ml) for the 
isolation of human eosinophils from buffy coat. The solution was stored at 4 
°C after opened. 
3.2.2.6. Phosphate Buffered Saline (PBS) 
The solution w a s sterilized and with pH adjusted at 7.4. It contained 0.2 g 
monobasic potassium phosphate, 0.2 g potassium chloride, 8 g sodium 
chloride and 1.15 g dibasic sodium phosphate. The solution was stored at 4 
after opened. 
3.2.2.7. Water 
Sterile deionized water was used in the study. It was pyrogen free (< 0.1 
EU/ml) as confirmed by the QCL-1000® Chromogenic Limulus Amebocyte 
Lysate (LAL) Test. It was stored at 4 
3.2.3. Dye for Cellular Staining 
3.2.3.1. Hemacolor® for Microscopy 
The kit contained three bottles of solution. Hemacolor Solution 1 was 
methanol for cell fixation, Solution 2 was a buffered color reagent red 
containing eosin, and Solution 3 was a buffered color reagent blue. All 
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staining solutions were light-protected and stored at room temperature. The 
solutions were used to stain cells after cytocentrifugation. 
3.2.3.2. Trypan Blue Dye 
The trypan blue solution contained 0.4% (w/v) trypan blue dissolved in 
0.817% sodium chloride and 0.06% dibasic potassium phosphate. To remove 
any precipitates and sediments, it was filtered through 0.2 jum 
polyethersulfone filter before use. The dye was stored at room temperature. 
3.2.4. Reagents for Flow Cytometry 
3.2A1. FACS Flow Sheath Fluid 
This w a s a ready-to-use balanced electrolyte solution containing sodium 
chloride, potassium chloride, disodium E D T A , sodium fluoride and anti-
microbial agent. The solution was kept at room temperature. 
3.2.4.2. FACS Wash Medium 
The buffer contained 0.5 % B S A (Sigma Chemical Co) and 0.01% sodium 
azide (NaNs) (Sigma Chemical Co) in P B S (1x). It was kept at 4°C and used 
for eel! washing in immunofluorescence staining. 
3.2.4.3. Paraformaldehyde 
Paraformaledhyde (Sigma Chemical Co) (1 % ) dissolved in P B S (Hyclone Co) 
was used for cell fixation in immunophenotyping. The pH was adjusted to 7.4. 
The solution was light protected and kept at 4°C until use. 
3.2.5. Special Equipments and Apparatus 
3.2.5.1. Magnetic Cell Sorting System (MACS) 
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The magnetic cell sorting system ( M A C S ) (Miltenyi Biotech) consisted of a 
MidiMACS Separation Unit, a M A C S MultiStand and a LS Separation 
Column which could separate maximal of 2 x 10^ total cells and 10® 
magnetically labeled cells. The set-up were used for the isolation of 
untouched eosinophils from peripheral blood by depletion of C D 1 6 positive 
neutrophils. 
— 
Chapter 3 - Materials and Methods 
3.3. Human Subjects 
3.3.1. Inclusion Criteria 
A total of 90 patients aged between 7 to 15 years with a physician diagnosis 
of asthma based on the American Thoracic Society's criteria w h o were on 
regular steroid inhalation therapy were recruited from the Prince of Wales 
Hospital and Tuen M u n Hospital, Hong Kong. Subjects fulfilling with the 
following criteria were included in the study: 
(1) A baseline F E V 1 < 80 % of expected for height and gender, and an 
increase in F E V 1 of > 15 % 20 to 30 min after inhalation of bronchodilator 
for at least twice prior to the start of the study. 
(2) A minimum asthma symptom score of 7 during the one-month run-in 
period. The symptoms of daytime wheeze, nighttime wheeze, morning 
chest tightness and cough were scored 1 to 5 (O=none, 5= very severe) 
on one or more days. 
(3) More than 1 asthmatic attack per month despite the use of inhaled steroid 
and bronchodilator therapy for the past 3 months. 
(4) Ability to perform reproducible spirometry, to keep detailed diary of 
symptoms and medications so as to seek additional medical attention and 
perform the P E F R assessment twice a day. 
3.3.2. Exclusion Crtieria 
Patients with any of the following conditions were excluded: 
(1) Cannot swallow capsule. 
(2) Currently receiving astemizole (within 3 months); nedocromil, cromolyn 
(oral or long-acting); theophylline (within 1 week); anticholinergics, and 
anticonvulsants (within 2 weeks). 
(3) In the judgement of the investigator unable to comply with protocol 
requirements. 
(4) Significant gastrointestinal, renal, hepatic, bronchopulmonary, 
— 
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neurological, cardiovascular, oncologic or allergic diseases. Such 
significance is defined as a disease condition that requires hospitalization 
or prolongs the hospitalization within the past 2 years. 
(5) A history of significant drug hypersensitivity. 
3.3.3. Medication 
The patients were assigned to receive their allocated treatment - placebo or 
Wheeze-Relief Formula - according to a computerized generated 
randomization table. Patients aged 7 to 12 were prescribed 6 capsules (total 
1.8 g) (placebo or Wheeze-Relief Formula) daily. Those aged 13 to 15 were 
prescribed 8 capsules (total 2.4 g) (placebo or Wheeze-Relief Formula) daily. 
The entire treatment lasted for six months. E D T A venous blood were 
collected before and after the treatment for immunological studies. 
3.3.4. Informed Consent and Patient Information 
According to the local laws and the Good Clinical Practices (GCP) Guidelines, 
informed consent was obtained prior to the study. Parent signature in the 
consent form was obtained for patients w h o were younger than the age of 18. 
Oral consent was acceptable for patients or parents w h o were unable to read. 
In such circumstances, an independent witness, w h o had to be present 
during the entire oral informed consent discussion, would then sign the 
consent form. 
Patients and their parents would also be given information about the nature, 
significance and scope of the study, tests to be performed and potential risks 
(Please refer to Appendix). Patients and their parents would also be 
informed about their right to revoke their consent at any time, without an 
obligation to explain and without prejudice to their further treatment. 
— 
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3.4. Animals 
3.4.1. Maintenance 
Female BALB/c mice and ICR mice aged 4 -6 weeks weighing 20g and 25g 
respectively were used for the in vivo anti-tumor and immunomodul3tory 
experiments. They were grown under normal laboratory conditions (21 土 2 °C, 
12 hour light-dark cycle) in University animal house and fed with standard 
rodent chow and water ad libitum. 
3.4.2. Survival Experiment Using Erhlich Ascites Tumor Bearing ICR 
Mice 
Erhlich ascites tumor (EAT) cells (1 x 1cells/mouse) was injected intra-
peritoneally into 6-week-old female ICR mice. The oral feeding scheme is 
depicted in Figure 3.1. The mice were divided into 2 groups 1 day and 1 
week later: the untreated controls, and mice given T C M preparations at 40 
mg/kg/day (previous unpublished study). H E R B S n S E N S E S ™ Cordyceps (40 
mg/kg/day) was applied to the mice one day and one week after the tumor 
inoculation, which respectively mimicked the condition of early- and late-
stage malignancy. Mice fed with H E R B S n S E N S E S ™ Cordyceps was 
designated Group A suffixing -1 or -7，which respectively refers to the therapy 
start-day. Natural C. sinensis (40 mg/kg/day) was fed to the mice one day 
after the tumor injection and this was Group B mice. The untreated controls 
were fed with distilled water as the placebo. The mouse were weighed on the 
10th day after tumor inoculation. Number(s) of survived and dead mice were 
counted everyday for the calculation of mean survival days. Dead mice were 
removed immediately from the mice cohort. 
M e a n survival days = (E (No of dead mice x Day number)) / Total no. of mice 
— 
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Figure 3.1. Oral feeding scheme of EAT tumor-bearing ICR mice. 
3.4.3. Experiments of Immunomodulatory activity in Sarcoma 180 
Bearing BALB/c Mice 
Sarcoma 180 (SC-180) cells (1 x 10® cells/mouse) were injected 
subcutaneously into 6-week-old female BALB/c mice. The oral feeding 
scheme is illustrated in Figure 3.2. The mice were divided into 2 groups 7 
days later: untreated controls (Group 3) and mice given H E R B S n S E N S E S ™ 
Cordyceps at 40 mg/kg/day (Group 4). BALB/c mice without tumor burden 
were also divided into two s a m e groups: untreated controls (Group 1) and 
mice given H E R B S n S E N S E S ™ Cordyceps at 40 mg/kg/day (Group 2). The 
mice were fed either with distilled water (placebo) or T C M accordingly for 14 
days. It was finally sacrificed for blood, spleen and tumor collection and for 
the experiments of immunomodulatory activities. 
Female BALB/c Mice 
^ ^ ' — ^ ^ 
Normal SC-180 inoculated 
I , ‘ 1 J — — • , _ 5 1 _ 
Placebo HERBSnSENSES"^ Placebo HERBSnSENSES 
(Distilled Water) Cordyceps (Distilled Water) ™ Cordyceps 
^ • ~ — 1 • ^ I 
• 广 、 ( \ ( \ 
• Group 1 L Group 2 L Group 3 L Group 4 
‘ J V J V J V 乂 
Figure 3.2. Oral feeding scheme of BALB/c mice with or without tumor 
burden. 
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3.5. Methodology 
3.5.1. Preparation of the Traditional Chinese Medicine 
3.5.1.1. Hot Water Extraction of Water Soluble Fraction of Natural 
Cordyceps sinensis 
Lipopolysaccharide or endotoxin was minimized by washing the natural C. 
sinensis in autoclaved deionized water. The caterpillar fungus was then cut 
into fine pieces with a width of only 2-3 m m . These fragments were allowed 
to air-dry overnight. The weight was measured and heated at 80 °C for 4 
hours. Five parts of autoclaved deionized water was used for extraction of 
one part of C. sinensis. Any precipitates were removed by centrifugation at 
5000 g for 30 minutes. The clear brown supernatant was then filtered through 
0.2 [xm polyethersulfone filter. This solution was dried by lyophilization into 
powder form, which was finally re-constituted to 100 mg/mL using P B S 
(Gibco™ Invitrogen Corp). The re-constitution was again filtered through 
0.2 |Lim polyethersulfone filter and finally stored at -20 In vitro and in vivo 
experiments were ready. 
3.5.1.2. Hot Water Extraction of Water Soluble Fraction of 
HERBSnSENSES™ Corydceps and the Wheeze-relief Formula 
for In vitro Experiments 
The H E R B S n S E N S E S ™ Corydceps had been delivered in capsular form. 
Each capsule contained approximately 250 m g brown drug powder. The 
Wheeze-Relief Formula was capsulated into 300 m g yellowish-brown powder 
per capsule. The extraction process of H E R B S n S E N S E S ™ Corydceps and 
Wheeze-Relief Formula was similar to the natural C. sinensis. The powder 
was heated at 80 °C for 4 hours in autoclaved deionized water. For every 
250-300 m g drug powder, approximately 30 m L deionized water was used for 
the hot water extraction. Precipitates were removed by centrifugation (5000 g 
for 10 mins at room temperature). The supernatant was filtered through 
0.2 |im polyethersulfone filter. The solution was then lyophilized into powder 
— 
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form, which w a s eventually re-constituted to 10 m g / m L using P B S (Gibco™ 
Invitrogen Corp). This re-constitution was filtered through 0.2 ^ im 
polyethersulfone filter. The dilution was either stored at -20 or for further 
experiments. 
3.5.1.3. HERBSnSENSES™ Corydceps for the In Vivo Experiments 
The H E R B S n S E N S E S ™ Corydceps powder was diluted to 25 m g / m L in 
autoclaved deionized water. The suspension was then sonicated for 30 
minutes. It w a s stored in 4 before oral feeding to female BALB/c or female 
ICR mice. 
3.5.1.4. Extraction Efficiency of the Hot Water Extracts 
The extraction efficiency of hot water extraction was calculated by the 
following formula: 
Extraction efficiency 
=(Weight of Final Hot Water Extracts / Weight of Starting R a w T C M ) x 100 
% 
3.5.2. Limulus Ameobocyte Lysate Test 
The endotoxin level of the testing T C M was quantified by the QCL-1000® 
Chromogenic Limulus Amebocyte Lysate (LAL) Test (BioWhittaker, Inc). The 
experimental procedures were carried out as recommended in the kit 
protocol. Briefly, the T C M solutions were diluted serially from stock to 10 
different concentrations. The T C M samples and the endotoxin standards 
were aseptically dispensed into appropriate well in a 96-well micro-titer plate. 
LAL was added to each reaction well except the negative control. After 
incubation at 37 °C for 10 minutes, the colorless synthetic substrate was 
added in the same order. The enzymatic reaction was further allowed to 
process at 37 for 6 minutes and then stopped with acetic acid (25 %). In 
the presence of endotoxin, the proenzyme in the LAL was activated to 
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catalyze the splitting of the yellow p-nitroaniline of the substrate, thereby 
yielding a yellow color product. Absorbance was then read at 370nm with 
reference wavelength at 490nm. The concentration of endotoxin in the testing 
T C M were calculated by comparing with the standard curve. 
3.5.3. Cell Preparation 
3.5.3.1. Isolation of Human Peripheral Blood Mononuclear Cells, 
Lymphocytes and Monocytes 
Both lymphocytes and monocytes were isolated from the peripheral blood 
mononuclear cells ( P B M C ) in human buffy coat. The buffy coat contained a 
collection of white blood cells that appeared as a layer of thin white sediment 
after centrifuging blood. 
Fresh buffy coat was diluted in P B S (Gibco™ Invitrogen Corp) at a ratio of 
1:2. The diluted buffy coat was then overlayed on Ficoll™-Paque Plus 
solution (Amersham Pharmacia Biotech Ltd) in a 50 m L centrifuge tube, 
which w a s centrifuged without break at 500 g for 17 minutes at 4 The 
uppermost plasma layer was removed by careful suction. The thin white 
middle layer P B M C were collected and transferred into a 50 m L centrifuge 
tube. The P B M C were centrifuged and washed once by Cell-Wash Medium 
(1X P B S in 2 % Fetal Bovine Serum (FBS)) at 300 g for 5 minutes at 4°C. 
Any remaining red blood cells were 丨ysed by hypotonic shock in autoclaved 
deionized water. Sodium chloride (1.8 % ) (Sigma Chemicals Co) was 
immediately added at equal volume. The P B M C were centrifuged to remove 
salt at 300 g for 5 minutes at 4 The P B M C were similarly washed in Cell-
W a s h Medium. The P B M C were either resuspended to the desire density in 
R P M I 1640 Medium (Gibco™ Invitrogen Corp) supplemented with 10 % 
HIFBS (Hyclone Co) for direct experiments or continued for the further 
purification of monocytes and lymphocyts. The cleaned P B M C was 
resuspended in 50 m L R P M I 1640 Medium plus 10 % HIFBS. This cellular 
suspension was poured into a 75 cm^ culture flask and incubated for two 
hours at 37 in 5 % C〇2. Those cells appeared as suspension were 
lymphocytes while those adherent cells were monocytes. The viability of the 
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cells w a s checked by trypan blue exclusion assay (Section 3.5.9). Only those 
isolated cells with 95 % or above viability were resuspended to the target 
concentration for experiments. 
3.5.3.2. Isolation of Eosinophils 
Fresh buffy coat (Hong Kong Red Cross) was diluted 1:2 with P B S (Gibco™ 
Invitrogen Corp) and centrifuged using an isotonic Percol™ solution 
(Amersham Pharmacia Biotech Ltd) at 4 for 30 min at 1000 g. The 
eosinophil-rich granulocyte fraction was collected and washed twice with 
P B S containing 2 % FBS. The cells were then incubated with anti-CD16 
magnetic beads (Miltenyi Biotec) at 4 for 45 min, and CD16-positive 
neutrophils were depleted by passing through a LS+ column (Miltenyi Biotec) 
within a magnetic field. With this preparation, the drop-through fraction 
contained eosinophils with a purity of at least 98 % as assessed by 
Hemacolor rapid blood smear stain (E Merck Diagnostica). The isolated 
eosinophils were cultured in R P M I 1640 medium (Gibco™ Invitrogen Corp) 
supplemented with 10 % defined HIFBS (Hyclone Co) and 20 m M Hepes 
(Gibco™ Invitrogen Corp) (Wong et al, 2003). 
3.5.3.3. Isolation of Spleen Cells from BALB/c Mice 
Spleen was removed from the euthanized BALB/c mice by incision over the 
left lateral abdominal wall. The spleen was cut into small pieces on top of a 
70 |Lim nylon mesh, which was located in a petric dish filled with 10 m L R P M I 
1640 medium supplemented with 10 % HIFBS. The spleen was ground on 
the mesh by a sterile soft plastic capped pistol. The spleen cells passed 
through the mesh and immediately immersed in the medium. The spleen 
cells were thereby purified by overlaying on Fico丨丨-Pague™ solution 
(Amersham Pharmacia Biotech) at a ratio of 1:1 in a 50 m L centrifuge tube. 
Centrifugation for 17 mins at 500 g and 18 resulted in an observable cell 
gradient. The middle cloudy-white layer was carefully collected and 
transferred to a new 15 m L sterile centrifuge tube. Any remaining red blood 
cells were lysed by hypotonic shock and the cell suspension was washed by 
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Cell-Wash medium. The purified spleen cells were resuspended in R P M I 
1640 medium (Gibco™ Invitrogen Corp) plus 10 % HIFBS (Hyclone Co) for 
further experiments. 
3.5.3.4. Murine Ehrlich Ascites Tumor (EAT), PU5-1.8, and Sarcoma 
180 (SC-180) Cell Lines 
These cell lines were maintained in D - M E M medium (Gibco™ Invitrogen 
Corp) supplemented with 10 % HIFBS (Hyclone Co) and was passed for 
every 3 days. It w a s kept and incubated at 5 % C O 2 and 37 in a saturated 
water vapor atmosphere. The E A T and SC-180 grew as suspension while 
PU5-1.8 w a s mainly suspension but with certain degree of adherence. 
3.5.3.5. Human Eosinophilic Leukemic Cell Line (EoL-1) 
It was maintained in suspension form in R P M I 1640 medium (Gibco™ 
Invitrogen Corp) plus 10 % HIFBS (Hyclone Co) by subculturing every 3 to 4 
days, and kept by incubating at 5 % C O 2 and 37 in a saturated water vapor 
atmosphere. 
3.5.3.6. Human Hepatocarcinoma Hep-3B Cell Line 
The cell line was maintained in adherent form in D - M E M (Gibco™ Invitrogen 
Corp) plus 10 0/0 F B S (Hyclone Co) by subculturing every 3 to 4 days. 
Trypsin-EDTA was used for detaching the cells when subcultured. The 
subculture were kept in 5 % C O 2 incubator at 37 °C in a saturated water vapor 
atmosphere. 
3.5.3.7. Human Leukemic Cell Line (HL-60) 
The suspension cell line was maintained in R P M I 1640 medium (Gibco™ 
Invitrogen Corp) supplemented with 20 % HIFBS (Hyclone Co) and was sub-
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cultured every 3 to 4 days. It was kept in 5 % C〇2 incubator at 37 in a 
saturated water vapor atmosphere. 
3.5.3.8. Human Mast Cell Line {HMC-1) 
The cell line were maintained in suspension form in 丨 M D M (Gibco™ 
Invitrogen Corp) supplemented with 1.2 m M a-thioglycerol (Sigma Chemicals 
Co) and 1 0 % HIFBS (Hyclone Co). The cells were seeded at 2 x 10^ 
cells/mL density and recultured every 4 days. It was kept and incubated at 
5 % C〇2 and 37 °C in a saturated water vapor atmosphere. 
3.5.4. Collection of Mouse Serum and Human Plasma 
BALB/c mice fed with water or T C M were anaesthetized with intraperitoneal 
injection of sodium pentobarbital (0.8 mg/mouse) (Sigma Chemicals Co). The 
murine blood was collected from the carotid artery by using a syringe, and 
w a s eventually transferred to a sterile 1.5 m L centrifuge tube. H u m a n blood 
was collected from the cubitol vein and was then transferred to E D T A tubes. 
Serum and plasma were respectively separated from the murine clotted 
blood and the human E D T A blood by centrifugation for 10 minutes at 2000 g 
and 4 °C. The collected serum and plasma were re-centrifuged for another 5 
minutes at 2000 g and 4 to ensure they were cell-free. The cell-free serum 
and plasma were stored at -80 until experiments. 
3.5.5. Collection of Culture Supernatant 
Target cells (1 x 10® cells/mL) seeded in 24-well plate were incubated with 
mitogens and/or various concentrations of the respective T C M preparation 
for 18 - 20 hours. The cell suspension were centrifuged for 5 minutes at 300 
g and 4 twice to obtain cell-free supernantant. The supernantant was 
stored in -80 °C until experiments. 
— 
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3.5.6. The Trypan Blue Exclusion Assay 
Cytotoxicity of T C M preparations w a s evaluated by the trypan blue exclusion 
assay. Cells (1 x 10® cells/mL) seeded in 96-well plate were treated with the 
target T C M preparation or culture medium alone for 24 hours. The cellular 
co-culture (10 |LLL) w a s added in equal volume to the trypan blue dye (10 JUL) 
(Sigma Chemicals Co). This mixture was then loaded into the counting 
chamber of a hemacytometer. Distribution of the cells can be observed under 
a light microscope and cells located in the central 1 mm-square region were 
counted. Viable cells appeared translucent while dead cells were blue. The 
extent of cytotoxicity of the drug is calculated by the following equation: 
Percentage of viable cells 
=(Total no. of cells — No. of dead cells) / Total no. of cells x 1 0 0 % 
3.5.7. Colorimetric 5-bromo-2'-deoxyuridine (BrdU) Ceil Proliferation 
Enzyme Linked Immunosorbent Assay (ELISA) 
The BrdU Cell Proliferation ELISA (Roche Diagnostics G m b H ) was used to 
quantitate the mitogenic activities of cells treated in various mitogens and the 
respective T C M . The assay was carried out according to the procedures 
recommended in the kit manual. BrdU was loaded to the cultured cells and 
this co-culture was reincubated for another 24 hours. During the labeling 
period, the pyrimidine analogue, BrdU, was incorporated in place of 
thymidine into the D N A of proliferating cells. The culture medium was then 
removed by centrifugation at 300 g for 10 minutes to fix cells onto the plate. 
D N A was denatured in one step by incubating with FixDenat for 30 minutes. 
The antibody, anti-BrdU-POD was further added to bind with the incorporated 
BrdU. After incubation for 2 hours, the substrate solution was added to detect 
the immune complex. Absorbance was read at 405 n m with reference 
wavelength at 470 n m . Cell proliferation was calculated by using the following 
formula: 
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Cell Proliferation 
=((Absorbance of treated cells - Absorbance of control cells) / Absorbance of 
control cells) x 100 % 
3.5.8. Immunophenotyping 
Cells at the final density 1 x 10® cells/mL were incubated for 18-20 hours with 
various concentrations of T C M . The co-culture (5 x 10^ cells) was then 
harvested and washed with F A S C Medium by centrifugation at 300 g for 5 
minutes. The cell pellet was re-suspended by 100 |LIL F A S C medium. H u m a n 
pooled serum (3 % ) w a s added to incubate for 20 minutes at 4°C for blocking 
non-specific binding sites. For direct immunofluorescent staining, the cells 
were incubated either with FITC-conjugated mouse anti-human (or anti-
mouse in the BALB/c mice experiments) monoclonal antibody or the 
corresponding fluorescein-conjugated mouse IgG Isotype for 30 min at 4°C in 
dark. For indirect immunofluorescent staining, the cells were first incubated 
with either purified mouse anti-human monoclonal antibody or mouse IgG 
Isotype for 30 min at 4°C, followed by the addition of a FITC-conjugated anti-
mouse secondary antibody (1:200) for another 30 min at 4°C in dark. The cell 
mixture was similarly washed by centrifugation and was finally resuspended 
by 400 |liL paraformaldehyde (1 %)• The cell surface antigens were ready to 
be analyzed by flow cytometer using the software CellQuest™ (BD 
Pharmingen Corp). A total of 10000 events (gated to exclude non-viable cells) 
were collected in the log m o d e and expressed as histograms of relative 
fluorescence intensity. 
3.5.9. The Cytometric Bead Array (CBA) Kits 
H u m a n inflammation cytokine and human chemokine C B A kits (BD 
Pharmingen Corp) were used to measure the inflammatory cytokines 
including IL-ip, IL-12p70, TNFa, IL-6, IL-10 and IL-8，and the chemokines 
including IL-8, R A N T E S , MIG, MCP-1 and IP-10, respectively. Mouse 
inflammation C B A kit was used for assaying mouse inflammatory cytokines 
including IL-6, IL-10, MCP-1, IFNy, T N F a and IL-12p70, and mouse Th1/Th2 
— 
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C B A kits w a s for the detection and quantification of cytokines IL-2,丨1_-4，IL-5, 
IFNy, and T N F a . 
The procedures were carried out according to the standard protocol provided. 
The C B A kits contained bead populations with distinct fluorescence 
intensities and have been coated with capture antibodies specific for the 
proteins under testing. Samples and standards were mixed with both capture 
beads and PE-conjugated detection antibodies and were incubated for two 
(mouse C B A kits) and three (human C B A kits) hours to form a sandwich 
complex. The sample/standard-antibodies-beads complex was washed by 
Buffer F by centrifugation at 200 g for 5 mins. The complex was eventually 
re-suspended and w a s ready for data acquisition by using flow cytometry. 
The concentration of cytokines was calculated by C B A software (BD 
Pharmingen Corp). 
3.5.10. Intracellular Florescence Staining for Reactive Oxygen 
Species 
The isolated monocytes (1 x 10® cells/mL) were incubated with various 
concentrations of T C M or merely culture medium for 3 hours. The co-culture 
(5x10^ cells) was collected in 12 x 75 m m sample acquisition tubes for flow 
cytometry. The non-florescent dye dihydrorhodamine-123 (DHR, 1 jug/mL) 
(Molecular Probe Europe BV) was incubated with the cells for 15 minutes in 
dark at 4 D H R was readily taken up by the phagocytes during respiratory 
burst and was converted to a green florescent compound. The extent of 
florescence intensity quantitated the reactive oxygen species (ROS) 
produced by the activated monocytes, and thereby determining the in vitro 
effects of T C M on macrophage function. Such intensity was measured by 
flow cytometry using the CellQuest™ Programme (BD Pharmingen Corp) 
(Emmendorffer et al, 1990). 
— 
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3.5.11 _ The Intracellular Zymosan Florescence Assay 
The isolated monocytes (1 x 10® cells/mL) were primed to macrophages 
under the stimulation of L P S (20 ^ig/mL) for 2 hours. Various concentrations 
of T C M or merely culture medium were added to allow incubation for 18 
hours. The macrophage (5 x 10^ cells) was collected in 5 m L 12 x 75 m m 
sample acquisition tubes for flow cytometry. The FITC-conjugated zymosan 
(15 ]Lig/mL) (Sigma Chemicals Co) was then added and incubated with the 
cells for 30 minutes in dark at 37 °C. The FITC-conjugated zymosan was 
phagocytosed by the macrophages. The florescence taken up by the 
macrophages w a s then measured by flow cytometry using the CellQuest™ 
Programme (BD Pharmingen Corp). 
3.5.12. Total Cellular RNA Extraction 
P B M C (5x10® cells) were treated with appropriate concentration of T C M for 
24 hours. Total R N A in P B M C was extracted by using the R N e a s y ® Total 
R N A Kit (Qiagen G m b H ) . The procedures were carried out according to the 
standard protocol provided by Qiagen. Briefly, the cells were first disrupted by 
adding the highly denaturing guanidine isothiocyanate (GITC)-containing 
Buffer RLT with (3-ME (1 %). The lysate were homogenized by passing 
through a 21-gauge needle-capped syringe at least five times. To optimize 
binding condition, equal volume of ethano丨（70 % ) was pipetted and mixed 
thoroughly with the homogenized lysate. Aliquots of this mixture were loaded 
successively onto an RNeasy mini column placed on a 2 ml collection tube 
and was centrifuged at 10000 g for 15 s. The flow-through fraction was 
discarded. To ensure the extracted R N A is DNA-free, DNase ! incubation mix 
was incubated on the silica-gel membrane of the RNeasy mini column for 15 
minutes in room temperature. Buffer R W 1 was further added into the column 
and the tube-colume set was centrifuged at 10000 g for 15 s. Contaminant 
was finally removed by adding Buffer R W 1 and R P E into the column and 
similarly centrifuged the colume-tube set. This washing step was repeated 
but prolonging the centrifugation to 2 mins at 10000 g. The collection tube 
was replaced with a pyrogen-free, DNase-free and RNase-free 1.5-mL 
— 
Chapter 3 - Materials and Methods 
collection tube. To elute the R N A adsorbed on the silica-gel membrane of the 
column, RNase-free water (32 |iL) was carefully added and the set was 
briefly centrifuged at 10000 g for 1 min. R N A concentration w a s determined 
by measuring the absorbance (A) at 260 n m . Experiments were proceeded 
only if the sample purity is assured (A260/A280 ratio around 1.8 to 2). The 
ready-to-use R N A was then frozen at -70。C until use. 
3.5.13. Gel Electrophoresis of RNA Integrity 
The integrity of total R N A was further confirmed by gel electrophoresis. Total 
R N A sample (2 |LIL) was mixed with gel loading buffer (2 LUL) (Sigma 
Chemicals Co) and RNase free water (6 |LIL). The sample mixture was loaded 
on agarose gel (1 % ) (Invitrogen Corp) stained with ethidium bromide (0.005 
0/0) (Invitrogen Corp), which was buffered in T A E solution (1x, pH 8.0). The 
size marker, D N A 100 bp ladder marker (0.5 |Lig) (Invitrogen Corp), was 
loaded similarly. Electrophoresis was started and maintained constantly at 
100 volts until the minute. The banding pattern of the gel was visualized 
under U V illumination. Samples with bands identified other than 18 s and 28 
s R N A were discarded and discontinued for further experiments. 
3.5.14. cDNA Expression Array 
Non-radioactive GEArray^^ Q-series Kits (Superarray Bioscience Corp) were 
used in conjunction with the GEArray^^ Probe Synthesis (AmpoLabeling-LPR) 
Kit (Superarray Bioscience Corp) to quantify the gene expression profiles of 
the treated cells. The procedures were carried out strictly according to the kit 
protocols. Briefly, the c D N A probe was synthesized by using total R N A (3 jug) 
as a template. The R N A was reverse-transcribed by gene-specific primers 
with biotin-16-dUTP. The Biotinylated c D N A probes were eventually 
denatured and added to the hybridization solution. The GEArray™ 
membranes were printed with gene-specific c D N A fragments with tetra-spot 
format. The membranes were pre-hybridized at 60 for 2 hours then 
hybridized overnight with the ready biotinylated c D N A probes. The 
membranes were washed and blocked with G E A blocking solution, and 
subsequently incubated with alkaline phosphatase conjugated streptavidin. 
— 
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The hybridized biotinylated c D N A probes were detected by the alkaline 
phosphatase substrate, CDP-Stai^ using the chemiluminescent method. The 
results were analyzed by using Bio-Rad Quantity O n e ™ software (Bio-Rad). 
The relative expression levels of a gene were estimated by comparing its 
signal intensity with the p-actin internal control. 
3.5.15. Cell Staining Using Cytospin 
Cytocentrifuge preparation was commonly used to examine the 
morphological changes of cells after treatment. The investigating tumor cells 
were co-cultured with appropriate concentration of T C M for 24 hours. The 
treated cells (5 x 10"^ ) were harvested and pipetted into the cytocentrifuge 
set — a plastic channel on a microscopic slide, with a piece of filter paper in 
between. The whole set were centrifuged by Shandon Cytospin 3 Centrifuge 
(Thermo Electronic Corp) at 300 rpm for 3 minutes to fix cells on the slide. 
The air-dried cells were then stained with the Hemacolor™ staining kit (E 
Merck Diagnostica) and mounted with Canada Balsam (Sigma Chemicals 
Co). The morphology of the cells could then be visualized in Nikon Eclipse 
E800 microscope (Nikon Corp). 
3.5.16. Annexin V-FITC/Propidium Iodide Apoptosis Detection 
T A C S ™ annexin V-FITC/propidium Iodide staining kit (Trevigen Inc) was 
used to quantify the percentage of apoptotic cells after T C M treatment. The 
procedure was carried out according to the protocol provided. Briefly, tumor 
cells were co-cultured with appropriate concentrations of T C M for 18 hours. 
The treated cells (3 x 10^) were collected in a 5 m L 12 x 75 m m sample 
acquisition tubes for flow cytometry. It was washed with cold P B S (1x) by 
centrifugation at 300 g for 5 minutes. Annexin V Incubation Reagent was 
then added to the treated cells and incubation was allowed for 15 minutes in 
dark and in room temperature. Binding buffer (1x) was finally added to each 
sample and analysis by the FACSCalibur™ flow cytometer was immediately 
started using software CellQuest (BD Pharmingen Corp). 
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3.5.17. Weighing the Spleen and Tumor 
Spleen w a s removed from the euthanized mice by incision over the lower left 
lateral abdominal wall. Solid tumor SC-180 w a s separated from the 
subcutaneous level. The weight of both spleen and tumor were measured by 
electronic balance. 
3.5.18. Preparing Samples for the Eosinophilic Cationic Protein 
Fluoroenzymeimmunoassay 
Eosinophils (1 x 10® cells/mL) were initially primed with G M - C S F (50 rig/ml) 
(Pepro Tech E C Ltd) 20 mins in prior to P A F (lOjuM) (Calbiochem Corp). The 
activated eosinophils were then co-cultured with different concentrations of 
Wheeze-Relief Formula for 18-24 hours. Supernatant w a s harvested by 
centrifuging the cell suspension for 5 mins at 300 g and 4°C. To neutralize 
the cationic charges exerted by E C P , the supernatant was collected and 
stored in tubes containing 0.3 % C T A B . The T C M inhibition on E C P release 
was quantified by Pharmacia C A P System ™ Specific IgE FEIA (Pharmacia 
Diagnostics AB). 
3.5.19. Statistical Analysis 
All numerical data were analysed using the Mann-Whitney U test or Kruskal-
Wallis test for non-parametric variables, and by unpaired student t test for 
parameters showing normal distribution. The longitudinal changes in plasma 
concentrations of IL-18，TARC, IFNy, TNFa, E D N , and IgE in asthmatic 
patients before and after Wheeze-Relief Formula treatment were also 
compared pairwise by Wilcoxon signed ranks test. The statistical analysis 
were performed by using the Statistical Package for the Social Sciences 
(SPSS) statistical software for Windows, version 11.5 (SPSS Inc, IL, USA). 
Statistical significance was only considered when p < 0.05. 
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Extraction, Endotoxin Measurement， 
In Vitro Cytotoxicity testing, and 
the Selection of Optimal Concentration 
4.1. Extraction efficiency 
4.1.1. Introduction 
To mimic the Chinese tradition, the water soluble ingredients of Cordyceps 
sinensis, H E R B S n S E N S E S ™ Cordyceps and the Wheeze-Relief Formula 
were extracted by hot-water extraction method (Section 3.5.1). 
4.1.2. Results 
As shown in table 4.1，the extraction efficiency was found to be 23.39 土 1.71 
% , 43.93 土 4.19 % , and 48.11 土 1.34 % respectively for natural C. sinensis， 
H E R B S n S E N S E S ™ Cordyceps, and Wheeze-Relief Formula. These results 
were based on three separate experiments. 
Before After 
Yield, % 
TCM Extraction, g Extraction, 
(Mean±SD) 
(Mean±SD) g(Mean±SD) 
Natural C. sinensis 12.5 土 0.3 2.92 土 0.21 23.39 土 1.71 
HERBSnSENSES^'^ 
0.27 ±0.01 0.12 ±0.01 43.93 ±4.19 
Cordyceps 
Whfeeze-Flelief 
:: 0.31±0.02 0.15±0.02 48.65 ± 3.62 
Formula 
Table 4.1. The extraction efficiency of natural C. sinensis, 
HERBSnSENSES^'^ Cordyceps, and Wheeze-Relief Formula. 
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4.2, Endotoxin Level 
4.2.1. Introduction 
Western medicines are usually purified chemical compounds produced by 
clean and qualified machinery, whereas the herbs used in T C M mainly c o m e 
from cultivated plants. T C M are therefore more susceptible to the 
contamination of G r a m negative bacteria, such as Escherichia coli and 
Salmonella. The G r a m negative bacteria compose of lipopolysaccharide (LPS) 
on the outer membrane of their cell wall. Such L P S complex consists of lipid A 
and polysaccharide, in which the former is largely attributed to endotoxin. 
Lethal dosage of endotoxin can culminate in sepsis and lethal shock. 
Sublethal dosage also stimulates the host immune responses (Peterson and 
Baron, 1996). Therefore, the endotoxin level of T C M should be determined 
first to (1) prove its safety and (2) ensure the resulting immunomodulation is 
contributed by the studied T C M alone. 
Currently, there are only two assays available for endotoxin measurement, 
namely, the Limulus ameobocyte lysate (LAL) test and the rabbit pyrogenicity 
test. The LAL test is more c o m m o n , sensitive and less expensive (Peterson 
and Baron, 1996). It was known that amebocyte is the sole phagocytic 
immune cell of the Horseshoe crab, Limulus polyphemus. Upon contact with 
the gram-negative bacteria, ameobocyte activates a proenzyme which 
ultimately leads to protein clotting (Levin and Bang, 1964). This enzymatic 
reaction ultimately leads to a color change which can be measured 
quantitatively (Section 3.5.2). 
4.2.2. Results and Interpretation 
Endotoxin contained in natural C. sinensis was found to be < 0.02 EU/mg 
using LAL test. By tradition, C. sinensis is usually prescribed between 4.5 to 
12 g (Bensky, 1993)> Therefore, the amount of endotoxin contained in the 
heaviest prescription (12 g) was < 240 ELL Experiments also showed that 
endotoxin contained in H E R B S n S E N S E S ™ Cordyceps was < 0.6 EU/mg. As 
a H E R B S n S E N S E S ™ Cordyceps capsule composed of 250 m g drug powder, 
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the endotoxin contained in each capsule was < 150 E U . The Wheeze-Relief 
Formula contained 300 m g drug powder per capsule. Its endotoxin level was 
estimated to be < 1 EU/mg and subsequently there were < 300 E U endotoxin 
per capsule. 
According to the Food and Drug Administration (FDA) in the United States, 
there is only set endotoxin limit for parenteral drug but not orally administered 
medicine. The safety of Cordyceps sinensis, H E R B S n S E N S E S ™ Cordyceps 
and Wheeze-Relief Formula, which all are oral drug, can only be predicted 
from the regulation for parenteral drug. F D A stated the maximal endotoxin 
that can be administered per hour without eliciting a pyrogenic response is 5 
EU/kg body weight. W h e n taking the average human weight to be 70 kg, a 
whole body dose of endotoxin is found to be 350 EU/hour. From our 
experiments, the endotoxin of C. sinensis (< 240 EU), H E R B S n S E N S E S ™ 
Cordyceps (< 150 EU), and Wheeze-Relief Formula (< 300 E U ) was much 
lower than this parenteral drug limit. Moreover, because of the less direct 
administration, pyrogenic responses triggered by the s a m e amount of 
endotoxin are less serious and rapid in oral drug than parenteral drug. The 
endotoxin levels in our investigating T C M s were therefore low enough for the 




Cytotoxicity is the degree to which something is toxic to living cells. Drugs with 
anti-tumor potential m a y possess cytotoxicity. With the hypothesis that C. 
sinensis and H E R B S n S E N S E S ™ Cordyceps m a y exert immunomodulatory 
or specifically anti-tumor activities, cytotoxicity tests were performed to 
confirm whether such pharmaceutical potential was due to direct cell killing. 
Trypan blue dye exclusion is one of the methods to estimate cytotoxicity 
(Kalthenbach et al, 1958). Trypan blue is an acid blue dye. The chromophore 
is negatively charged and reacts only when the cell membrane loses its 
— 
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permeability, as in dead cells. Therefore, non-viable cells appear blue while 
viable cells remain translucent when view under microscope (Phillips et al, 
1957). Cytotoxicity of C. sinensis, H E R B S n S E N S E S ™ Cordyceps and 
Wheeze-Relief Formula on P B M C and the cytotoxicity of Wheeze-Relief 
Formula on eosinophils were evaluated by trypan blue exclusion assay 
(Section 3.5.6). 
4.3.2. Results and Interpretation 
Figure 4.1-2 shows that all three T C M preparations exerted in vitro 
cytotoxicity in a dose dependent manner. The increasing concentration of 
T C M w a s accompanied by an increasing number of cell deaths. 
4.3.2.1. Peripheral Blood Mononuclear Cells (PBMC) 
As shown in Figure 4.1，C. sinensis, H E R B S n S E N S E S ™ Cordyceps and 
Wheeze-Relief Formula at 1 mg/mL induced cell death respectively at the 
percentages 6.99 土 3.29，7.58 土 3 and 3.26 土 0.79. However, at 5 mg/mL, the 
percentages of dead cells were raised to 23.38 土 5.37 % , 37.13 土 8.26 % and 
31.67 土 3.98 %，respectively for the C. sinensis, H E R B S n S E N S E S ™ 
Cordyceps and Wheeze-Relief Formula. 
4.3.2.2. Eosinophils 
Figure 4.2 shows that Wheeze-Relief Formula similarly possessed 
dose-dependent cytotoxicity on eosinophils. The percentages of dead cells 
were 9.06 土 7.17 and 25.71 土 7.48 at 1 mg/mL and 5 mg/mL, respectively. 
Cytotoxicity is inversely proportional to the viability of cells. The lower the 
cytotoxicity exerted by the T C M , the greater the viability of cells for that 
respective T C M . Results indicated that all the three T C M s retained P B M C 
and eosinophil viability over 70 % at concentration 5 mg/mL. The optimal 
range of test doses in the functional assays would be most appropriate if < 5 
mg/mL. 
— 
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Figure 4.1-2 shows that T C M at high concentration m a y induce cell death. 
This m a y be accounted for by the increasing viscosity in the culture medium 
which resulted in physical inhibition, or the increasing concentration of 
unidentified inhibitory components present in the hot water extract. 
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Figure 4.1. Cytotoxicity of (a) Cordyceps sinensis, (b) 
HERBSnSENSES™ Cordyceps and (c) Wheeze-Relief Formula on PBMC. 
P B M C (1 X 10 6 cell/mL) were cultured with various concentrations of (a) C. 
sinensis, (b) H E R B S n S E N S E S ™ Cordyceps and (c) Wheeze-Relief Formula 
for 18 hours. The cytotoxicity was evaluated by trypan blue exclusion assay. 
Results were presented by mean 士 S D of triplicate experiments. 
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Figure 4.2. Cytotoxicity of Wheeze-Relief Formula on eosinophils. 
Eosinophils (1 x 10 ® cell/mL) were cultured with various concentrations of 
Wheeze-Relief Formula for 18 hours. The cytotoxicity was evaluated by 
trypan blue exclusion assay. Results were presented by m e a n 士 S D of 
triplicate experiments. 
_ _ — 
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4.4. The Optimal Concentration (OC) 
4.4.1. Introduction 
The optimal concentrations (OC) of natural C. sinensis, H E R B S n S E N S E S ™ 
Cordyceps and Wheeze-Relief Formula on P B M C , and that of Wheeze-Relief 
Formula on eosinophils, were evaluated by BrdU proliferation E U S A (Section 
3.5.7). By plotting percentage of proliferative cells vs log drug's concentration 
as the dose-response curve (Figure 4.3-4), the O C can be titrated, which m a y 
suggest the best test dose used in the functional assays. 
4.4.2. Results and Interpretation 
As shown in Figure 4.3, C. sinensis at around 3 mg/mL, H E R B S n S E N S E S ™ 
Cordyceps at around 1 mg/mL, and Wheeze-Relief Formula < 0.8 mg/mL 
exerted neither proliferative nor inhibitory effects on P B M C . The neutral 
effects exerted at the mentioned concentrations were useful for clearly 
elucidating parameters in the latter described functional assays. In addition, 
the above trypan blue exclusion assay supported well that these 
concentrations retained cell viability up to 80 % . C. sinensis at 3 mg/mL, 
H E R B S n S E N S E S ™ Cordyceps at 1 mg/mL and Wheeze-Relief Formula at 
0.5 mg/mL subsequently became our basic test dose and optimal 
concentrations (OC) for the in vitro P B M C study. 
Figure 4.4 demonstrates that the Wheeze-Relief Formula inhibited eosinophil 
proliferation at all dosages tested (0.2 mg/mL to 5 mg/mL). Because 
anti-asthmatic drugs m a y target at the reduction of eosinophil activities and 
count, the concentration at which Wheeze-Relief Formula inhibited 50 % 
eosinophil to proliferate was 1 mg/mL and was suggested as the O C or basic 
test dose for the functional assays. 
In addition, a series of concentrations higher and lower than the basic test 
dose were included in the functional assays for elucidating any dose 
dependence exerted by the T C M preparations. 
“ ^ 
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Figure 4.3. Dose-response curve of (a) natural C. sinensis and (b) 
HERBSnSENSES™ Cordyceps (c) Wheeze-Relief Formula on PBMC. 
P B M C (1 X 10 6 cell/mL) were cultured with various concentrations of (a) C. 
, sinensis, (b) H E R B S n S E N S E S ™ Cordyceps and (c) Wheeze-Relief Formula 
for 18 hours. The percentage of cell proliferation was evaluated by BrdU 
Proliferation ELISA. The dose-response curve was plotted by cytotoxicity vs 
the logarithmic T C M concentration. 
— 
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Figure 4.4. Dose-response curve of Wheeze-Relief Formula on 
eosinophils. Eosinophils (1 x 10 ® cell/mL) were cultured with various 
concentrations of Wheeze-Relief Formula for 18 hours. The percentage of cell 
proliferation was evaluated by BrdU Proliferation ELISA. The dose-response 






Mitogens are agents capable of inducing mitosis or cell transformation. 
Lipopolysaccharide (LPS) present on the G r a m negative bacterial cell wall 
and phytohaemaglutinin (PHA), a lectin most commonly extracted from red 
kidney bean Phaseolus vulgaris, are two typical mitogens which can stimulate 
proliferation of peripheral blood mononuclear cells (PBMC). Reports have 
shown that P H A preferentially possesses mitogenic stimulation to 
T-lymphocytes (Nowell, 1960; Ozato et al, 1975) while L P S is more prone to 
enhance B-lymphocytes and monocytes (Petit and Unanue, 1974). Agents 
counteracting these mitogenic effects m a y be immunosuppressive in the 
immune milieu, which m a y implicate therapeutic value in, for example, 
auto-immune diseases. The present study screened for our hypothesis that 
natural C. sinensis and H E R B S n S E N S E S ™ Cordyceps possess their 
immunomodulatory activities through the achievement of homeostasis in the 
abundance of immune effector cells. 
Mitogenic activity of C. sinensis and H E R B S n S E N S E S ™ Cordyceps were 
assessed by BrdU Cell Proliferation ELISA (Section 3.5.7). A total of four 
P B M C groups were treated with various concentrations of C. sinensis and 
H E R B S n S E N S E S ™ Cordyceps. These groups were the normal, LPS- or 
PHA-activated, and LPS and P H A co-activated P B M C . The normal group was 
the control for the experiment. The LPS and P H A co-activated group was to 
test for any synergistic effects possessed. 
5.2. Results 
Both C. sinensis and H E R B S n S E N S E S ™ Cordyceps promoted P B M C 
proliferation dose-dependently (Figure 5.1-2). As shown in Figure 5.1，C. 
Chapter 5 - Mitogenic Activity 
sinensis exerted mitogenicity to normal P B M C at concentrations lower than 3 
mg/mL, but such mitogenicity was gradually retarded at higher dosages (> 3 
mg/mL). Similarly, H E R B S n S E N S E S ™ Cordyceps proliferated normal P B M C 
at low dosages (< 1 mg/mL), but such mitogenicitiy was reduced at higher 
dosages (> 1 mg/mL) (Figure 5.2). Proliferation of all groups of 
mitogen-activated P B M C were analogously suppressed by C. sinensis and 
HERBSnSENSES丁M Cordyceps at nearly all dosages tested. Mitogenicity 
possessed by C. sinensis (< 500 i^g/mL) on LPS-activated P B M C m a y only be 
an artifact because the percentage of cell proliferation was less than 10 % 
with up to 10 % standard deviation. 
5.3. Discussion 
Results indicates that C. sinensis (< 3 mg/mL) and H E R B S n S E N S E S ™ 
Cordyceps (< 1 mg/mL) were mitogens to basal unstimulated cells. C. 
sinensis and H E R B S n S E N S E S ™ Cordyceps m a y therefore enhance the 
immunity by heightening number of immune effecter cells such as T cells. T 
cells conduct the immune responses by activating macrophages from the 
innate immunity for pathogen engulfment and removal, and inducing 
antibodies synthesis from B cells for adaptive humoral immune responses. 
This result implicates the therapeutic value of C. sinensis and 
H E R B S n S E N S E S ™ Cordyceps in preventing infectious diseases, probably 
by improving firewalls of the body's defence. Conversely, C. sinensis and 
H E R B S n S E N S E S ™ Cordyceps remarkably suppressed the 
mitogen-activated cells. The two T C M preparations tended to push back the 
over-excited cells to the basal state by strongly inhibiting their cell proliferation. 
Therefore, C. sinensis and H E R B S n S E N S E S ™ Cordyceps m a y also exert 
medicinal implications to detrimental conditions like autoimmune diseases 
and leukemia, which are triggered by the tremendous and un-controlled 
production of immune effecter cells. 
Chapter 5 - Mitogenic Activity 
8 0 . 0 0 -1 
_ 6 0 . 0 0 -
2 40.00 - ill I T 
- c 20.00 - m T _ i . 
7 •芸 0.00 I I M r ^ M I ' m I I jj^m I _ I ‘ i^m ‘ ‘ 
^ 2 -20.00 - - ^^  - p m m _ 乡_ m _ _ 
^ ^ -40.00 ^ ---- f ； • _ M 1 1 i 
I 2 -60.00 - 丄T … . . . I i _ _ 11 _ 
S -80.00 — 丄 T 卻 \ M 11 m 
O -100.00 — 丄 T T i y p j 
- 1 2 0 . 0 0 -
-140.00 J 
0.05 0.1 0.2 0.5 1 2 3 6 12 25 50 
[Cordyceps] mg/mL 
• Control P B M C 0 LPS-activated P B M C 
固 PHA-activated P B M C B LPS- and PHA-activated P B M C 
Figure 5.1. Mitogenic activity of natural C. sinensis on PBMC. PBMC (1 x 
10® cells/mL) were treated with culture medium, or LPS (20 jig/mL), or P H A (4 
|ig/mL), or L P S and P H A for 1 hour before the addition of natural C. sinensis. 
The cellular suspension was incubated for 22 hours before performing BrdU 
Prolfieration ELISA, which was used for the quantification of cell proliferation. 
The percentage of cell proliferation was obtained by comparing the treated 
cell groups with their respective controls. Results were presented as m e a n 士 
S D of triplicate experiments. 
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Figure 5.2. Mitogenic activity of HERBSnSENSES™ Cordyceps on PBMC. 
P B M C (1 X 10® cells/mL) were treated with culture medium, or L P S (20 
lig/mL), or P H A (4 lug/mL), or LPS and P H A for 1 hour before the addition of 
H E R B S n S E N S E S ™ Cordyceps. The cellular suspension was incubated for 
22 hours before the start of BrdU Prolfieration ELISA, which was used for the 
quantification of cell proliferation. The percentage of cell proliferation was 
obtained by comparing the treated cell groups with their respective controls. 
Results were presented as mean 士 S D of triplicate experiments. 
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6.1. Introduction 
Cytokines are important soluble signaling molecules that participate and 
coordinate immune responses (Xing et al, 1999). They are usually 
glycosylated extracellular signaling proteins, which usually have less than 80 
kDa in size. They are produced de novo in response to an immune stimulus 
and act by binding to specific membrane receptors (Decker, 2003). They act 
on target cells to cause a wide array of cellular functions including activation, 
proliferation, chemotaxis, immunomodulation, release of other cytokines or 
mediators, growth and cell differentiation, and apoptosis. W e postulated that 
G. sinensis and H E R B S n S E N S E S ™ Cordyceps m a y also exert their 
immunomodulatory activities through the induction of cytokines. In the present 
study, an in vitro system involving human periperhal blood mononuclear cells, 
lymphocytes and monocytes from healthy individuals were constructed for the 
investigation of cytokine induction by C B A (Section 3.5.9), cell surface 
expression of cytokine receptor IL-2 receptor a by immunophenotyping 
(Section 3.5.8), and gene expression of cytokines and cytokine receptors by 
c D N A expression array (Section 3.5.14). 
6.2. Results 
6.2.1. Effects of Natural Cordyceps sinensis and HERBSnSENSES™ 
Cordyceps on the Induction of Cytokines from Lymphocytes 
6.2.1.1. TNFa 
Both C. sinensis and H E R B S n S E N S E S ™ Cordyceps dose dependently act 
on TNFa release from lymphocytes. As shown in Figure 6.1，C. sinensis 
progressively heightened TNFa liberation at increasing dosages. Conversely, 
_ — 
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the higher the concentration of H E R B S n S E N S E S ™ Cordyceps, the lesser 
T N F a w a s generated from lymphocytes (Figure 6.2). W h e n compared to the 
negative control, C. sinensis and H E R B S n S E N S E S ™ Cordyceps significantly 
stimulated T N F a production from all dosages examined (p<0.05). 
6.2.1.2. IL-6 
As shown in Figure 6.3，C. sinensis enormously elevated the IL-6 release 
from lymphocytes. W h e n compared to the negative control, statistical 
significances were obtained in all treatment groups (p < 0.05). Figure 6.4 
shows the dose-dependent effect of H E R B S n S E N S E S ™ Cordyceps on the 
generation of IL-6 from lymphocytes. The higher the concentration of 
H E R B S n S E N S E S ™ Cordyceps, the lesser the IL-6 was produced from 
lymphocytes. All treatment groups demonstrated statistical significance when 
compared each to the negative control (p < 0.05). 
6.2.1.3. IL-10 
Figure 6.5 demonstrates that C. sinensis enhanced the induction of IL-10 from 
lymphocytes in a dose-dependent manner. At 5 mg/mL, the production of 
lymphokine IL-10 was regressed when compared to C. sinensis < 5 mg/mL. 
All treatment groups demonstrated statistical significance when compared 
each to the negative control (p < 0.05). As shown in Figure 6.6， 
H E R B S n S E N S E S ™ Cordyceps induced the IL-10 release dose-dependently. 
The higher the concentration of H E R B S n S E N S E S ™ Cordyceps, the lesser 
IL-10 was produced from lymphocytes. H E R B S n S E N S E S ™ Cordyceps at 0.5 
m g / m L demonstrated significant difference when compared to the negative 
control (p < 0.05). 
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Figure 6.1. In vitro effects of natural Cordyceps sinensis on the 
induction of TNFa from lymphocytes. Lymphocytes (1x10® cells/mL) were 
incubated with medium or different concentrations of C. sinensis for 20 hours. 
Supernatant was collected for T N F a assay using C B A . Experiment was 
repeated five times. The box-plot was plotted by concentration of TNFa vs 
concentration of C. sinensis. Treatment groups were compared with the 
control for statistical significance using Kruskal-Wallis test. 
* p < 0.05，A outliner. 
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Figure 6.2. In vitro effects of HERBSnSENSES™ Cordyceps on the 
induction of TNFa from lymphocytes. Lymphocytes (1 x 10^ cells/mL) were 
incubated with medium or different concentrations of H E R B S n S E N S E S ™ 
Cordyceps for 20 hours. Supernatant was collected for TNFa assay using 
C B A . Experiment was repeated five times. The box-plot was plotted by 
concentration of TNFa vs concentration of H E R B S n S E N S E S ™ Cordyceps. 
Treatment groups were compared with the control for statistical significance 
using Kruskal-Wallis test. * p < 0.05 
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Figure 6.3. In vitro effects of natural Cordyceps sinensis on the 
induction of IL-6 from lymphocytes. Lymphocytes (1 x 10® cells/mL) were 
incubated with medium or different concentrations of C. sinensis for 20 hours. 
Supernatant was collected for IL-6 assay using C B A . Experiment was 
repeated five times. The box-plot was plotted by concentration of IL-6 vs 
concentration of C. sinensis. Treatment groups were compared with the 
control for statistical significance using Kruskal-Wallis test. * p < 0.05 
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Figure 6.4. in vitro effects of HERBSnSENSES™ Cordyceps on the 
induction of IL-6 from lymphocytes. Lymphocytes (1x10® cells/mL) were 
incubated with medium or different concentrations of H E R B S n S E N S E S ™ 
Cordyceps for 20 hours. Supernatant was collected for IL-6 assay using C B A . 
Experiment was repeated five times. The box-plot was plotted by 
concentration of IL-6 vs concentration of H E R B S n S E N S E S ™ Cordyceps. 
Treatment groups were compared with the control for statistical significance 
using Kruskal-Wallis test. * p < 0.05; ^  outliner. 
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Figure 6.5. In vitro effects of natural Cordyceps sinensis on the 
Induction of IL-10 from lymphocytes. Lymphocytes (1x10® cells/mL) were 
incubated with medium or different concentrations of C. sinensis for 20 hours. 
Supernatant was collected for IL-10 assay using C B A . Experiment was 
repeated five times. The box-plot was plotted by concentration of 丨L-10 vs 
concentration of C. sinensis. Treatment groups were compared with the 
control for statistical significance using Kruskal=Wallis test. * p < 0.05 
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Figure 6.6. In vitro effects of HERBSnSENSES™ Cordyceps on the 
induction of IL-10 from lymphocytes. Lymphocytes (1x10® cells/mL) were 
incubated with medium or different concentrations of H E R B S n S E N S E S ™ 
Cordyceps for 20 hours. Supernatant was collected for IL-10 assay using 
C B A . Experiment was repeated five times. The box-plot was plotted by 
concentration of IL-10 vs concentration of H E R B S n S E N S E S ™ Cordyceps. 
Treatment groups were compared with the control for statistical significance 
using Kruskal-Wallis test. * p < 0.05，^outliner 
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6.2.2. Effects of Natural Cordyceps sinensis and HERBSnSENSES™ 
Cordyceps on the Induction of Cytokines from Monocytes 
6.2.2.1. IL-1P 
As shown in Figure 6.7，C. sinensis enormously elevated the IL-1p release 
from monocytes in a dose-dependent manner. W h e n compared to the 
negative control, statistical significances w e m obtained in all treatment groups 
(p < 0.05). Figure 6.8 shows the dose-dependent effect of 
H E R B S n S E N S E S ™ Cordyceps on the generation of IL-ip from monocytes. 
Increasing concentration of HERBSnSENSES™ Cordyceps was 
accompanied with an elevated median IL-1p production. However, differences 
between negative control and all treatment groups could not reach statistical 
significance (p > 0.05). 
6.2.2.2. IL-6 
As shown in Figure 6.9, C. sinensis enormously enhanced the IL-6 release 
from monocytes. W h e n compared to the negative control, statistical 
significances were obtained in all treatment groups (p < 0.05). Figure 6.10 
shows the dose-dependent effect of H E R B S n S E N S E S ™ Cordyceps on the 
generation of IL-6 from monocytes. At 2 mg/mL, median IL-6 liberation was 
profoundly retarded when compared to that of H E R B S n S E N S E S ™ 
Cordyceps < 2 mg/mL. Statistical significance was achieved for all treatment 
groups when compared each to the control (p < 0.05). 
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Figure 6.7. \n vitro effects of natural Cordyceps sinensis on the 
induction of IL-ip from monocytes. Monocytes (1 x 10® cells/mL) were 
incubated with medium or different concentrations of C. sinensis for 20 hours. 
Supernatant was collected for IL-ip assay using C B A . Experiment was 
repeated five times. The box-plot was plotted by concentration of IL-1p vs 
concentration of C. sinensis. Treatment groups were compared with the 
control for statistical significance using Kruskal-Wallis test. * p < 0.05 
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Figure 6.8. In vitro effects of HERBSnSENSES™ Cordyceps on the 
induction of IL-ip from monocytes. Monocytes (1 x 10® cells/mL) were 
incubated with medium or different concentrations of H E R B S n S E N S E S ™ 
Cordyceps for 20 hours. Supernatant was collected for IL-1(3 assay using 
C B A . Experiment was repeated five times. The box-plot was plotted by 
concentration of !L-1p vs concentration of H E R B S n S E N S E S ™ Cordyceps. 
Treatment groups were compared with the control for statistical significance 
using Kruskal-Wallis test. 
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Figure 6.9. In vitro effects of natural Cordyceps sinensis on the 
induction of IL-6 from monocytes. Monocytes (1 x 10® cells/mL) were 
incubated with medium or different concentrations of C. sinensis for 20 hours. 
Supernatant was collected for IL-6 assay using C B A . Experiment was 
repeated five times. The box-plot was plotted by concentration of IL-6 vs 
concentration of C. sinensis. Treatment groups were compared with the 
control for statistical significance using Kruskal-Wallis test. * p < 0.05 
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Figure 6.10. In vitro effects of HERBSnSENSES™ Cordyceps on the 
induction of IL-6 from monocytes. Monocytes (1 x 10® cells/mL) were 
incubated with medium or different concentrations of H E R B S n S E N S E S ™ 
Cordyceps for 20 hours. Supernatant was collected for IL-6 assay using C B A . 
Experiment was repeated five times. The box-plot was plotted by 
concentration of IL-6 vs concentration of H E R B S n S E N S E S ™ Cordyceps. 
Treatment groups were compared with the control for statistical significance 
using Kruskal-Wallis test. * p < 0.05 
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6.2.2.3. IL-10 
As shown in Figure 6.11，C. sinensis enormously heightened the IL-10 
release from monocytes. Effect of C. sinensis was culminating at 1 mg/mL but 
w a s gradually retarded beyond this dosage. Statistical differences were 
achieved for all treatment groups when compared each to the negative control 
(p < 0.05). Figure 6.12 shows the dose-dependent effect of 
H E R B S n S E N S E S ™ Cordyceps on the generation of IL-10 from monocytes. 
Increasing concentration of H E R B S n S E N S E S ™ Cordyceps was 
accompanied with an decreasing median IL-10 production. However, there 
w a s no significant difference for all treatment groups when compared each to 
the negative control (p > 0.05). 
6.2.2.4. TNFa 
Figure 6.13 shows that C. sinensis enormously promoted the T N F a release 
from monocytes. Statistical differences were achieved for all treatment groups 
when compared each to the negative control (p < 0.05). As shown in Figure 
6.14, increasing concentration of H E R B S n S E N S E S ™ Cordyceps was 
accompanied by an elevating median TNFa liberation. W h e n compared to the 
control, H E R B S n S E N S E S ™ Cordyceps at 0.5 and 1 mg/mL significantly 
promoted T N F a release from monocytes (p < 0.05). 
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Figure 6.11, In vitro effects of natural Cordyceps sinensis on the 
induction of IL-10 from monocytes. Monocytes (1 x 10® cells/mL) were 
incubated with medium or different concentrations of C. sinensis for 20 hours. 
Supernatant was collected for IL-10 assay using C B A . Experiment was 
repeated five times. The box-plot was plotted by concentration of IL-10 vs 
concentration of C. sinensis. Treatment groups were compared with the 
control for statistical significance using Kruskal-Wallis test. 
* p < 0.05，A outliner. 
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Figure 6.12. In vitro effects of HERBSnSENSES™ Cordyceps on the 
induction of IL-10 from monocytes. Monocytes (1 x 10® cells/mL) were 
incubated with medium or different concentrations of H E R B S n S E N S E S ™ 
Cordyceps for 20 hours. Supernatant was collected for IL-10 assay using 
C B A . Experiment was repeated five times. The box-plot was plotted by 
concentration of IL-10 vs concentration of H E R B S n S E N S E S ™ Cordyceps. 
Treatment groups were compared with the control for statistical significance 
using Kruskal-Wallis test. * p < 0.05, • outliner. 
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Figure 6.13. In vitro effects of natural Cordyceps sinensis on the 
induction of TNFa from monocytes. Monocytes (1 x 10® cells/mL) were 
incubated with medium or different concentrations of C. sinensis for 20 hours. 
Supernatant was collected for T N F a assay using C B A . Experiment was 
repeated five times. The box-plot was plotted by concentration of T N F a vs 
concentration of C. sinensis. Treatment groups were compared with the 
control for statistical significance using Kruskal-Wallis test. 
* p < 0.05, A outliner. 
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Figure 6.14. In vitro effects of HERBSnSENSES™ Cordyceps on the 
induction of TNFa from monocytes. Monocytes (1 x 10® cells/mL) were 
incubated with medium or different concentrations of H E R B S n S E N S E S ™ 
Cordyceps for 20 hours. Supernatant was collected for TNFa assay using 
C B A . Experiment was repeated five times. The box-plot was plotted by 
concentration of T N F a vs concentration of H E R B S n S E N S E S ™ Cordyceps. 
Treatment groups were compared with the control for statistical significance 
using Kruskal-Wallis test. * p < 0.05，a outliner. 
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6.2.3. Effects of Natural Cordyceps sinensis and HERBSnSENSES™ 
Cordyceps on the Expression of Cytokine Receptor 
Figure 6.15 and 6.16 respectively show the dose-dependent enhancement of 
C. sinensis and H E R B S n S E N S E S ™ Cordyceps on the surface expression of 
IL-2a receptor (CD25). W h e n comparing to the control, C. sinensis 
significantly elevated C D 2 5 expression at 3 mg/mL (p = 0.016) and 5 mg/mL 
(p = 0.008) (Figure 6.15), while H E R B S n S E N S E S ™ Cordyceps analogously 
induced C D 2 5 expression at 1 mg/mL (p = 0.007) and 1.5 mg/mL (p = 0.002) 
(Figure 6.16). 
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Figure 6.15. In vitro effects of natural Cordyceps sinensis on the cell 
expression of \L-2a receptor (CD25). Lymphocytes (1 x 10® cells/mL) were 
incubated with medium or different concentrations of C. sinensis for 20 hours. 
The cells were then subjected to immunostaining and the expression of C D 2 5 
w a s measured by flow cytometry. Experiment was repeated five times. The 
box-plot was plotted by percentage of C D 2 5 expression vs concentration of C. 
sinensis. Treatment groups were compared with the control for statistical 
significance using Kruskal-Wallis test. * p < 0.05. 
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Figure 6.16. In vitro effects of HERBSnSENSES頂 Cordyceps on the cell 
expression of IL-2a receptor (CD25). Lymphocytes (1 x 10® cells/mL) were 
incubated with medium or different concentrations of H E R B S n S E N S E S ™ 
Cordyceps for 20 hours. The cells were then subjected to immunostaining and 
the expression of C D 2 5 was measured by flow cytometry. Experiment was 
repeated six times. The box-plot was plotted by percentage of C D 2 5 
expression vs concentration of H E R B S n S E N S E S ™ Cordyceps. Treatment 
groups were compared with the control for statistical significance using 
Kruskal-Wallis test. * p < 0.05, a outliner. 
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6.2.4. Effects of Natural Cordyceps sinensis and HERBSnSENSES™ 
Cordyceps on the Gene Expression of Cytokines and Cytokine 
Receptors in Peripheral Blood Mononuclear Cells 
Representative result of the gene expression array is shown in Figure 6.13. 
Description of the genes and their respective location is presented in Table 
6.1. Detailed results from triplicated experiments is depicted in Table 6.2. 
Results shows that C. sinensis and H E R B S n S E N S E S ™ Cordyceps 
prominently stimulated genes for cytokines IL-1a, IL-1p, IL-6, IL-12p40, IL-15, 
and cytokine receptors IL-12p，IL-1, IL-2a, IL-2p. Genes for the C C 
chemokine and C C chemokine receptors were either down-regulated or 
up-regulated. Gene expression will only be considered profound when the 
m e a n percentage of gene expression was < -50 % and > 50 % . 
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(a) (b) (c) 
A B C D E F G H 
1 BLR1 CCR1 CCR2 CCR3 CCR4 CCR5 CCR6 CCR7 
2 CCR8 CCR9 CCXCR1 CX3CR1 CXCR4 IFNG IL10 IL10RA 
3 IL10RB IL11 IL11RA IL12A IL12B IL12RB1 IL12RB2 IL13 
4 IL13RA1 IL13RA2 IL15 IL15RA IL16 IL17 IL17R IL18 
5 IL18R1 IL1A IL1B IL1R1 IL1R2 IL2 IL20 IL21 
6 IL25 IL2RA IL2RB IL2RG IL4 IL5 IL5RA IL6 
7 IL6R IL6ST IL9 IL9R LEP LTA LTB LTBR 
8 MIF SCYA1 SCYA11 SCYA13 SCYA14 SCYA15 SCYA16 SCYA17 
9 SCYA18 SCYA19 SCYA2 SCYA20 SCYA21 SCYA22 SCYA23 SCYA24 
1 0 SCYA25 SCYA3 SCYA4 SCYA5 SCYA7 SCYA8 SCYB10 SCYB11 
11 SCYB13 SCYB5 SCYB6 SCYC1 SCYC2 SCYD1 SCYE1 SDF1 
12 SDF2 TGFA TGFB1 TGFB2 TGFB3 TNF TNFRSF1A TNFRSF1B 
1 3 PUC18 PUC18 PUC18 BLANK BLANK BLANK GAPD GAPD 
1 4 PPIA PPIA PPIA PPIA RPL13A RPL13A ACTB ACTB 
(d) 
Figure 6.13. Representative gene expression profile of (a) PBMC, (b) 
PBMC treated with C. sinensis (2 mg/mL) and (c) HERBSnSENSES™ 
Cordyceps (1 mg/mL). PBMC (1 x 10® cells/mL) were treated with C. 
sinensis (2 mg/mL) and HERBSnSENSES™ Cordyceps (1 mg/mL) for 24 
hours. RNA was isolated by using RNeasy® Total RNA Kit (Qiagen GmbH, 
Hilden, Germany). Gene expression was determined by using GEArray Q 
series human inflammatory cytokines and receptors gene array (Superarray 
Bioscience Corp, Bethesda, MD USA), (d) Location of each gene in the array 
was denoted correspondingly. The gene located at G13 and H13 (GAPD) 
were the internal positive control for each array. 
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Position Symboi Gene Description 
A1 CXCR5 CXCR5 Homo sapiens Burkitt lymphoma receptor 1, GTP-binding 
protein 
B1 CCR1 CCR1 Chemokine (C-C motif) receptor 1 
C1 CCR2 CCR2 Chemokine (C-C motif) receptor 2 
D1 CCR3 CCR3 Chemokine (C-C motif) receptor 3 
E1 CCR4 CCR4 Chemokine (C-C motif) receptor 4 
F1 CCR5 CCR5 Chemokine (C-C motif) receptor 5 
G1 CCR6 CCR6 Chemokine (C-C motif) receptor 6 
H1 CCR7 CCR7 Chemokine (C-C motif) receptor 7 
A 2 CCR8 CCR8 Chemokine (C-C motif) receptor 8 
B2 CCR9 CCR9 Chemokine (C-C motif) receptor 9 
C2 CCXCR1 XCR1 Homo sapiens chemokine (C motif) XC receptor 1 
D2 CX3CR1 CX3CR1 Chemokine (C-X3-C) receptor 1 
E2 CXCR4 CXCR4 Chemokine (C-X-C motif), receptor 4 (fusin) 
F2 IFNG IFNy Interferon, gamma 
G2 IL10 IL1-0 Interleukin 10 
H2 IL10RA IL10-Ra Interleukin 10 receptor, alpha 
A 3 IL10RB IL10-Rp Interleukin 10 receptor, beta 
B3 IL11 IL-11 Interleukin 11 
Q3 IL11RA 丨L-11IRa Interleukin 11 receptor, alpha 
D3 IL12A IL-12A Interleukin 12A, p35 
E 3 IL12B IL-12B Interleukin 12A, p40 
F3 IL12RB1 1L-12R(31 Interleukin 12 receptor, beta 1 
G3 IL12RB2 IL-12R(32 Interleukin 12 receptor，beta 2 
H3 IL13 IL-13 Interleukin 13 
A 4 丨L13RA1 IL-13Ra1 Interleukin 13 receptor, alpha 1 
B 4 IL13RA2 IL-13Ra2 interleukin 13 receptor, alpha 2 
C4 IL15 IL-15 Interleukin 15 
D4 1L15RA IL-15Ra Interleukin 15 receptor, alpha 
E4 IL16 IL-16 Interleukin 16 (lymphocyte chemoattractant factor) 
P4 IL17 IL-17 Interleukin 17 (cytotoxic T-lymphocyte-associated serine 
esterase 8) 
Q 4 IL17R IL-17R Homo sapiens Interleukin 17 receptor mRNA 
H4 IL18 IL-18 Interleukin 18 (Interferon-gamma-inducing factor) 
!L18R1 IL-18R1 Interleukin 18 receptor 1 
B5 IL1A IL-1a Interleukin 1, alpha 
Q 5 IL1B IL-1p Interleukin 1, beta 
D5 IL1R1 IL-1R1 Interleukin 1 receptor type I 
E5 IL1R2 IL-1R2 Interleukin 1 receptor type II 
F5 IL2 IL-2 Interleukin 2 
G 5 IL20 IL-20 Interleukin 20 
H5 IL21 IL-21 Homo sapiens Interleukin 21 
A 6 IL25 IL-25 Likely ortholog of mouse Interleukin 25 
B6 IL2RA IL-2Ra Interleukin 2 receptor, alpha 
C6 IL2RB IL-2R(3 Interleukin 2 receptor, beta 
D6 IL2RG IL-2RY Interleukin 2 receptor, gamma (severe combined 
immunodeficiency) 
IL4 IL-4 Interleukin 4 
F6 IL5 IL-5 Interleukin 5 (colony-stimulating factor, eosinophil) 
G6 IL5RA IL-5Ra Interleukin 5 receptor, alpha 
H6 IL6 IL-6 Interleukin 6 (Interferon, beta 2) 
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A 7 IL6R IL-6Ra Interleukin 6 receptor 
B 7 IL6ST Gp130 Interleukin 6 signal transducer (gp 130, oncostatin M 
receptor) 
C 7 IL9 IL9/p40 Interleukin 9 
D7 IL9R IL-9Ra Interleukin 9 receptor 
E7 LEP Leptin Leptin (murine obesity homolog) 
F7 LTA TNF-b/Lta Lymphotoxin-alpha (TNF superfamily, member 1) 
G 7 LTB Lt-b Lymphotoxin-beta 
H7 LTBR LTbR Homo sapiens lymphotoxin beta receptor (TNFR 
superfamily) 
A 8 MIF MIF Macrophage migration inhibitory factor (glycosylation 
inhibiting factor) 
B 8 SCYA1 1-309 Small inducible cytokine A1 (1-309，homologous to mouse 
Tca-3) 
C 8 SCYA11 Eotaxin Small inducible cytokine subfamily A (Cys-Cys), member 
11 
D8 SCYA13 MCP-4 Small inducible cytokine subfamily A (Cys-Cys), member 
13 
E8 SCYA14 HCC-1 Small inducible cytokine subfamily A (Cys-Cys), member 
14 
F8 SCYA15 MIP-1 alpha Small inducible cytokine subfamily A (Cys-Cys), member 
15 
G 8 SCYA16 HCC-4 Small inducible cytokine subfamily A (Cys-Cys), member 
16 
H8 SCYA17 TARC Small inducible cytokine subfamily A (Cys-Cys), member 
17 
A 9 SCYA18 PARC Small inducible cytokine subfamily A (Cys:5ysrmemt)er 
18 
B 9 SCYA19 SCYA19 Small inducible cytokine subfamily A (Cys-Cys), member 
19 
C9 SCYA2 MCP-1 Small inducible cytokine A2 
D9 SCYA20 MIP-3a Small inducible cytokine subfamily A (Cys-Cys), member 
20 
E9 SCYA21 MIP-2 Small inducible cytokine subfamily A (Cys-Cys), member 
21 
F9 SCYA22 MDC Small inducible cytokine subfamily A (Cys-Cys), member 
22 
G9 SCYA23 MPIF-1 Small inducible cytokine subfamily A (Cys-Cys), member 
23 
H9 SCYA24 MPIF-2 Small inducible cytokine subfamily A (Cys-Cys), member 
24 
A 1 0 SCYA25 TECK Human chemokine (TECK) 
B 1 0 SCYA3 MIP-1 a Small inducible cytokine A3 (homologous to mouse 
Mip-1a) 
C 1 0 SCYA4 MIP-1 b Small inducible cytokine A4 (homologous to mouse 
Mip-1b) 
D10 SCYA5 RANTES Small inducible cytokine A5 
E10 SCYA7 MCP-3 Homo sapiens mRNA for monocyte chemotactic protein-3 
F10 SCYA8 MCP-2 Small inducible cytokine subfamily A (Cys-Cys), member 8 
G 1 0 SCYB10 P10 (IP-10) Gamma-interferon inducible early response gene 
H10 SCYB11 l-TAC (IP9) Small inducible cytokine subfamily B (Cys-X-Cys), member 
11 
A 1 1 SCYB13 SCYB13 Small inducible cytokine subfamily B (Cys-X-Cys), member 
13 
B11 SCYB5 ENA-78 Small inducible cytokine subfamily B (Cys-X-Cys), member 
5 
C 1 1 SCYB6 GCP-2 Human chemokine alpha 3 (CKA-3) mRNA 
D11 SCYC1 Lymphotacti Small inducible cytokine subfamily C, member 1 
n 
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E11 SCYC2 SCYC2 Small inducible cytokine subfamily C, member 2 
F11 SCYD1 Fractalkine Small inducible cytokine subfamily D, member 1 
G 1 1 SCYE1 SCYE1 Small inducible cytokine subfamily E, member 1 
H11 SDF1 SDF1 Stromal cell-derived factor 1 
A 1 2 SDF2 SDF2 Homo sapiens mRNA for SDF2 
B 1 2 TGFA TFG-a Transforming growth factor, alpha 
C 1 2 TGFB1 TGF-P1 Transforming growth factor, beta 1 
D12 TGFB2 TGF-(32 Transforming growth factor, beta 2 
E12 TGFB3 TGF-P3 Transforming growth factor, beta 3 
F12 TNF TNFa Tumor necrosis factor (TNF superfamily, member 2) 
G 1 2 TNFRSF1A TNFR1 Tumor necrosis factor receptor superfamily, member 1A 
H12 TNFRSF1B TNFR2 Human tumor necrosis factor receptor 2 
(TNFSF1B) 
A 1 3 PUC18 pUC18 PUC18Plasmid DNA 
B 1 3 PUC18 pUC18 PUC18 Plasmid DNA 
C13 PUC18 pUC18 PUC18 Plasmid DNA 
D13 BLANK BLANK 
E13 BLANK BLANK 
F13 BLANK BLANK 
G13 GAPD GAPDH Glyceraldehyde-3-phosphate dehydrogenase 
H13 GAPD GAPDH Glyceraldehyde-3-phosphate dehydrogenase 
A 1 4 PPIA Cyclophilin Homo sapiens peptidylprolyl isomerase A 
A 
B 1 4 PPIA Cyclophilin Homo sapiens peptidylprolyl isomerase A 
A 
C 1 4 PPIA Cyclophilin Homo sapiens peptidylprolyl isomerase A 
A 
D14 PPIA Cyclophilin Homo sapiens peptidylprolyl isomerase A 
A 
E14 RPL13A RPL13A Ribosomal protein IL13a (23 Kda highly basic protein) 
F14 RPL13A RPL13A Ribosomal protein IL13a (23 Kda highly basic protein) 
G 1 4 ACTB b-actin Beta Actin 
H14 ACTB b-actin Beta Actin 
Table 6.1. List of genes shown in the GE Array Q Series Human 
Inflammatory Cytokine/Receptor Gene Array. 
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% of Expression (Mean ± SD) 
Gene Coordinate C. sinensis HERBSnSENSES^"^ 
(2 mg/mL) Cordyceps (1 mg/mL) 
CCR1 B1 -51.8±4.2 -50.2±22.9 
CCR2 C1 -21.5±10.7 -15.4±12.4 
CCR3 D1 -59.8±9.3 -59.3±23.3 
CCR4 E1 2.9±48.0 21.7±45.5 
CCR5 F1 -18.1±7.9 -8.3±17.7 
CCR6 G1 2.7±66.3 1.8±57.1 
CCR7 H1 395.9±502.6 554.5±819.6 
CCR8 A2 149.9±281.6 -90.7±97.3 
CCR9 B2 -8.9±18.1 -11.2±36.9 
CCXCR1 C2 -45.2±6.7 -52.9±26.0 
CX3CR1 D2 -62.6±17.7 -32.3±24.9 
CXCR4 E2 -8.0±4.3 8.0+26.4 
IFNG F2 16.4±38.8 -35.3±7.3 
IL10 G2 -10.4±+6.8 -2.4±14.8 
IL10RA H2 -16.3±13.2 -2.5±36.8 
IL10RB A3 -22.5±11.6 -47.1±46.7 
IL11 B3 9.4±21.1 -98.0±18.5 
IL11RA C3 -80.3±75.6 -104.9±1.6 
IL12A D3 -85.3±41.0 -72.0±9.5 
IL12B E3 238.4±380.1 53.6±163.1 
IL12RB1 F3 -50.8±19.5 -57.9±7.1 
IL12RB2 G3 61.7±181.9 17.5±98.2 
IL13RA1 A4 -43.0±32.7 -59.5±43.1 
IL15 C4 320.4±169.4 116.3±99.0 
IL16 E4 9.6±64.6 7.4±54.5 
IL17R G4 -10.3±0.8 -6.7+5.7 
IL18R1 A5 166.0±38.1 -161.6±34.2 
IL1A B5 5018.6±6611.3 1481.3±1083.9 
IL1B C5 11846.7±19617.8 13042.0±21752.1 
IL1R1 D5 237.9±87.6 142.8±91.5 
IL1R2 E5 26.8±166.6 6.4±146.9 
IL25 A6 831.0±145G.0 -131.9±158.8 
IL2RA B6 1448.2±1731.8 53.7±147.2 
IL2RB C6 636.1 ±672.0 276.9±454.5 
IL2RG D6 22.1±119.6 -5.9±35.7 
IL4 E6 -143.3±125.7 -147.2±3.2 
IL5 F6 38.9±205.8 0.6±175.3 
IL5RA G6 -21.6±30.1 -60.8±30.6 
IL6 H6 551.9±354.4 211.4±145.5 
IL6ST B7 -0.6±25.6 2.9±42.1 
IL9 C7 25.3±61.1 -19.1±65.3 
LEP E7 -245.1±237.8 -225.2±79.3 
LTB G7 84.5±169.8 109.2±248.8 
1-309 B8 271.4±327.5 98.0±224.3 
Eotaxin C8 -13.4±29.9 -58.7±34.0 
MCP-4 D8 82.5±237.6 17.9±148.8 
HCC-1 E8 1.4±143.4 -18.7±129.0 
MIP-1a F8 70.7±185.5 1.8±160.2 
HCC-4 G8 -158.5±137.2 -670.9±803.4 
TARC H8 -7.4±104.5 -31.6±121.8 
PARC A9 801.4±1165.8 414.8±555.5 
SCYA19 B9 3855.6±6626.2 2133.2±3725.1 
MCP-1 C9 144.7±91.3 74.6±91.7 
MIP-3a D9 234.3±239.7 200.3±132.6 
MIP-2 E9 -36.0±26.6 -62.2±20.8 
MDC F9 -1.7±0.9 -37.0±38.5 
-110-
Chapter 6 - Cytokines and Cytokine Receptors 
MPlF-1 G9 95.5±156.5 5.2±153.0 
MPIF-2 H9 --111.0125.8 -100.1 ±49.8 
MIP-1a B10 4.7±8.2 16.6±38.5 
MIP-1b C10 218.4±209.4 68.9±61.7 
RANTES D10 -25.8±13.8 -20.3 土 1.6 
MCP-3 E10 146.8±266.6 141.1±314.8 
MCP-2 F10 -18.5±40.7 -80.0±21.3 
P10(IP-10) G10 -93.5±20.4 -108.9±14.7 
l-TAC (IP9) H10 -138.0±32.1 -155.0±65.5 
SCYB13 A11 3.0±12.7 -27.5±39.1 
ENA-78 B11 150.9±138.4 91.8±126.4 
GCp-2 C11 104.4±98.8 49.2±95.6 
Lymphotactin D11 4.8±23.4 -35.6±18.7 
SCYC2 E11 15.4±42.8 -33.5±35.4 
Fractalkine F11 40.0±71.6 -8.1±11.9 
SCYE1 G11 t, -42.7±28.4 -55.1±21.8 
SDF1 H11 -104.2±5.6 -114.0±44.9 
SDF2 A12 31.7±87.6 70.3±111.8 
TGFA B12 155.2±276.9 125.9±315.2 
TGF-pl C12 -2.5±12.1 2.5±14.0 
TGF-P2 D12 -64.2±25.8 -61.7±1.9 
TGF-P3 E12 -59.6±20.5 -77.0±7.8 
TNFa F12 -21.5±28.6 38.8±66.6 
TNFR1 G12 -23.9±2.4 -24.0±23.5 
TNFR2 H12 3.9±43.4 -3.1 ±22.3 
Table 6.2. In vitro effects of Cordyceps sinensis and HERBSnSENSES™ 
Cordyceps on the the gene expression of PBMC. PBMC (5x10® cells) 
were incubated with culture medium, C. sinensis (2 mg/mL) or 
H E R B S n S E N S E S ™ Cordyceps (1 mg/mL) for 24 hours. R N A was isolated by 
using R N e a s y ® Total R N A Kit (Qiagen G m b H , Hilden, Germany). Gene 
expression was determined by using GEArray Q series human inflammatory 
cytokines and receptors gene array (Superarray Bioscience Corp, Bethesda, 
M D USA). Percentage of gene expression was calculated by comparing the 
gene expression of treatment vs control. Results are presented from triplicate 
experiments. Up-regulated and down-regulated genes were respectively 
highlighted in pink and blue. 
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6.3. Discussion 
Cytokines regulate cell proliferation, survival, differentiation, antigen 
presentation and trafficking to control immune processes (Durum, 2000). In 
the present study, C. sinensis and H E R B S n S E N S E S ™ Cordyceps 
demonstrated prominent stimulatory effects on the cytokine network. 
Cytokines induced by C. sinensis and H E R B S n S E N S E S ™ Cordyceps are 
intimately related to modulate the cell-mediated immunity. 
IL-1 is a proinflammatory cytokines which can be subdivided into two major 
forms, the cell associated IL-1a and the secreted IL-ip. The gene expression 
of these cytokines was up-modulated by C. sinensis and H E R B S n S E N S E S ™ 
Cordyceps (Table 6.2). The in vitro system also concurred by demonstrating 
enormous release of IL-1 (3 from monocytes into the culture medium (Figure 
6.7-8). Heightened production of IL-ip from monocytes m a y implicate an 
activation of the innate immune response. Recent evidence has illustrated 
that synergy between IL-1 (3 and C D 4 0 ligand gp39 (CD40L) can activate 
dentritic cells through a T-cell independent mechanism during the earliest 
stages of inflammatory responses (Luft et al, 2002). In addition, an in vivo 
system demonstrated by Boraschi et al has shown that IL-ip possesses 
immunostimulatory activities while IL-1 a m a y act as a down regulator of the 
IL-ip effect. The enhancement of both IL-1a and IL-ip gene expression by C. 
sinensis and H E R B S n S E N S E S ™ Cordyceps m a y suggest a tightly regulated 
immunomodulation. Furthermore, elevation of the gene expression of IL-1 
receptor type I by C. sinensis and H E R B S n S E N S E S ™ Cordyceps increased 
binding sites for IL-1. The elevated IL-1 cytokine-receptor type I ligands can 
mediate IL-6 production and other inflammatory responses (Van D a m et al, 
1998; Sironi et al, 1989). 
Synchronously, the present results also demonstrated upregulation of IL-6 
from lymphocytes and monocytes by C. sinensis and H E R B S n S E N S E S ™ 
Cordyceps (Figure 6.3-4，Figure 6.9-10). This upmodulation of IL-6 production 
is acted at the gene level (Table 6.2) and may be mediated by the heightened 
liberation of IL-1 (Van D a m et al, 1998; Sironi et al, 1989). IL-6 is a 
proinflammatory cytokine with functions similar to IL-1. Evidence has 
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suggested that IL-6 is involved in both B cell and T cell activation, growth and 
differentiation (Van Snick, 1990; Houssiau and Van Snick, 1992; Kopf et al, 
1995). IL-6 also induces C D 2 5 , IL-2 receptor a chain, expression in T cell line 
(Noma et al, 1987)，and in thymocytes (Le et al, 1988), and functions as a 
second signal for IL-2 production by murine T cells (Garman et al, 1987). A 
recent report has pointed out that IL-6 plays a dual role in Th1/Th2 
differentiation (Diehl and Rincon, 2002). Upregulation of IL-6 by C. sinensis 
and H E R B S n S E N S E S ™ Cordyceps m a y enhance the cell-mediated 
immunity. 
The present upregulation of IL-1 and IL-6 m a y be due to the induction of 
T N F a (Panzer et al, 1993). Results demonstrated that liberation of T N F a was 
increased in the presence of C. sinensis and H E R B S n S E N S E S ™ Cordyceps, 
although not at gene transcriptional level. T N F a along with IL-1 and IL-6 
regulate the immune response, hematopoiesis, and inflammation. IL-1 and 
IL-6 synergistically stimulate the growth and differentiation of T cells (Mizutani 
et al, 1989). Evidence has shown that exogenously added IL-ip, IL-6 and 
T N F a induces IL-2 receptor upregulation and IL-2 production, and 
subsequently proliferation of CD4+ and CD8+ T cells (Holsti and Raulet, 1989; 
Panzer et al, 1993). 
The present study also showed that the low affinity IL-2 receptor a were 
increased in gene and cell surface expression (Figure 6.15-16, Table 6.2), 
while the moderate affinity IL-2 receptor (3 were up-regulated in gene 
expression (Table 6.2). The enhanced expression of IL-2 receptors allows T 
cells to respond at low concentration of IL-2 cytokines. The binding of IL-2 
cytokines to IL-2 receptors subsequently triggers rapid proliferation and 
differentiation of T cells (Taniguchi and Minami, 1993), resulting in an 
enhancement of the cell-mediated immunity. This upregulation of IL-2 
receptor expression m a y be mediated by the co-stimulatory effects of IL-1, 
IL-6 and T N F a (Holsti and Raulet, 1989; Panzer et al, 1993). Evidence has 
shown that IL-6 depends on IL-2 in stimulating B cells for immunoglobulin 
production (Splawski et al, 1990). C. sinensis and H E R B S n S E N S E S ™ 
Cordyceps m a y also promote the humoral immunity. 
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Besides, results also demonstrated that C. sinensis and H E R B S n S E N S E S ™ 
Cordyceps enhanced expression of IL-12p40 at gene level (Table 6.2). 
Secretion of the biologically active IL-12 heterodimer (p70) is regulated at the 
level of p40 chain transcription (Ma et al, 1996). IL-12 represents a growth 
factor for activated CD4+ T cells, CD8+ T cells, natural killer (NK) cells (Gately 
et al, 1991) and lymphokine-activated killer (LAK) cells (Kobayashi et al, 1989; 
Gately et al, 1992), suggesting the anti-tumorigenic and anti-infectious role of 
C. sinensis and H E R B S n S E N S E S ™ Cordyceps (Hsieh et al, 1993; Manetti et 
al, 1993). IL-12 also promotes Th1-specific immune response by inducing 
IFNy and IL-18 (Wong and Lam, 2003) for cell-mediated immunity. IL-12 is 
capable of inducing its own inhibitor 丨L-10 (Daftarian et al, 1996; Jeannin et al, 
1996; Meyaard et al, 1996) for modulating IL-12 induced immune response. 
Liberation of the anti-inflammatory cytokines IL-10 from P B M C was induced 
under the in vitro activation of C. sinensis and H E R B S n S E N S E S ™ 
Cordyceps (Figure 6.5-6 and 6.11-12). The induced IL-10 production was 
probably regulated at gene transcriptional level (Table 6.2). IL-10 modulates 
IL-1a, IL-1P, IL-6，IL-10 itself, IL-12 and T N F a by strongly inhibiting their 
production (Fiorentino et al, 1991; de Waal Malefyt et al, 1991, 1993; 
D'Andrea et al, 1993; Grubere^ a/, 1994; Berkman et al, 1995; Marfaing-Koka 
et al, 1996). Analogously, IL-6 inhibits IL-ip and T N F a at transcriptional level 
(Schindler et al, 1990). The negative regulation induced by IL-6 and IL-10 
thereby modulates the immune system. Results also showed that the 
chemokines and chemokine receptors were either up-regulated or 
suppressed. These two contrasting regulations also suggest that 
immunomodulatory activities of C. sinensis and H E R B S n S E N S E S ™ 
Cordyceps were highly regulated. 
At the optimal concentration, immunomodulatory activities exerted by C. 
sinensis were more potent than H E R B S n S E N S E S ™ Cordyceps. Results 
demonstrated that C. sinensis up-regulated the induction of cytokines and 
gene expression of cytokines and cytokine receptors to a greater extent. This 
m a y because the H E R B S n S E N S E S ™ Cordyceps is only the fruiting bodies of 
C. sinensis. Potential active ingredients contained in H E R B S n S E N S E S ™ 
Cordyceps m a y be comparatively fewer than C. sinensis. Furthermore, the 
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higher the concentration of H E R B S n S E N S E S ™ Cordyceps, the lesser IL-6, 
T N F a and IL-10 was produced from lymphocytes. This m a y because high 
dosage of H E R B S n S E N S E S ™ Cordyceps accumulated inhibitory substances 
for the suppression of IL-6, T N F a and IL-10 release. The dosage of 
H E R B S n S E N S E S ™ Cordyceps m a y need to be carefully adjusted before 
prescription. 
The present experiments showed that several inflammatory markers, 
including the cytokines T N F and IL-10, m a y express only at transcriptional 
level in the presence of C. sinensis and H E R B S n S E N S E S ™ Cordyceps. 
Western blot m a y be carried out to further confirm the protein expression of 
these cytokines and therefore our speculation. O n the other hand, results 
from the gene expression microarray showed relatively high discrepancies in 
triplicate but identical experiments. Reverse transcriptase - polymerase chain 
reaction (RT-PCR) m a y be performed for validating the current data. 
Our result concurs with a previous study demonstrated by Chen et al. They 
showed that polysaccharide extracts of C sinensis m a y elevate the liberation 
of T N F a and IL-1 from P B M C (Chen et al, 1997). However, researches 
carried out by Chen et al had neither investigated the surface expression of 
cytokine receptors and gene expression of cytokine and cytokine receptors. 
Our system m a y be rather novel in studying the immunomodulatory activities 
of C. sinensis. 
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Macrophage Functions: Phagocytosis and 
Release of Reactive Oxygen Species (ROS) 
7.1. Introduction 
Macrophages are critical frontline cellular effectors of nonspecific host 
defense (Metchnikoff, 1905). They eliminate pathogens mainly by 
phagocytosis and generation of toxic reactive oxygen species (ROS) 
(Janeway et al, 2001). Agents which enhance macrophage functions relate to 
a more equipped innate immune system (Aderem, 2003). Immunological 
activities of herbal T C M related to monocytes/macrophages have been 
undergone intensive research. Dai et al has shown that glycyrrhizin from the 
liquorice root m a y enhance the IL-12 induced production of IL-12， a 
monocyte/macrophage-derived cytokine and marker for macrophage function, 
from LPS-induced peritoneal macrophages (Dai et al, 2001). Reports have 
shown that polysaccharide fraction of Astragalus membranaceus mediates 
macrophage activation via the toll-like receptors (TLR) 4 molecule - a 
recognition molecule for inflammatory responses (Shao et al, 2004; 
Dunzendorfer et al, 2004). Oldenlandia diffusa and Scutellaria barbata, two 
herbal T C M traditionally used for treating liver, lung and rectal tumors, have 
been shown to enhance in vitro macrophage functions by upregulating 
oxidative burst (Wong et al, 1996). It has also been demonstrated that 
betulinic acid (BA), a pentacyclic triterpene isolated from Lycopus lucidus, 
induced activation of macrophage in vitro (Yun et al, 2003). The T C M formula 
Xio-Qing-Long-Tang has exhibited protection of macrophage function in 
hypercholesterolemia (Inoue et al, 1996). Furthermore, evidence has also 
manifested that ethanol extracts of C. sinensis enhance macrophage 
functions via the in vivo elevation of carbon clearance (Shin et al, 2003)，while 
water extracts from mycelia of C. sinensis promote secretion of 
proinflammatory cytokine IL-6 (Koh et al, 2002). W e therefore speculate that 
the hot water extracts of C. sinensis and H E R B S n S E N S E S ™ Cordyceps m a y 
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also promote macrophage activity through the elevation of phagocytic activity 
and release of toxic R O S . In the present study, phagocytic activity of 
macrophages w a s assessed by the intracellular zymosan fluorescence assay 
as depicted in Section 3.5.11, while the amount of R O S generated was 
quantitated by intracellular florescence staining as described in Section 
3.5.10. 
7.2. Results 
7.2.1. In vitro Effects of C. sinensis and HERBSnSENSES™ Cordyceps 
on Macrophage Phagocytosis 
Figure 7.1-3 shows the dose-dependent activation of phagocytosis by C. 
sinensis and H E R B S n S E N S E S ™ Cordyceps. W h e n compared to the control, 
C. sinensis significantly enhance phagocytosis at 7 mg/mL (p = 0.032) (Figure 
7.1), while H E R B S n S E N S E S ™ Cordyceps significantly enhanced such 
engulfment process at concentration 2 mg/mL (p = 0.008) (Figure 7.2). 
Phagocytosis was heightened respectively by 18.88 土 13.97 % and 22.44 土 
10.23 % at the 〇C of C. sinensis and H E R B S n S E N S E S ™ Cordyceps when 
compared to the control, although no statistical significance was obtained at 
these concentrations. 
7.2.2. In vitro Effects of C. sinensis and HERBSnSENSES™ Cordyceps 
on the Release of Reactive Oxygen Species (ROS) from 
Macrophages 
As shown in figure 7.4-6, both C. sinensis and H E R B S n S E N S E S ™ 
Cordyceps elevated R O S production dose-dependently. C. sinensis 
significantly enhanced the R O S synthesis by 40 % at concentrations above 
0.5 mg/mL (p < 0.05). Plateau was reached beyond the dosage point at 1 
mg/mL (Figure 7.4). H E R B S n S E N S E S ™ Cordyceps, on the other hand, 
significantly upregulated the release of R O S at concentration 1 mg/mL or 
higher (p < 0.04) (Figure 7.5). Compared to the control, the R O S synthesis 
was heightened by 37.93 土 12.6 % and 13.84 ± 2.45 % at the O C of C. 
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sinensis and H E R B S n S E N S E S ™ Cordyceps, respectively. 
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Figure 7.1. In vitro effects of Cordyceps sinensis on the phagocytosis of 
macrophages/monocytes. Monocytes ( 1 x 1 0 ® cells/mL) were primed with 
L P S (20 jug/mL) for two hours before incubating with various concentrations of 
C. sinensis for another 18 hours. The cells were harvested and immediately 
subjected to intracellular zymosan florescence assay. Percentage of 
phagocytic cells was measured by flow cytometry using CellQuest™ 
Programme with the acquiring data presented as histogram plot (florescence 
count vs zymosan-FITC). Experiments were repeated five times. Statistical 
analysis were carried out by using non-parametric Mann-Whitney U Test. 
Statistical significance were obtained at 7 mg/mL (* p = 0.032) of C. sinensis. 
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Figure 7.2. In vitro effects of HERBSnSENSES™ Cordyceps on the 
phagocytosis of macrophages/monocytes. Monocytes (1 x 10 ® cells/mL) 
were primed with LPS (20 |ig/mL) for two hours before incubating with various 
concentrations of H E R B S n S E N S E S ™ Cordyceps for another 18 hours. The 
cells were harvested and immediately subjected to intracellular zymosan 
florescence assay. Percentage of phagocytic cells was measured by flow 
cytometry using CellQuest™ Programme with the acquiring data presented as 
histogram plot (florescence count vs zymosan-FITC). Experiments were 
repeated five times. Statistical analysis were carried out by using 
non-parametric Mann-Whitney U Test. Statistical significance were obtained 
at 2 mg/mL p = 0.008) of H E R B S n S E N S E S ™ Cordyceps. 
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Figure 7.3. Representative flow cytometry histograms depicting the effects of 
(a-e) C. sinensis and (f-i) HERBSnSENSES™ Cordyceps on the phagocytosis 
of macrophages/monocytes. Monocytes (1 x 10 ® cells/mL) were primed with LPS 
for two hours before incubating with various concentrations of TCM for another 18 
hours. The cells were harvested and immediately subjected to intracellular zymosan 
florescence assay. Florescence of cells was acquired by using software CellQuest™ 
Program (BD, CA, USA) and FASCalibur flow cytometry (BD, CA, USA). Figure (a) to 
(e) illustrated the dose dependent effects of C. sinensis at (a) 1 mg/mL, (b) 3 mg/mL, 
(c) 5 mg/mL, (d) 7 mg/mL, and (e) 9 mg/mL. The green thin peaks referred to control; 
the red thick peak was C. sinensis-treated cells. Figure (f) to (i) respectively showed 
the effects of HERBSnSENSES™ Cordyceps at 0.5 mg/mL, 1 mg/mL, 1.5 mg/mL 
and 2 mg/mL. The blue thin peaks referred to control; the pink thick peak was 
HERBSnSENSES™ Cordyceps-treated cells. 
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Figure 7.4. Production of Reactive Oxygen Species (ROS) in the 
presence of Cordyceps sinensis. Monocytes (1 x 10 ® cells/mL) were 
treated with various concentrations of T C M preparations for 3 hours. The cells 
were immediately subjected to intracellular florescence staining for R O S . 
Results were plotted by percentage of R O S production vs concentrations of 
the T C M samples. The experiments were repeated five times. Statistical 
analysis were carried out by using non-parametric Mann-Whitney U Test. * p 
<0.05. 
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Figure 7.5. Production of Reactive Oxygen Species (ROS) in the 
presence of HERBSnSENSES™ Cordyceps. Monocytes ( 1 x 1 0 ® cells/mL) 
were treated with various concentrations of T C M preparations for 3 hours. 
The cells were immediately subjected to intracellular florescence staining for 
R O S . Results were plotted by percentage of R O S production vs 
concentrations of the T C M samples. The experiments were repeated five 
times. Statistical analysis were carried out by using non-parametric 
Mann-Whitney U Test. * p < 0.05. 
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Figure 7.6. Representative flow cytometry histogram depicting the effects of (c-f) C. 
sinensis and (g-i) HERBSnSENSES™ Cordyceps on the production of reactive 
oxygen species. Monocytes (1 x 10 ® cells/mL) were treated with various concentrations 
of TCM preparations for 3 hours. The cells were immediately subjected to intracellular 
florescence staining for ROS. The mean florescence intensities emitted by the 
monocytes was measured by FASCalibur flow cytometry using the CellQeust™ 
Programme (BD, CA, USA), (a) In the absence of DHR, un-treated macrophages 
showed little auto-fluorescence (pink peak), (b) PMA activated ROS production from 
macrophages. The released ROS reacted readily with DHR to fluoresce (red peak). PMA 
was the positive control for this experiment. Figure (c) to (f) depicted the dose dependent 
effects of C. sinensis at (c) 0.5 mg/mL, (d) 1 mg/mL, (e) 3 mg/mL, and (f) 5 mg/mL . The 
black peaks referred to untreated control; the red peak was C. s/ne/is/s-treated cells. 
Figure (g) to (i) respectively showed 0.5 mg/mL, 1 mg/mL, and 1.5 mg/mL of 
H E R B S n S E N S E S 丁 M Cordyceps. The purple peaks referred to untreated control; the blue 
peak was HERBSnSENSES™ Corofyceps-treated cells. 
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7.3. Discussion 
Macrophage contributes to the first line defence of the host immune 
responses. Activation of macrophages thereby prevents an infection from 
being established. Results showed that both natural C. sinensis and 
H E R B S n S E N S E S ™ Cordyceps promoted macrophage functions by 
upregulating the phagocytic activities and R O S synthesis. A m o n g the two 
T C M preparations, results indicated that H E R B S n S E N S E S ™ Cordyceps was 
the better trigger of phagocytosis while C. sinensis m a y activate the R O S 
production more promptly. This m a y be accounted for by the fact that 
H E R B S n S E N S E S ™ Cordyceps is the cultured fruiting bodies of C. sinensis. 
Active ingredients contributed to the induction of R O S release m a y be chiefly 
allocated in parts other than the fruiting bodies of C. sinensis. Conversely, the 
fruiting bodies m a y contain more potent stimulants for phagocytosis. 
Enhancement of phagocytosis by C. sinensis and H E R B S n S E N S E S ™ 
Cordyceps m a y promote engulfment of apoptotic cells (Roos et al, 2004), 
which is known to be important in the remodeling of tissues (Fadeel, 2003). 
The elevation of R O S production by C. sinensis and H E R B S n S E N S E S ™ 
Cordyceps implicated the potential anti-tumor activities exerted by these two 
T C M preparations. It has been known that the H2O2 secreted by 
macrophages can lyse tumor cells without phagocytosis (Nathan et al, 1981). 
Experiments have also demonstrated that H2O2 and N O were used in concert 
against a human ovarian cancer cell line (Farias-Eisner et al, 1996). Because 
C. sinensis seemed to be a better stimulant for R O S release, results therefore 
suggested the more potent role of C. sinensis in possessing anti-tumor 
activities. Furthermore, C. sinensis and H E R B S n S E N S E S ™ Cordyceps m a y 
modulate the innate immunity through the R O S cell signaling pathways. 
Recent findings have suggested that R O S regulates intracellular signaling of 
the immune system (Remick et al, 1996; Forman et al, 2002; Foley et al, 
2003). The R O S m a y regulate through TLR4 via their effects on nuclear factor 
kappa B (NF-kappa B) activation (Asehnoune et al, 2004; Ryan et al, 2004). 
Dead cells triggered macrophage phagocytosis. Our cytotoxicity test showed 
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that C. sinensis at 7 mg/mL and H E R B S n S E N S E S ™ Cordyceps at 2 m g / m L 
retained cell viability by more than 75 % . Therefore, the significant phagocytic 
activities resulted by the stimulation of C. sinensis (7 mg/mL) and 
H E R B S n S E N S E S ™ Cordyceps (2 mg/mL) m a y chiefly contributed to the 
ingredients contained in the T C M preparations rather than to the present dead 
cells. Moreover, although statistical significance cannot be obtained at the O C 
of the two T C M preparations, there was observable increase in the 
percentage of phagocytic cells under the influences of C. sinensis and 
H E R B S n S E N S E S ™ Cordyceps. 
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Apoptosis of Selected Cancer Cell Lines 
8.1. Introduction 
Apoptosis, a physiological process for killing cells, is critical for the normal 
development and functioning of multicellular organisms (Arends et al, 1991; 
Strasser et al, 2000). Abnormalities in the cell death control can contribute to 
cancer. 
Apoptosis is characterized by a number of well-defined features including 
cellular morphological change, chromatin condensation, oligonucleosomal 
D N A cleavage, membrane blebbing, translocation of phosphatidylserine from 
the inner to the outer leaflet of the plasma membrane, and activation of a 
family of cysteine proteases called caspase (Kerr et al, 1972; Wyllie et al, 
1980; Cohen et al, 1992; Thornberry et al, 1998; Earnshaw et al, 1999). The 
present study primarily investigated apoptotic effects of C. sinensis and 
H E R B S n S E N S E S ™ Cordyceps on the cellular morphological change and 
translocation of phosphatidylserine of seven selected cancer cell lines, which 
included four human and three mouse cancer cell lines. The human cell lines 
were the myeloid leukemia Eosinophilic Leukemic Cell Line (EoL-1), the 
hepatocellular carcinoma Hep-3B Cell Line, promyelocytic leukemia H u m a n 
Leukemic Cell Line (HL-60), and the mast cell leukemia H u m a n Mast Cell 
Line (HMC-1). The mouse cancer cell lines included the lymphoid tumor 
PU5-1.8, carcinoma Ehrlich Ascites Tumor (EAT), and the sarcoma 
Sarcoma-180 (SC-180) cells. Specifically, EoL-1 was established from the 
peripheral blood of a 33-year-old m a n with acute eosinophilic leukemia and 
hypereosinophilic syndrome (Saito et al, 1985). Hep-3B is a human 
hepatoma-derived cell line (Aden et al, 1979). HL-60 was derived from the 
peripheral blood leukocytes of a 36-year-old Caucasian female with acute 
promyelocytic leukemia (Collins et al, 1977). H M C - 1 was initially established 
from a 52-year-old patient with mast cell leukemia (Butterfield et al, 1988). 
E A T is a poorly differentiated malignant tumor which appeared originally as a 
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spontaneous breast carcinoma in mice (Sato et al, 1961). It has been 
commonly used as a screening tool for anti-cancer agent. PU5-1.8 is a 
monocytes/macrophages cell line established from the lymphoid tumor of 
mouse Mus musculus (Ralph et al, 1974). SC-180 is a highly malignant 
sarcoma cell (Lackie et al, 1999) initially established from Foley et al in 1959. 
These cell lines were incubated with C. sinensis and H E R B S n S E N S E S ™ 
Cordyceps for 24 hours. Cytotoxicity was measured by trypan blue exclusion 
assay as described in Section 3.3.10. Cell proliferation and apoptosis were 
detected by BrdU Proliferation ELISA (Section 3.5.7) and T A G S ™ annexin 
V-FITC/PI staining kit (Section 3.5.16)，respectively. Cells were stained to 
further confirm cellular morphological changes (Section 3.5.15). Results were 
presented as follows. 
8.2. Results 
8.2.1. Differential Cytotoxic Effects of natural Cordyceps sinensis and 
HERBSnSENSES™ Cordyceps on Various Cancer Cell Lines In 
vitro 
Results showed that C. sinensis and H E R B S n S E N S E S ™ Cordyceps did not 
impose significant (p > 0.05) cytotoxicity to all cancer cell lines tested (Figure 
8.1). However, H E R B S n S E N S E S ™ Cordyceps showed prominent but not 
significant cytotoxicity to the murine macrophage/monocytes cell line PU5-1.8 
(p > 0.05). Viability of cancer cells retained > 80 % at the highest 
concentrations tested (C. sinensis at 9 mg/mL and H E R B S n S E N S E S ™ 
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8.2.2. Differential Anti-Proliferative Effects of natural Cordyceps 
sinensis and HERBSnSENSES^"^ Cordyceps on Various Cancer 
Cell Lines In vitro 
Figure 8.2 shows the in vitro effects of C. sinensis and H E R B S n S E N S E S ™ 
Cordyceps on the proliferation of various cancer cell lines. Results indicated 
that different cell lines employed different sensitivity to s a m e dose of the T C M 
preparation. The order of sensitivity of cancer cell lines to C. sinensis (3 
mg/mL) and H E R B S n S E N S E S ™ Cordyceps (1 mg/mL) were EoL-1 > 
PU5-1.8 > SC-180 > E A T > Hep-3B > H M C - 1 > HL-60 and PU5-1.8 > EoL-1 > 
H M C - 1 > E A T > Hep-3B > HL-60 > SC-180, respectively. The higher the 
concentrations of the T C M preparations, the greater the inhibition of cell 
proliferation. Results also showed that low concentrations of 
H E R B S n S E N S E S ™ Cordyceps (< 1 mg/mL) was mitogenic to HL-60 and 
SC-180. Yet natural C. sinensis inhibited cell proliferation of the cancer cell 
lines at all experimented dosages. 
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Figure 8.2. In vitro Effects of (a) C. sinensis and (b) HERBSnSENSES™ 
Cordyceps on the proliferation of EAT, EoL-1, HEP3B, HL60, HMC-1, 
PU5-1.8 and SC-180 cancer cell lines. Cancer cells (1x10® cells/mL) were 
treated with various concentrations of C. sinensis and H E R B S n S E N S E S ™ 
Cordyceps as indicated in the figure for 20 hours, followed by BrdU 
proliferation ELISA. The graph was plotted from triplicate results and by 
percentage of cell proliferation vs concentrations of the T C M preparations. 
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8.2.3. Differential Apoptotic Effects of Natural Cordyceps sinensis and 
HERBSnSENSES™ Cordyceps on Various Cancer Cell Lines In 
vitro 
8.2.3.1. Peripheral Blood Mononuclear Cells 
H u m a n peripheral blood mononuclear cells were used as a normal control for 
the investigating human cell lines. Results indicated that C. sinensis protected 
P B M C from apoptosis at 1 mg/mL. Apoptotic cells increased from 20 % to 26 
and 36 % under the effects of C. sinensis at 3 and 5 mg/mL, respectively. O n 
the other hand, H E R B S n S E N S E S ™ Cordyceps induced apoptosis from 20 % 
to 23，28 and 34 % under the treatment of H E R B S n S E N S E S ™ Cordyceps at 
0.5, 1，and 2 mg/mL, respectively. Results showed that both C. sinensis and 
H E R B S n S E N S E S ™ Cordyceps did not induce significant apoptosis on P B M C 
from triplicate experiments (p > 0.05) (Figure 8.3). 
8.2.3.2. Hepatocarcinoma Hep-SB 
As shown in Figure 8.4, C. sinensis increased apoptosis of Hep-3B from 4 % 
to 19，15，and 14 % under the effects of C. sinensis at 1, 3 and 5 mg/mL, 
respectively, while H E R B S n S E N S E S ™ Cordyceps induced apoptosis from 4 
% to 16 and 21 % at concentrations 1 and 2 mg/mL，respectively. Results 
showed that both C. sinensis and H E R B S n S E N S E S ™ Cordyceps promoted 
apoptosis of Hep-3B in a dose-dependent manner. Yet，the higher the 
concentration of C. sinensis, the lesser apoptosis was induced; while 
H E R B S n S E N S E S ™ Cordyceps yielded a higher percentage of apoptotic cells 
in high concentrations. Both C. sinensis and H E R B S n S E N S E S ™ Cordyceps 
did not induce significant apoptosis on Hep-3B from triplicate experiments (p 
> 0.05). 
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Figure 8.3. In vitro apoptotic effects of (b-d) natural C. sinensis and (e-g) 
HERBSnSENSES™ Cordyceps on peripheral blood mononuclear cells (PBMC). 
(a) Control PBMC; C. sinensis at (b) 1 mg/mL, (c) 3 mg/mL, (d) 5 mg/mL; 
HERBSnSENSES™ Cordyceps at (e) 0.5 mg/mL, (f) 1 mg/mL, and (g) 2 mg/mL. 
PBMC (1 X 10® cells/mL) were cultured with various concentrations of C. sinensis and 
HERBSnSENSES™ Cordyceps for 24 hours, followed by annexin V-FITC / PI 
apoptosis assay. The apoptotic cells were detected by flow cytometry and were 
presented in dot plot of PI vs Annexin V-FITC. This figure shows a representative 
result from three separated experiments. The percentage of cells in each quadrant is 
displayed on the right hand corner of the corresponding dot plot. 
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Figure 8.4. In vitro apoptotic effects of (b-d) natural C. sinensis and (e-f) 
HERBSnSENSES™ Cordyceps on Hep-3B cancer cell line, (a) Control 
Hep-3B; C. sinensis at (b) 1 mg/mL, (c) 3 mg/mL, (d) 5 mg/mL; 
H E R B S n S E N S E S ™ Cordyceps at (e) 1 mg/mL and (f) 2 mg/mL. Hep-3B (1 x 
10® cells/mL) were cultured with various concentrations of C. sinensis and 
H E R B S n S E N S E S ™ Cordyceps for 24 hours, followed by annexin V-FITC / PI 
apoptosis assay. The apoptotic cells were detected by flow cytometry and 
were presented in dot plot of PI vs Annexin V-FITC. This figure shows a 
representative result from triplicate experiments. The percentage of cells in 
each quadrant is displayed on the right hand corner of the corresponding dot 
plot. 
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8.2.3.3. Human Eosinophilic Leukemic Cell Line 
Figure 8.5 shows the apoptotic effects of C. sinensis and H E R B S n S E N S E S ™ 
Cordyceps on the myeloid leukemia EoL-1 cell line. Apoptosis of EoL-1 was 
increased from 9 % to 18，23 and 33 % in the treatment of C. sinensis at 1, 3 
and 5 mg/mL, respectively, while H E R B S n S E N S E S ™ Cordyceps induced 
apoptosis remarkably from 9 % to 54, 56 and 49 % at concentrations 0.5, 1 
and 1.5 mg/mL，respectively. The side scatter (SSC) vs forward scatter (FSC) 
dot plots showed observable morphological changes of EoL-1 in the action of 
H E R B S n S E N S E S ™ Cordyceps. This result was confirmed by using 
Hemacolor™ stain of the EoL-1 cells (Figure 8.5i). Apoptotic bodies can be 
clearly observed under microscope when EoL-1 was treated with 
H E R B S n S E N S E S ™ Cordyceps (1.5 mg/mL). However, there was not much 
morphological changes of EoL-1 induced by natural C. sinensis. There was 
statistical significance from six separated experiments when compared the 
treatment group with the control (p < 0.05). 
8.2.3.4. Human Mast Cell Line 
As shown in Figure 8.6, C. sinensis increased apoptosis of H M C - 1 from 10 % 
to 15, 16，and 16 % under the in vitro effects of C. sinensis at 1 mg/mL, 3 
m g / m L and 5 mg/mL, respectively, while H E R B S n S E N S E S ™ Cordyceps 
induced apoptosis from 10 % to 14, 12 and 11 % at concentrations 0.5 mg/mL, 
1 mg/mL and 2 mg/mL，respectively. Results showed that both C. sinensis 
and H E R B S n S E N S E S ™ Cordyceps promoted apoptosis of Hep-3B in a 
dose-dependent manner. The higher the concentration of 
H E R B S n S E N S E S ™ Cordyceps, the lesser apoptosis was induced; while C. 
sinensis yielded a higher percentage of apoptotic cells in high concentrations. 
The S S C vs F S C dot plot also showed that there was not much morphological 
changes induced by the two T C M preparations. Moreover, both C. sinensis 
and H E R B S n S E N S E S ™ Cordyceps did not induce significant apoptosis on 
H M C - 1 cells from triplicate experiments (p > 0.05). 
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Figure 8.5. In vitro apoptotic effects of (B-D) natural C. sinensis and (E-G) 
HERBSnSENSES™ Cordyceps on EoL-1 cancer cell line. (A) Control 
EoL-1; C. sinensis at (B) 1 mg/mL, (C) 3 mg/mL, and (D) 5 mg/mL; 
H E R B S n S E N S E S ™ Cordyceps at (E) 0.5 mg/mL, (F) 1 mg/mL and (G) 1.5 
mg/mL. EoL-1 (1 x 10® cells/mL) were cultured with various concentrations of 
C. sinensis and H E R B S n S E N S E S ™ Cordyceps for 24 hours, followed by 
annexin V-FITC / PI apoptosis assay. The apoptotic cells were detected by 
flow cytometry and were presented in dot plot of (ii) side scatter (SSC) vs 
forward scatter (FSC) and (iii) PI vs Annexin V-FITC. Morphological change 
was further confirmed by (i) Hemacolor™ stained cells under 400x 
microscope. This figure shows a representative result from six separated 
experiments. The percentage of cells in each quadrant is displayed on the 
right hand corner of the corresponding dot plot. 
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Figure 8.6. In vitro apoptotic effects of (B-D) natural C. sinensis and (E-G) 
HERBSnSENSES™ Cordyceps on human HMC-1 cancer cell line. (A) 
Control HMC-1; C. sinensis at (B) 1 mg/mL, (C) 3 mg/mL, (D) 5 mg/mL; 
H E R B S n S E N S E S ™ Cordyceps at (E) 0.5 mg/mL, (F) 1 mg/mL and (G) 2 
mg/mL. H M C - 1 (1 x 10® cells/mL) were cultured with various concentrations of 
C. sinensis and H E R B S n S E N S E S ™ Cordyceps for 24 hours, followed by 
annexin V-FITC / PI apoptosis assay. The apoptotic cells were detected by 
flow cytometry and were presented in dot plot of (i) side scatter (SSC) vs 
forward scatter (FSC) and (ii) PI vs Annexin V-FITC. This figure shows a 
representative result from three separated experiments. The percentage of 
cells in each quadrant is displayed on the right hand corner of the 
corresponding dot plot. 
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8.2.3.5. Human Leukemic Cell Line (HL-60) 
Figure 8.7 shows the apoptotic effects of C. sinensis and H E R B S n S E N S E S ™ 
Cordyceps on the promyeloid leukemia HL-60 cell line. Apoptosis of HL-60 
w a s very slightly induced from 6.01 % to 6.03，7.79 and 11.16 % in the 
treatment of C. sinensis at 1，3 and 5 mg/mL, respectively, while 
H E R B S n S E N S E S ™ Cordyceps also slightly induced apoptosis from 6 % to 9， 
14 and 19 % at concentrations 0.5, 1 and 1.5 mg/mL，respectively. The S S C 
vs F S C dot plots did not showed significant morphological changes of HL-60 
in the action of both C. sinensis and H E R B S n S E N S E S ™ Cordyceps. There 
w a s no statistical significance from triplicate experiments when compared the 
treatment group with the control (p > 0.05). 
8.2.3.6. Murine Macrophages/Monocytes Cell Line PU5-1.8 
As shown in Figure 8.8，C. sinensis increased apoptosis of PU5-1.8 from 5 % 
to 11，50, and 78 % under the in vitro effects of C. sinensis at 1，3，and 5 
mg/mL, respectively, while H E R B S n S E N S E S ™ Cordyceps induced 
apoptosis from 5 % to 62，64 and 64 % at concentrations 0.5，1 and 1.5 
mg/mL，respectively. Results showed that only C. sinensis promoted 
apoptosis of PU5-1.8 in a dose-dependent manner. Increasing concentrations 
of C. sinensis were accompanied by an increased apoptotic effects on 
PU5-1.8 cell lines. However, H E R B S n S E N S E S ™ Cordyceps immediately 
showed its apoptotic effectiveness at concentration as low as 0.5 mg/mL. The 
S S C vs F S C dot plot also demonstrated that there were prominent 
morphological changes induced by H E R B S n S E N S E S ™ Cordyceps, but slight 
morphological changes in natural C. sinensis. These results were confirmed 
by using Hemacolor™ stain, which showed that there were tremendous 
increase of vacuoles in PU5-1.8 treated with C. sinensis (> 1 mg/mL) and 
H E R B S n S E N S E S ™ Cordyceps (> 0.5 mg/mL). There was statistical 
significance from triplicate experiments when compared the treatment group 
with the controls (p < 0.05). 
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Figure 8.7. In vitro apoptotic effects of (B-D) natural C. sinensis and (E-G) 
HERBSnSENSES™ Cordyceps on HL-60 cancer cell line. (A) Control 
HL-60; C. sinensis at (B) 1 mg/mL, (C) 3 mg/mL, (D) 5 mg/mL; 
H E R B S n S E N S E S ™ Cordyceps at (E) 0.5 mg/mL, (F) 1 mg/mL and (G) 1.5 
mg/mL. HL-60 (1x10® cells/mL) were cultured with various concentrations of 
C. sinensis and H E R B S n S E N S E S ™ Cordyceps for 24 hours, followed by 
annexin V-FITC / PI apoptosis assay. The apoptotic cells were detected by 
flow cytometry and were presented in dot plot of (i) side scatter (SSC) vs 
forward scatter (FSC) and (ii) PI vs Annexin V-FITC. This figure shows a 
representative result from three separated experiments. The percentage of 
cells in each quadrant is displayed on the right hand corner of the 
corresponding dot plot. 
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Figure 8.8. In vitro apoptotic effects of (B-D) natural C. sinensis and (E-G) 
HERBSnSENSES™ Cordyceps on PU5-1.8 cancer cell line. (A) Control 
PU5-1.8; C. sinensis at (B) 1 mg/mL, (C) 3 mg/mL, and (D) 5 mg/mL; 
H E R B S n S E N S E S ™ Cordyceps at (E) 0.5 mg/mL, (F) 1 mg/mL and (G) 1.5 
mg/mL. PU5-1.8 (1 x 10® cells/mL) were cultured with various concentrations 
of C. sinensis and H E R B S n S E N S E S ™ Cordyceps for 24 hours, followed by 
annexin V-FITC / PI apoptosis assay. The apoptotic cells were detected by 
flow cytometry and were presented in dot plot of (i) side scatter (SSC) vs 
forward scatter (FSC) and (ii) PI vs Annexin V-FITC. Morphological change 
was further confirmed by (i) Hemacolor™ stained cells under 400x 
microscope. This figure shows a representative result from three separated 
experiments. The percentage of cells in each quadrant is displayed on the 
right hand corner of the corresponding dot plot. 
"“ -141-
Chapter 8 - Apoptosis of Selected Cancer Cell Lines 
8.2.3.7. Murine Erhlich Ascites Tumor (EAT) 
Figure 8.9 shows the apoptotic effects of C. sinensis and H E R B S n S E N S E S ™ 
Cordyceps on the murine carcinoma E A T cell line. Apoptosis of E A T was 
slightly heightened from 5 % to 12，12 and 14 % in the treatment of C. 
sinensis at 1, 3 and 5 mg/mL, respectively, while H E R B S n S E N S E S ™ 
Cordyceps induced apoptosis from 5 % to 13，19 and 30 % at concentrations 
0.5, 1 and 2 mg/mL，respectively. The S S C vs F S C dot plots did not showed 
profound morphological changes of HL-60 in the action of both C. sinensis 
and H E R B S n S E N S E S ™ Cordyceps. There was no statistical significance 
from triplicate experiments (p > 0.05). 
8.2.3.8. Murine Sarcoma 180 (SC-180) 
As shown in Figure 8.10，SC-180 treated with C. sinensis and 
H E R B S n S E N S E S ™ Cordyceps did not show apoptosis. There was no 
.statistical significance from triplicate experiments (p > 0.05). The S S C vs F S C 
dot plot also did not show any morphological changes induced by the T C M 
preparations. 
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Figure 8.9. In vitro apoptotic effects of (B-E) natural C. sinensis and (F-H) 
HERBSnSENSES™ Cordyceps on E A T cancer cell line. (A) Control EAT; 
C. sinensis at (B) 1 mg/mL, (C) 3 mg/mL, (D) 10 mg/mL; H E R B S n S E N S E S ™ 
Cordyceps at (E) 0.5 mg/mL, (F) 1 mg/mL and (G) 2 mg/mL. E A T (1x10® 
cells/mL) were cultured with various concentrations of C. sinensis and 
H E R B S n S E N S E S ™ Cordyceps for 24 hours, followed by annexin V-FITC / PI 
apoptosis assay. The apoptotic cells were detected by flow cytometry and 
were presented in dot plot of (i) side scatter (SSC) vs forward scatter (FSC) 
and (ii) PI vs Annexin V-FITC. This figure shows a representative result from 
three separated experiments. The percentage of cells in each quadrant is 
displayed on the right hand corner of the corresponding dot plot. 
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Figure 8.10. In vitro apoptotic effects of (B-E) natural C. sinensis and 
(F-H) HERBSnSENSES^"^ Cordyceps on SC-180 cancer cell line. (A) 
Control SC-180; C. sinensis at (B) 1 mg/mL, (C) 3 mg/mL, (D) 10 mg/mL; 
H E R B S n S E N S E S ™ Cordyceps at (E) 1 mg/mL, (F) 2 mg/mL and (G) 5 
mg/mL. SC-180 (1 x 10® cells/mL) were cultured with various concentrations 
of C. sinensis and H E R B S n S E N S E S ™ Cordyceps for 24 hours, followed by 
annexin V-FITC / PI apoptosis assay. The apoptotic cells were detected by 
flow cytometry and were presented in dot plot of (i) side scatter (SSC) vs 
forward scatter (FSC) and (ii) PI vs Annexin V-FITC. This figure shows a 
representative result from three separated experiments. The percentage of 
cells in each quadrant is displayed on the right hand corner of the 
corresponding dot plot. 
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8.3. Discussion 
The prolongation of life span in human beings has been associated with an 
escalation of age-related diseases such as cancer. Subversion of apoptosis is 
one of the cause for tumorigenesis. Therefore, agents capable of inducing 
apoptosis in tumor cells are thought to have therapeutic values in control of 
malignancy. Recent researches have contributed much to the search of a 
chemopreventive agent to induce apoptosis (Reed, 2002; Sun et al, 2004). In 
our present study, w e screened for the apoptotic activities possessed by C. 
sinensis and H E R B S n S E N S E S ™ Cordyceps on four human and three murine 
cancer cell lines. A m o n g these cancer cell lines, only the human myeloid 
cancer cell line EoL-1 and murine macrophage/monocytes cancer cell line 
PU5-1.8 exhibited apoptosis upon the treatment. The optimal concentration of 
H E R B S n S E N S E S ™ Cordyceps induced apoptosis to a greater extent than 
that of C. sinensis on these two cell lines. These data suggested that 
H E R B S n S E N S E S ™ Cordyceps m a y be a better inducer of apoptosis. 
Cytotoxicity test showed that treated EoL-1 and PU5-1.8 cells reserved their 
viability above 90 % . Cell proliferation assay showed also a strong inhibition 
on the treated EoL-1 and PU5-1.8 cells. These data postulated that C. 
sinensis and H E R B S n S E N S E S ™ Cordyceps exerted their in vitro anti-tumor 
activities by programmed cell death rather than necrosis or direct killing. 
Compared to the control cell P B M C , w e could confirm the profound apoptosis 
in PU5-1.8 and EoL-1 were specific to the cells itself. Yet, the HL-60 cells, 
another myeloid cell line, cannot respond to apoptosis. This suggest that C. 
sinensis and H E R B S n S E N S E S ™ Cordyceps m a y induce apoptosis to human 
myeloid and murine lympoid tumor but further study are required before 
presenting a concluding remark. Mechanistic study of the apoptotic effects of 
C. sinensis and H E R B S n S E N S E S ™ Cordyceps are necessary for the 
confirmation that these T C M preparations are potent therapeutic agents in 
apoptosis induction. 
Furthermore, although certain degree of apoptosis was observed in the 
human hepatocarcinoma Hep-3B, human mast cell line HMC-1, human 
leukemic cell line HL-60, and murine Erhlich ascites tumor EAT, these 
apoptosis were rather non-specific when compared to the control P B M C cells. 
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Apoptosis induced on these cell lines in the presence of C. sinensis and 
H E R B S n S E N S E S ™ Cordyceps m a y chiefly because of the increasing 
viscosity or inhibitors in the medium which affects signaling pathways of 
apoptosis. 
Recent experiments, however, have suggested that the extracts of C. sinensis 
do not prevent Fas-receptor and hydrogen peroxide-induced T-cell apoptosis 
(Buenz et a/, 2004). Conversely, Yang et al have shown that extracts of C. 
sinensis m a y promote apoptosis by down regulating anti-apoptotic Bcl-2 
family members (Yang et al, 2003). Therefore, w e speculated that the 
Yin-yang double invigorated C. sinensis m a y affect apoptosis from two ways, 
depending on the microenvironment of the tumor cells and the types of the 
tumor. This m a y explain our findings that not all tumor cells apoptosed in 
responded to C. sinensis and H E R B S n S E N S E S ™ Cordyceps, and two 
myeloid cells can have very different response to the Cordyceps treatment. 
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9.1. Introduction 
Escalation of cancer prevalence has m a d e the search of chemopreventive 
agents an urgent necessity. The recently established correlation between 
cancer and diet (de Burgh, 2004) has intensified the search through natural 
occurring agents (Dasgupta et al, 2004; Gagandeep et al, 2004; Sharma et al, 
2004; Zhang et al, 2004; Saha et al, 2004，Ito et al, 2004; Jang et al, 2004). 
Report has shown that Paecilomyces japonica, a close relative of C. sinensis, 
possesses anti-tumor and immuno-stimulating activities (Shin et al, 2003). 
Extracts from Cordyceps militaris, another Cordyceps species, have 
demonstrated in vivo growth repression of melanoma B16-F10 cells in mice 
(丫00 et al, 2004). The potential anti-tumor role of C. sinensis has therefore 
been suggested in Chapter 1. Furthermore, the theories of 
immunosurveillance (Burnet, 1957) and immunoediting (Dunn et al, 2002) 
speculate an intimacy of tumor ablation with the immune system. The 
anti-tumor activities of C. sinensis, if present, m a y relate to the immunity. In 
addition, mouse is a valuable disease model because it shares many genetic, 
physical, physiological, and biological traits with humans (Weiss and Shannon, 
2002). Difficulty in carrying out chemopreventive trials in large human cohorts 
can be overcomed by modeling human diseases in the murine system. In this 
study, w e therefore harnessed the mouse as an in vivo model for examining 
the potential role of H E R B S n S E N S E S ™ Cordyceps, a commercially available 
form of C. sinensis, in immunomodulation and anti-tumorigenicity. The 
anti-tumor activity of H E R B S n S E N S E S ™ Cordyceps is compared with the 
natural C. sinensis. 
T w o murine models were structured in the experiments, namely, the ICR 
survival model, and the BALB/c immunomodulation and anti-tumor model. 
The former m a d e use of the carcinoma Erhlich ascites tumor (EAT) as a 
modeling cancer, while the latter harnessed sarcoma SC-180. The ICR and 
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BALB/c mice assays were carried out accordingly as described in Section 
3.4.2 and 3.4.3. The mice were grouped according to their treatments. ICR 
mice receiving H E R B S n S E N S E S ™ Cordyceps were designated Group A 
mice, with a suffix of 1 or 7 to denote the start-date of H E R B S n S E N S E S ™ 
Cordyceps oral feeding after E A T inoculation. ICR mice fed with natural C. 
sinensis were named Group B mice. The BALB/c mice were grouped into 
Group 1，2，3 and 4，which respectively represented control mice, mice with 
H E R B S n S E N S E S ™ Cordyceps, tumor-bearing mice, and tumor bearing mice 
with H E R B S n S E N S E S ™ Cordyceps. 
9.2. Results 
9.2.1. The ICR Mice Model 
9.2.1.1. In vivo Effects of Natural C. sinensis and HERBSnSENSES™ 
Cordyceps on the Ascitic Fluid Production of ICR Mice 
Table 9.1 shows that there was no significant difference between the weights 
of treated mice and its respective control on the day after tumor injection 
(p > 0.05) (Table 9.1). 
Mean Weight (body) I g (Mean ± SD) 
Group N Survival 
Day 0 Day 10 
(days) 
A 7 Control ^ ^ 25.8 ± 1.1 45.7 ±2.4 
A J ^ 1^4 24.7 ±2.6 44.3 ±3.1 
A 1 Control ^ 26.2 ± 2.9 46.9 ± 3.3 
M ^ T ^ 25.9 ± 1.2 47.8 ±3.8 
^ B Control 10 28.7 ± 3.4 42.4 ± 5.6 
B To 14 27.4 ± 1.8 4 3 . 9 ± 1.7 
Table 9.1. Effects of C. sinensis and HERBSnSENSES™ Cordyceps on 
the survival and weights of EAT-bearing mice. 
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9.2.1.2. Effects of Natural C. sinensis and HERBSnSENSES™ 
Cordyceps on the Survival of Tumor-bearing ICR Mice 
As shown in Table 9.1, the m e a n survival days of Group A 7 mice were 
prolonged by nearly two-fold. However, survival of the Group A 1 and B mice 
were not significantly lengthened (Table 9.1). Figure 9.1 shows that the death 
of Group B mice w a s delayed by three days but begun sharply thereafter. Yet, 
the whole batch of Group B mice died one day sooner than its control group. 
As shown in Figure 9.2 and 9.3, the dying trend of both Group A-1 and A-7 
mice and their respective control were resembled. The death of Group A-1 
began only one day later than its control but both groups were completely 
sacrificed on the 17th day after tumor-injection, while the death of Group A-7 
w a s shifted and delayed by two days when compared to its control. 
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Figure 9.1. In vivo effects of C. sinensis on the survival of EAT-bearing 
mice. Twenty tumor bearing ICR mice were equally divided into control and 
treated group. Natural C. sinensis was applied on the day after tumor 
inoculation. The survival curve is plotted by no. of viable mice vs day of 
treatments. 
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Figure 9.2. In vivo effects of HERBSnSENSES™ Cordyceps on the 
survival of EAT-bearing mice with therapy-start day on Day 1. Forty-two 
tumor bearing ICR mice were equally divided into control and treated group. 
H E R B S n S E N S E S ™ Cordyceps was applied on the ft day after tumor 
inoculation. The survival curve is plotted by no. of viable mice vs day of 
treatments. 
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Figure 9.3. In vivo effects of HERBSnSENSES™ Cordyceps on the 
survival of EAT-bearing mice with therapy-start day on Day 7. 
Twenty-eight tumor bearing ICR mice were equally divided into control and 
treated group. H E R B S n S E N S E S ™ Cordyceps was applied on the day 
after tumor inoculation. The survival curve is plotted by no. of viable mice vs 
day of treatments. 
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9.3. The BALB/c Mice Model 
9.3.1. In vivo Effects of HERBSnSENSES™ Cordyceps on Spleen and 
Tumor Weight 
As shown in Table 9.2，spleen weight of Group 2 mice was slightly elevated 
by 6 % when compared to that of Group 1 mice (p > 0.05). Conversely, spleen 
weight of Group 4 mice was significantly suppressed by 36 % when compared 
to Group 3 mice (p = 0.039). Similarly, tumor weight was repressed by 47 % 
w h e n compared Group 4 vs Group 3 mice (p > 0.05). 
Spleen Weight Tumor Weight / 
Gp. Treatment Group N I g g 
(Mean 土 SD) (Mean 土 SD) 
1 Normal mice Tl 0.109 ± 0.015 
Normal mice fed with N/A 
2 • 11 0.116 ±0.016 
H E R B S n S E N S E S ™ Cordyceps 
T u m o r bearing mice 11 0.176 土 0.087 1.126 ± 0.780 
T u m o r bearing mice fed with 
4 ,,, 11 0.113 ±0.013 0.605 ±0.257 
H E R B S n S E N S E S ™ Cordyceps 
Table 9.2. In vivo effects of HERBSnSENSES™ Cordyceps on spleen 
and tumor weight of BALB/c mice and tumor-bearing BALB/c mice. N/A: 
Not Applicable. 
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9.3.2. Effects of HERBSnSENSES™ Cordyceps on the Mitogenic 
Activities of Spleen Cells 
A s shown in Figure 9.4a, mitogenicity of Group 2's spleen cells was elevated 
to 23.14 土 13.41 % when compared to that of Group 1. Conversely, the 
mitogenic activity of spleen cells of Group 4 mice was suppressed by 38.07 土 
11.13 % when compared to that of Group 3. Figure 9.4b and c show that the 
mitogenicity of LPS-activated spleen cells was generally upregulated in all 
four groups. In Figure 9.4b, the LPS-activated spleen cells of Group 2 were 
heightened when compare to that of Group 1，yet no significant difference can 
be obtained (p > 0.05). However, the LPS-activated spleen cells of Group 4 
w a s significantly promoted when compared to that of Group 3 (p = 0.025). As 
shown in Figure 9.4c, Mitogenicity of PHA-activated spleen cells was also 
significantly enhanced in Group 4 when compared to that in Group 3 (p = 
0.021), yet no significant difference can be acquired when comparing Group 2 
vs Group 1 (p > 0.05). 
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Figure 9.4. Effects of HERBSnSENSES™ Cordyceps on the mitogenic 
activities of (a) normal，（b) LPS-activated, and (c) PHA-activated spleen 
cells. Spleen cells were freshly isolated from the spleens of Group 1，2，3， 
and 4 mice. The cells (1 x 10® cells/mL) were incubated with medium, or LPS 
(20 i^g/mL), or PHA (4 ^ig/mL) for 24 hours followed by BrdU proliferation 
ELISA. Percentage of mitogenic acitivity were calculated by respectively 
comparing (a) the control spleen cells of Group 2 and 4 with that of Group 1 
and 3; (b) the LPS-activated spleen cells of Group 1，2, 3 and 4 with the 
normal spleen cells of Group 1，2，3 and 4; (c) the PHA-activated spleen cells 
of Group 1，2，3 and 4 with the normal spleen cells of Group 1，2, 3, and 4. 
The bar-chart was plotted by percentage of mitogenic activity vs treatment 
group of the BALB/c mice. Results are expressed by mean 士 S D for triplicate 
experiments. Statistical analysis was calculated by using unpaired Student's t 
test. A single experiment pooled spleen cells from five mice in the same 
group. 
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9.3.3. In vivo Effects of HERBSnSENSES™ Cordyceps on the Cell 
Surface Expression of CDS, CD4, and CDS 
As shown in Figure 9.5, C D S expression was heightened from 7.72 % in 
Group 1 mice to 36.47 % in Group 2 mice. The florescence counts in M 2 
region of Group 2 mice was enormously increased by 209 % when compared 
to that of Group 1 mice. O n the other hand, the C D S expression of Group 4 
mice w a s enhanced from 13.57 % to 21.1 % when compared to that of Group 
3 mice. The florescence counts in M 2 region of Group 4 mice was elevated by 
24 % when compared to Group 3 mice. 
Figure 9.6 shows that the C D 4 expression was enhanced from 1.97 % to 13.4 
% when compared Group 2 to Group 1 mice. The florescence counts in M 2 
region w a s heightened by 120 % when compared Group 2 to Group 1 mice. 
Similarly, the C D 4 expression was elevated from 12 % in Group 3 mice to 23 
% in Group 4 mice. The florescence counts in M 2 region was increased by 42 
% when compared Group 4 to Group 3 mice. 
As shown in Figure 9.7, C D S expression was only slightly increased from 0.6 
% in Group 1 mice to 2.2 % in Group 2 mice. The florescence counts in M 2 
region of Group 2 mice was merely heightened by 14 % when compared to 
that of Group 1 mice. Similarly, the C D S expression of Group 4 mice was 
enhanced from 1.38 % to 1.50 % when compared to that of Group 3 mice. 
The florescence counts in M 2 region of Group 4 mice was insignificantly 
elevated by 2 % when compared to Group 3 mice. 
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Figure 9.5. Effects of HERBSnSENSES™ Cordyceps on the cell surface 
expression of CDS on spleen cells, (a), (b)，(c) and (d) were respectively 
the isotypic control of C D S expression of (e) Group 1，(f) Group 2，(g) Group 3， 
and (h) Group 4. Spleen cells were freshly isolated from the spleen of Group 1， 
2，3，and 4 mice. The cells (1 x 10^ cells) were then subjected to 
immunopheotyping. C D S Expression was read by flow cytometry and data 
were plotted in a (i) dot plot and (ii) histogram, (i) The percentage of cells in 
each quadrant is displayed on the upper section of the corresponding dot plot, 
(ii) M 1 and M 2 were specially margined to show the region of non-specific and 
specific binding, respectively. A single experiment pooled spleen cells from 
five mice in the same group. Representative results are shown from triplicated 
experiments with essentially identical results. 
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Figure 9.6. Effects of HERBSnSENSES™ Cordyceps on the cell surface 
expression of CD4 on spleen cells, (a), (b), (c) and (d) were respectively 
the isotypic control of C D 4 expression of (e) Group 1 ’（f) Group 2，(g) Group 3， 
and (h) Group 4. Spleen cells were freshly isolated from the spleen of Group 1， 
2，3，and 4 mice. The cells (1 x 10^ cells) were then subjected to 
immunopheotyping. C D 4 Expression was read by flow cytometry and data 
were plotted in a (i) dot plot and (ii) histogram, (i) The percentage of cells in 
each quadrant is displayed on the upper section of the corresponding dot plot, 
(ii) M 1 and M 2 were specially margined to show the region of non-specific and 
specific binding, respectively. A single experiment pooled spleen cells from 
five mice in the same group. Representative results are shown from triplicated 
experiments with essentially identical results. 
- -159-
Chapter 9 - In vivo Animal Study 
I-： u II 0 ' § 
S i 9 9 . 9 3 0 . 0 7 g i 0 0 o ： 
“运； 二 —— 99.37 0.63 - 1—1 
讓 1 0 I I 0 1： 0 I 0 ~ ] h 
8i "99：^""^ gi 97.79 2.21 §： , trw- , •“ I I I I 
： o inS m i s - 的苟•； Ml ^ 
(b) ⑴ 國 , 
、—P^^- - f^^^ii. 1. "...I， H—Jj "M， I, 10 to' 10" 10^  10' 10, 10' CD8FITC CD8FITC 
C D S F I T C C D S F I T C 
li 宭 1 §. 
gj Q 0 gi ji 0 0 o1 
9 9 . 8 4 0 . 1 6 S i 9 8 . 6 2 1 . 3 8 
tii ^ iii  
(c) _ %. ( g ) 職 u . 
ir io' 10丄 10^  10® iqI 10」10^  10^  io' w 』 l o . ® lo' lo^  mP 
CD8FITC CD8FITC CDS FITC CDS FITC 
i-j 0 I I 0 謹1 0 I I 0 n z] 
9 9 . 7 4 0 . 2 6 g - ； 9 8 . 5 | 1 . 5 0 
⑷ • 一 (h) Wf 
o -nrmLi • o jpBfjW^ i \ O、 rv- • ••"•/d => i'WIHPWAni I I J 
1 0 ® 1 0 ^ 1 0 ^ 1 0 ^ 1 0 ' 1 0 ^ 1 0 ^ 1 0 ' 1 0 」 i r 1 0 ^ 1 0 ^ t o " 1 0 ^ 1 0 ^ 1 0 ^ 
CDS FITC CDS FITC CD8 FITC CD8FITC 
(i) (ii) (i) (ii) 
Figure 9.7. Effects of HERBSnSENSES™ Cordyceps on the cell surface 
expression of CDS on spleen cells, (a), (b), (c) and (d) were respectively 
the isotypic control of C D S expression of (e) Group 1，(f) Group 2, (g) Group 3, 
and (h) Group 4_ Spleen cells were freshly isolated from the spleen of Group 1， 
2，3，and 4 mice. The cells (1 x 10^ cells) were then subjected to 
immunopheotyping. C D S Expression was read by flow cytometry and data 
were plotted in a (i) dot plot and (ii) histogram, (i) The percentage of cells in 
each quadrant is displayed on the upper section of the corresponding dot plot, 
(ii) M 1 and M 2 were specially margined to show the region of non-specific and 
specific binding, respectively. A single experiment pooled spleen cells from 
five mice in the same group. Representative results are shown from triplicated 
experiments with essentially identical results. 
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9.3.4. Effects of HERBSnSENSES™ Cordyceps on the Cytokine Release 
from Cultured Spleen cells 
9.3.4.1. TNFa 
As shown in Figure 9.8a, median liberation of T N F a was only slightly 
enhanced in Group 2 mice when compared to its control Group 1 mice (p > 
0.05). Conversely, the release of T N F a was suppressed in Group 4 when 
compared to that in Group 3 mice (p > 0.05). There was a general elevation of 
TNFa production in the tumor-bearing mice (Group 3 and 4) when compared 
to the normal mice (Group 1 and 2)，though the differences did not reach 
statistical significance (p > 0.05). 
Figure 9.8b illustrated the induction of T N F a in the LPS-activated spleen cells. 
Statistical significance cannot be obtained when comparing Group 1 vs 2， 
Group 2 vs 4，Group 1 vs 3 and Group 3 vs 4 mice (p > 0.05). Yet, there was 
observable reduction of T N F a liberation when compared Group 4 vs Group 3 
(p > 0.05). 
Figure 9.8c depicted the induction of T N F a in the PHA-activated spleen cells. 
Results showed that T N F a production in the tumor-bearing Group 4 mice was 
significantly elevated when compared to the normal Group 2 mice (p < 0.05). 
The production of T N F a was undetectable in Group 1 and 2 mice. Statistical 
differences of T N F a liberation between Group 3 and 4 could not be obtained 
but was observable in triplicate experiments. There was a general 
up-regulation of T N F a production in the tumor-bearing mice (Group 3 and 4) 
when compared to the normal mice (Group 1 and 2). 
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9.3.4.2. IFNy 
Figure 9.9a shows that the median production of IFNy was greatly enhanced 
in the Cordyceps-treated tumor bearing mice (Group 4)，though statistical 
significance cannot be acquired (p > 0.05). Conversely, Group 1，2，and 3 
produced undetectable amount of IFNy. 
Figure 9.9b and 9.9c respectively show the amount of IFNy liberation in the 
LPS-activated and PHA-activated spleen cells. The median production of 
IFNy in Group 4 mice was repressed when compared to Group 3 mice. 
Results showed that median IFNy production was more prominent in 
tumor-bearing mice (Group 3 and 4)，while the normal mice (Group 1 and 2) 
synthesized undetectable amount of IFNy. 
9.3.4.3. IL-2 
As shown in Figure 9.10a, median liberation of IL-2 was heightened in the 
tumor bearing mice but culminating in Group 4 mice. The synthesis of IL-2 
w a s undetectable in Group 1 and 2 mice. Figure 9.10b and 9.10c depicts IL-2 
production in the mitogen-activated spleen cells. Results demonstrated that 
the IL-2 liberation in tumor-bearing mice was more prominent than the normal 
mice. Figure 9.10c presents significant difference when compared Group 4 
mice with Group 2 mice (p < 0.05). 
9.3.4.4. IL-4 
Figure 9.11 shows that the IL-4 production in normal, LPS-activated and 
PHA-activated spleen cells were rather undetectable. However, when 
compared IL-4 production in the PHA-activated spleen cells, there was 
statistical significance for the Group 1 and 3 mice (p < 0.05). 
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9.3.4.5. IL-6 
A s shown in Figure 9.12a, b, and c, there was a general increase of IL-6 
production in the tumor-bearing mice (Group 3 and 4) when compared to the 
normal mice (Group 1 and 2). In the mitogen-activated spleen cells of Group 4 
mice, IL-6 liberation was markedly suppressed when compared to Group 3 
mice. 
9.3.4.6. IL-10 
Figure 9.13b shows that the median production of IL-10 was up-regulated in 
the Group 3 mice when compared to that of Group 1 and 2. The 
Corofyceps-treatment of Group 4 mice suppressed the IL-10 production 
significantly (p < 0.05). The observable trend of the IL-10 liberation was vague 
as shown in Figure 9.13a and c. However, there seemed to be a general 
repression of IL-10 synthesis when compared Group 4 to 3 mice. 
9.3.4.7. IL-12p70 
Figure 9.14 shows that the liberation of IL-12p70 from normal, LPS-activated 
and PHA-activated spleen cells were rather undetectable. There was no 
prominent and observable trend for the amount of IL-12p70 synthesized from 
spleen cells. 
9.3.4.8. Monocyte Chemoattractant Protein(MCP)-1 
As shown in Figure 9.15a, the production of chemokine MCP-1 was promoted 
in the Cordyceps-ireaied Group 2 and Group 4 mice when compared to their 
respective control Group 1 and Group 3 mice. Moreover, the synthesis of 
M C P - 1 was undetectable in the control Group 1 and Group 3 mice. Figure 
9.15b and c show that the liberation of MCP-1 was suppressed in Group 4 
mice when compared to Group 3 mice. 
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9.3.5. In vivo Effects of HERBSnSENSES™ Cordyceps on the Cytokine 
Synthesis 
As shown in Figure 9.16 and 9.17，the median serum level of cytokine T N F a 
and chemokine M C P - 1 was statistically insignificant (p < 0.05) but repressed 
in Group 4 mice. However, the amount of cytokines IL-2, IL-4, IL-6, IL-10, 
IL-12p70 and IFNy in the murine serum was undetectable. 
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Figure 9.16. Effects of HERBSnSENSES™ Cordyceps on cytokine TNFa 
liberation. Serum was centrifuged from the freshly collected clotted blood of 
Group 1，2, 3，and 4 mice. The cytokine content in the serum was measured 
by C B A . Experiment was repeated three times with same laboratory 
conditions. Statistical significance was calculated by unpaired Student's t-test. 
The data was plotted by concentration of T N F a vs treatment group. 
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Figure 9.17. Effects of HERBSnSENSES™ Cordyceps on chemokine 
MCP-1 liberation. Serum wase centrifuged from the freshly collected clotted 
blood of Group 1，2，3，and 4 mice. The cytokine content in the serum was 
measured by C B A . Experiment was repeated three times with s a m e 
laboratory conditions. Statistical significance was calculated by unpaired 
Student's t-test. The data was plotted by concentration of MCP-1 vs treatment 
group. 
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9.4. Discussion 
H E R B S n S E N S E S ^ ^ Corydceps is a dietary supplement frequently used in 
Hong Kong and U S A . Previous in vitro study demonstrated that its health 
benefits m a y lie in immunomodulation (Chapter 5-7). The present animal 
study aimed at validating our in vitro observation. W e found that normal mice 
fed with H E R B S n S E N S E S ^ ^ Corydceps or control vehicle did not possess 
remarkable differences in cytokine production (Figure 9.8-17). This result 
assured the safety of H E R B S n S E N S E S ™ Corydceps by suggesting that 
consecutive use over 14 days did not raise auto-immunity or inflammation in 
normal individuals via the over-liberation of cytokines (Miossec, 2003). W e 
found that spleen cell proliferation was enhanced in normal mice fed with 
H E R B S n S E N S E S T M Corydceps (Figure 9.4a). The proliferative spleen cells 
were probably the T helper cells, as suggested from the heightened cell 
surface expression of CD4+ spleen cells (Figure 9.5-6). Spleen weight of 
normal mice fed with H E R B S n S E N S E S ™ Corydceps, however, did not 
significantly increase when compared to their placebo-treated control. This 
implicates that the proliferation of T helper cells was regulated to avoid 
splenomegaly. From these results, w e speculate that H E R B S n S E N S E S ™ 
Corydceps exerts its immunomodulatory effects directly on the T cell surface 
receptors, probably through the polysaccharides contained in 
H E R B S n S E N S E S ^ ^ Corydceps, rather than by cytokine signaling. The 
activated T cells contribute to the enhanced cell-mediated immunity in a 
normal individual, which ultimately enhance the body's immune system 
against invading pathogens. In addition, spleen cells were also activated by 
mitogen in the experiments to mimic the disease condition that 
micro-organism invades and thereby activates the immune system. Results 
demonstrated that spleen cells of normal mice fed with H E R B S n S E N S E S ^ ^ 
Corydceps was more prone to be induced by mitogens, suggesting a 
beneficial role of the drug in enhancing the immune system during infections 
(Figure 9.4b-c). 
The present study also demonstrated anti-tum〇「 potential of 
H E R B S n S E N S E S ™ Corydceps based on a series of immunological 
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parameters. Macroscopically, w e found that SC-180 tumor growth, spleen cell 
proliferation, spleen size and cytokine production were elevated profoundly in 
SC-180-bearing mice treated with the control vehicle. However, daily feeding 
of H E R B S n S E N S E S ™ Corydceps over 14 days restored spleen size, 
remarkably suppressed SC-180 growth, spleen cell proliferation and cytokine 
production. Yet the expression of tumor ablator cytotoxic CD8+ T cells in mice 
treated with H E R B S n S E N S E S ™ Corydceps was not elevated. These 
observations lead us to the hypothesis that H E R B S n S E N S E S ™ Corydceps 
m a y act robustly to eliminate SC-180 cells during the early days of feeding, 
which eventually relieves the anti-tumor immunity on Day 21 after SC-180 
inoculation. To confirm this speculation, further experiments must be carried 
out by experimenting the parameters on different days (e.g. Day 10，14，18 
and 21) after feeding of H E R B S n S E N S E S ™ Corydceps on the tumor 
inoculated mice. 
Tumor-bearing mice fed with H E R B S n S E N S E S ™ Corydceps or control 
vehicle did not show remarkable differences in the cytokine release from 
unstimulated spleen cells (Figure 9.8-17). The monocyte and B cell mitogen, 
LPS, or T cell mitogen, P H A , was added to the spleen cell culture to scale up 
the cytokine liberation. Compared to the placebo treated SC-180-bearing 
mice, w e found that H E R B S n S E N S E S ™ Corydceps apparently repressed 
synthesis of IFNy, T N F a and IL-6 in the mitogen stimulated spleen cells of 
SC-180-bearing mice. In vivo studies have shown that IFNy is a potential 
anti-tumor cytokine (Tannenbaum and Hamilton, 2000; Shankaran et al, 
2001). It has been postulated that IFNy plays a crucial role in mediating the 
anti-tumor immunity (Dunn et al, 2002). T N F a is a multifunctional cytokine 
which induce the differentiation and or maturation of dentritic cells (Jonuleit et 
al, 1996). The activated dendritic cells induce tumor-specific CD4+ T helper 
cells expressing IFNy that facilitate the development of tumor-specific CD8+ T 
cells (Pardoll, 2002; Gerosa et al, 2002; Ferlazzo et al, 2002; Piccioli et al, 
2002). Evidence has also shown that IL-6 effectively antagonize T G F - p i , 
which is secreted by tumor cells to inhibit host's anti-tumor immunity (Ohta et 
al, 2000; Hsiao et al, 2003). Thus, down-regulation of TNFa, IFNy and IL-6 
synthesis in the presence of H E R B S n S E N S E S ™ Corydceps suggested 
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mitigation of the anti-tumor immunity, which was probably because 
H E R B S n S E N S E S ™ Corydceps has already effectively reduced the tumor 
size. However, the exact anti-tumor mechanism exerted by 
H E R B S n S E N S E S ™ Corydceps requires further studies. 
Compare with the control normal mice, IL-2 synthesis significantly increased 
in T cells (PHA-activated spleen cells) of SC-180-bearing mice fed with 
H E R B S n S E N S E S ™ Corydceps, which subsequently lead to an elevation of 
CD3+ and CD4+ T cell expression. These results suggest that 
H E R B S n S E N S E S ™ Corydceps m a y exert its anti-tumor activity via the 
cell-mediated immunity. Besides acting as a T cell growth factor, IL-2 also 
activates lymphokine-activated killer (LAK) cells in tumor immunity (Anwer et 
al, 1993; Kaufman et al, 2002). Further experiments demonstrating the 
anti-tumor activity of H E R B S n S E N S E S ^ ^ Corydceps on other tumor killer 
cells are necessary. Possible tumor killer cells include N K cells, natural killer T 
(MKT) cells, L A K cells, A D C C effector cells and tumor infiltrating lymphocytes 
(TIL) (Girardi et al, 2001 ； Smyth et al, 2001). 
In normal mice, the proportion of CD3+ in spleen T cells ranges 30 - 40 % , 
whereas approximately 2/3 of the T cells in the spleen is CD4+ and 1/3 is 
CD8+. However, the present study was unable to demonstrate this known fact. 
This was probably due to the unavoidable transportation which aimed at 
delivering dead mice from the animal house to the culture cabinet for the in 
vitro experiments on spleen cells. 
The ICR mice model did not show significant life prolongation and reduction of 
E A T cell number in treated tumor-bearing mice. Our results contradicted to a 
previous report prepared by Yoshida et al in 1989，who professed that warm 
water (40°C) extraction of C. sinensis (2-3 protein content/mL) is able to exert 
in vivo anti-tumor activities through immunomodulation. They claimed that 
SC-180 prolong the median survival time of the EAT-bearng BALB/c mice by 
300 % . In our present study, w e made use of the similar murine system and 
performed experiments on both the warm water (80°C) extraction of natural C. 
sinensis and H E R B S n S E N S E S ™ Corydceps. Yet, w e could not obtain similar 
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results of the Yoshida's group. This m a y because the E A T tumor is so 
invasive and enormous that oral feeding of C. sinensis and 
H E R B S n S E N S E S ™ Corydceps at 40 mg/kg/day is too mild to ablate it. 
Difficulty in oral feeding lie mainly in the unpredictable bioavailability of the 
drugs. Further studies by intraperitoneally injecting C. sinensis and 
H E R B S n S E N S E S ™ Corydceps onto E A T m a y be carried out for direct 
investigation of the T C M preparations on in vivo tumor. Analogously, 
comprehensive experiments m a y be performed by injecting C. sinensis and 
H E R B S n S E N S E S ™ Corydceps through intravenous, intramuscular, 
subcutaneous and also intraperitoneal into the normal or tumor-bearing 
female BALB/c mice. 
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In vitro Studies on Eosinophils and 
Peripheral Blood Mononuclear Cells 
10.1. Introduction 
Allergic diseases such as asthma are characterized by heightened numbers 
of eosinophils in the affected tissue (Wardlaw et al, 1995). Recruitment of 
eosinophils into airways is regulated by chemoattractant and an increased 
expression of adhesion molecules such as integrin very late activation 
antigen(VLA)-4 (CD29/CD49d) on the eosinophil surface (Henricks et al, 
1997). Activated eosinophils are degranulated in the asthmatic lungs to 
release granular toxic proteins including eosinophil cationic protein (ECP) 
(Thomas and Warner, 1996). E C P causes surfactant dysfunction which 
subsequently results in airway obstruction (Hohlfeld et al, 2003). 
Th2 cells orchestrate the allergic inflammation by producing a series of 
cytokines and chemokines to induce the synthesis of IgE antibodies by B cells, 
and to promote the infiltration of mast cells and eosinophils into target tissues. 
The allergen-bound specific IgE bind to the high affinity IgE receptor (FcsRI) 
on mast cells, triggering mast cell degranulation and subsequently allergic 
response (Owen, 2002). IgE also binds to low affinity receptor (FcsRII, CD23) 
on lymphocytes and monocytes for feedback regulation (Yu et al, 1994; 
Busse and Lemanske, 2001). Th2 cytokines such as IL-5, however, is crucial 
for the maturation, terminal differentiation，survival and function of eosinophils 
(Hamid et al, 1991; Tai et al, 1991; Denburg, 1998). 
The Wheeze-Relief Formula composed of C. sinensis, Radix astragali, Radix 
Stemonae, Bulbus Fritillariae cirrhosae and Radix Scutellariae. W e 
hypothesized that the Wheeze-Relief Formula possessed anti-asthmatic 
activities. In the present study, w e investigated the in vitro effects of 
Wheeze-Relief Formula on the functions of eosinophils and peripheral blood 
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mononuclear cells (PBMC). The survival effects of Wheeze-Relief Formula on 
IL-5 stimulated eosinophils and normal eosinophils were first examined by 
BrdU proliferation E U S A as described in Section 3.5.7. In vitro effects of 
Wheeze-Relief Formula on eosinophil degranulation was measured by E C P 
fluoroenzymeimmunoassay with preparation procedures as described in 
Section 3.5.18, whereas the expression of adhesion molecules and 
chemokine receptors were quantitated by immunopheonotyping (Section 
3.5.8). Similarly, liberation of cytokines and the gene expression of 
cytokines and cytokine receptors of P B M C were respectively investigated by 
C B A (Section 3.5.9) and c D N A microarray (Section 3.5.14). Surface 
expression of the low affinity IgE receptor (CD23) was also measured by 
immunophenotyping to elucidate the regulatory role of Wheeze-Relief 
Formula on IgE synthesis. 
-179-
Chapter 10 - In vitro Studies on Eosinophils and Peripheral Blood Mononuclear Cells 
10.2. Results 
10.2.1. In vitro Effects of Wheeze-Relief Formula on the Survival of IL-5 
Enhanced Eosinophils 
Figure 10.1a confirms the effects of IL-5 on eosinophil proliferation. Figure 
10.1b shows the proliferative effects of Wheeze-Relief Formula on IL-5 
stimulated or untreated eosinophils. Wheeze-Relief Formula possessed 
neither mitogenicity on IL-5 treated and unstimulated eosinophils. However, 
Wheeze-Relief Formula mildly antagonized the eosinophilic enhancement by 
IL-5. There w a s dose-dependent suppression of Wheeze-Relief Formula on 
the proliferation of IL-5 stimulated eosinophils. 
10.2.2. In vitro Effects of Wheeze-Relief Formula on the Degranulation 
of Eosinophils 
As shown in Figure 11.2, Wheeze-Relief Formula suppressed E C P release 
from G M - C S F (50 ng/mL) and P A F (10 juM) activated eosinophils in a 
dose-dependent manner. Wheeze-Relief Formula at 500 lug/mL significantly 
inhibited the stimulated eosinophils from degranulation (p < 0.05). W h e n 
compared to the control, Wheeze-Relief Formula at 1 mg/mL and 1.5 mg/mL 
showed observable suppression on E C P release, though statistical 
significance could not be obtained (p > 0.05). 
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Figure 10.1. (a) In vitro effects of IL-5 (20 i^g/mL) on the proliferation of 
eosinophils, (b) In vitro effects of Wheeze-Relief Formula on the viability of IL-5 
activated eosinophils. Eosinophils (1 x 10® cells/mL) were incubated with medium 
or IL-5 (20 lug/mL) for 30 minutes. Various concentrations of Wheeze-Relief Formula 
were added accordingly. The co-culture was then incubated for 18 hours before the 
BrdU Prolfieration ELISA. Experiment was repeated three times with essentially 
identical laboratory conditions. The graph was plotted by percentage of cell 
proliferation vs concentration of the Wheeze-Relief Formula. Proliferation percentage 
of normal and IL-5 stimulated eosinophils was calculated by comparing the 
Wheeze-Relief-Formula-treated eosinophils with the untreated control. 
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Figure 10.2. In vitro effects of Wheeze-Relief Formula on the 
degranulation of eosinophils. Eosinophils (1x10® cells/mL) were primed 
with G M - C S F (50 ng/mL) and P A F (10 |iM) for 30 minutes. Wheeze-Relief 
Formula was then incubated with the co-culture for 18 hours. The amount of 
E C P generated was quantified by using E C P fluorescence enzyme 
immunoassay kit (Pharmacia & Upjohn Diagnostic AB, Uppsala, Sweden). 
Experiment was repeated six times. The graph was plotted by concentration 
of E C P vs treatment. Statistical differences were calculated by comparing the 
control with the Wheeze-Relief Formula-treated eosinophils using 
Mann-Whitney U test. Neg Ctr = Eosinophils only; Ctr = Eosinophils primed 
with G M - C S F and PAF; N S = Not significant; * p < 0.05. 
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10.2.3. In vitro Effects of Wheeze-Relief Formula on the Surface 
Expression of Adhesion Molecules and Chemokine Receptors 
on Eosinophils 
Figure 10.3a and 10.4a show the stimulatory effects of P A F on the expression 
of chemokine receptors C C R 3 and adhesion molecules C D 4 9 d on 
eosinophils. As shown in Figure 10.3b-d and 10.4b-d, Wheeze-Relief Formula 
(1 mg/mL) remarkably inhibited the expression of chemokine receptor C C R 3 
and adhesion molecule C D 4 9 d on PAF-stimulated eosinophils. There were 
statistical differences when compared the C C R 3 and C D 4 9 d expression 
between the Wheeze-Relief-Formula-treated cells and their respective 
controls in triplicate experiments (p < 0.05). The suppression of both the 
chemokine C C R 3 and adhesion molecule C D 4 9 d were in a dose-dependent 
manner. However, w e could not observe any inhibitory effects of 
Wheeze-Relief Formula on the eosinophilic expression of adhesion molecule 
CD11b, C D 1 8 a n d ICAM-1. 
10.2.4. In vitro Effects of Wheeze-Relief Formula on the Surface 
Expression of Adhesion Molecules on Eosinophils 
As shown in Figure 10.5, the C D 2 3 surface expression of the stimulated 
P B M C dropped from 43.54 土 6.43 % to 38.1 土 6.24 % by the effect of 
Wheeze-Relief Formula, although statistical significance could not be 
obtained (p > 0.05). 
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Figure 10.3. In vitro effects of Wheeze-Relief Formula on the 
eosinophilic surface expression of chemokine receptor CCR3. 
Eosinophils (1x10® cells/mL) were stimulated with 10 |liM PAF for 30 minutes 
before incubating with medium or Wheeze-Relief Formula. After 18 hours 
incubation, eosinophils ( 5 x 1 0 ^ cells) were harvested for immunostaining. 
The m e a n florescence intensities were measured by flow cytometry using the 
CellQeust™ Programme (Beckton Dickinson, CA, USA). Solid peak = 
PAF-stimulated eosinophils; Dotted-line peak = unstimulated eosinophils; 
Line peak = Wheeze-Relief Formula at (i) 400 ing/mL, (ii) 800 lug/mL, (iii) 1 
mg/mL. This is a representative result from triplicate experiments with 
essentially identical laboratory conditions. 
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Figure 10.4. In vitro effects of Wheeze-Relief Formula on the 
eosinophilic surface expression of adhesion molecule CD49d. 
Eosinophils (1 x 10® cells/mL) were stimulated with 10 iliM P A F for 30 minutes 
before incubating with medium or Wheeze-Relief Formula. After 18 hour 
incubation, eosinophils ( 5 x 1 0 ^ cells) were harvested for immunostaining. 
The m e a n florescence intensities were measured by flow cytometry using the 
CellQeust™ Programme (Beckton Dickinson, CA, USA). Solid peak = 
PAF-stimulated eosinophils; Dotted-line peak = unstimulated eosinophils; 
Line peak = Wheeze-Relief Formula at (i) 400 lug/mL, (ii) 800 i^g/mL, (iii) 1 
mg/mL. This is a representative result from triplicate experiments with 
essentially identical laboratory conditions. 
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Figure 10.5. In vitro effects of Wheeze-Relief Formula on the CD23 
expression of house dust mite activated PBMC. PBMC (1 x 10® cells/mL) 
were incubated with medium, recombinant house dust mite Der p 1 (10 lug/ml), 
or Der p 1 and Wheeze-Relief Formula (1 mg/mL) for 18 hours. Cells were 
harvested for CD23 immunostaining. Experiment was repeated five times. 
The graph was plotted by percentage of CD23 expression vs treatments. 
Statistical differences were calculated by comparing the Control with the 
TCM-treated house-dust-mite-activated P B M C using Mann-Whitney U test. 
Iso Ctr = Isotypic Control; H D M = house dust mite stimulated P B M C ; T C M = 
Wheeze-Relief Formula; N S 二 Not significant; * p < 0.05. 
“ -186-
Chapter 10- In vitro Studies on Eosinophils and Peripheral Blood Mononuclear Cells 
10.2.5. In vitro Effects of Wheeze-Relief Formula on the Cytokine 
Release from Peripheral Blood Mononuclear Cells 
As shown in Figure 10.6, 10.7 and 10.8, Der p 1 enormously elevated the 
production of T N F a , IL-5 and IL-10 from P B M C . The addition of 
Wheeze-Relief Formula to Der p 1 -activated cells significantly reduced the 
liberation of T N F a (p < 0.05). There was observable suppression of 
Wheeze-Relief Formula on the IL-5 and IL-10 production from stimulated 
P B M C , though statistical differences could not be obtained (p > 0.05). 
10.2.6. In vitro Effects of Wheeze-Relief Formula on the Gene 
Expression Profile of Cytokines and Cytokine Receptors of 
Peripheral Blood Mononuclear Cells 
Representative results of the gene expression array are shown in Figure 10.9. 
Description of the genes and their respective location is presented in Table 
10.1. Results from triplicated experiments were depicted in Table 10.2. As 
shown in Figure 10.9, the gene expression of chemokine M C P - 2 (Coordinate 
F10), M C P - 1 (Coordinate C9), and M D C (Coordinate F9) and cytokine 
receptor IL-2a (Coordinate B6) was heightened enormously in the Der p 1 
activated P B M C . The addition of Wheeze-Relief Formula into the P B M C 
culture profoundly down-regulated gene expression of MCP-1, MCP-2, M D C 
and IL-2 receptor a (Table 10.2). However, w e could not observe remarkable 
suppression of Wheeze-Relief Formula on other inflammatory genes. 
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Figure 10.6. In vitro effects of Wheeze-Relief Formula on the release of 
T N F a from house dust mite activated P B M C . P B M C (1 x 10® cells/mL) 
were either incubated with recombinant house dust mite Der p 1 (10 |Lig/ml) or 
Der p 1 and Wheeze-Relief Formula (1 mg/mL) for 18 hours. Supernatant was 
harvested for T N F a assay using C B A . Experiment was repeated five times. 
The graph was plotted by concentration of T N F a vs treatments. Statistical 
analysis was calculated by using Mann-Whitney U test. Nil = Control P B M C 
without treatment; H D M = House dust mite Der p 1 stimulated P B M C ; T C M = 
Wheeze-Relief Formula; * p < 0.05. 
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Figure 10.7. in vitro effects of Wheeze-Relief Formula on the release of 
lL-5 from house dust mite activated P B M C . P B M C (1 x 10® cells/mL) were 
either incubated with recombinant house dust mite Der p 1 (10|il /1 x 10® cells) 
or Der p 1 and Wheeze-Relief Formula (1 mg/mL) for 18 hours. Supernatant 
w a s harvested for IL-5 assay using C B A . Experiment was repeated five times. 
The graph was plotted by concentration of IL-5 vs treatments. Statistical 
analysis was calculated by using non-parametric Mann-Whitney U test. Nil = 
Control P B M C without treatment; H D M = House dust mite Der p 1 stimulated 
P B M C ; T C M = Wheeze-Relief Formula; * p < 0.05; N S = not significant. 
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Figure 10.8. !n vitro effects of Wheeze-Relief Formula on the release of 
IL-10 from house dust mite activated P B M C . P B M C (1 x 10^ cells/mL) were 
either incubated with recombinant house dust mite Der p 1 (10 jug/ml) or Der p 
1 and Wheeze-Relief Formula (1 mg/mL) for 18 hours. Supernatant was 
harvested for IL-10 assay using C B A . Experiment was repeated five times. 
The graph was plotted by concentration of IL-10 vs treatments. Statistical 
analysis was calculated by using Mann-Whitney U test. Nil = Control P B M C 
without treatment; H D M = House dust mite Der p 1 stimulated P B M C ; T C M = 
Wheeze-Relief Formula; * p < 0.05; N S = not significant. 
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Figure 10.9. Representative gene expression profile of (a) PBMC, (b) 
PBMC treated with Der p 1 (10 |Lig/ml) and (c) PBMC treated with Der p 1 
and Wheeze-Relief Formula (1 mg/mL). PBMC (5x10® cells) were treated 
accordingly as mentioned for 24 hours. RNA was isolated by using RNeasy® 
Total RNA Kit (Qiagen GmbH, Hilden, Germany). Gene expression was 
determined by using GEArray Q series human inflammatory cytokines and 
receptors gene array (Superarray Bioscience Corp, Bethesda, MD USA), (d) 
Location of each gene in the array was denoted correspondingly. The gene 
located at G13 and H13 (GAPD) were the internal positive control for the data 
analysis. 
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A 1 CXCR5 CXCR5 Homo sapiens Burkitt lymphoma receptor 1 
B 1 CCR1 CCR1 Chemokine (C-C motif) receptor 1 
C 1 CCR2 CCR2 Chemokine (C-C motif) receptor 2 
D 1 CCR3 CCR3 Chemokine (C-C motif) receptor 3 
E 1 CCR4 CCR4 Chemokine (C-C motif) receptor 4 
F1 CCR5 CCR5 Chemokine (C-C motif) receptor 5 
G 1 CCR6 CCR6 Chemokine (C-C motif) receptor 6 
H 1 CCR7 CCR7 Chemokine (C-C motif) receptor 7 
A 2 CCR8 CCR8 Chemokine (C-C motif) receptor 8 
B 2 CCR9 CCR9 Chemokine (C-C motif) receptor 9 
C 2 CCXCR1 XCR1 Homo sapiens chemokine (C motif) XC receptor 1 
D 2 CX3CR1 CX3CR1 Chemokine (C-X3-C) receptor 1 
E 2 CXCR4 CXCR4 Chemokine (C-X-C motif), receptor 4 (fusin) 
F2 IFNG IFN-y Interferon, gamma 
G 2 IL10 IL1-0 Interleukin 10 
H 2 ILIORA IL10-Ra Interleukin 10 receptor, alpha 
A 3 IL10RB IL10-R(3 Interleukin 10 receptor, beta 
B 3 IL11 IL-11 Interleukin 11 
C 3 IL11RA IL-11Ra Interleukin 11 receptor, alpha 
D3 IL12A IL-12A Interleukin 12A, p35 
E3 IL12B IL-12B Interleukin 12A, p40 
F3 IL12RB1 |L-12R(31 Interleukin 12 receptor, beta 1 
G 3 IL12RB2 IL-12RP2 Interleukin 12 receptor, beta 2 
H3 IL13 IL-13 Interleukin 13 
A 4 IL13RA1 IL-13Ra1 丨nterleukin 13 receptor，alpha 1 
B 4 IL13RA2 IL-13Ra2 Interleukin 13 receptor, alpha 2 
C 4 IL15 iL-15 Interleukin 15 
D 4 IL15RA IL-15Ra 丨nterleukin 15 receptor, alpha 
E 4 IL16 IL-16 Interleukin 16 (lymphocyte chemoattractant factor) 
P4 丨L17 IL-17 Interleukin 17 (cytotoxic T-lymphocyte-associated serine 
esterase 8) 
Q 4 IL17R IL-17R Homo sapiens Interleukin 17 receptor mRNA 
H 4 丨L18 IL-18 Interleukin 18 (Interferon-gamma-inducing factor) 
A 5 IL18R1 IL-18R1 Interleukin 18 receptor 1 
B 5 IL1A IL-1 a Interleukin 1, alpha 
C 5 IL1B IL-ip Interleukin 1, beta 
D5 IL1R1 IL-1R1 Interleukin 1 receptor type I 
E5 IL1R2 IL-1R2 Interleukin 1 receptor type II 
P5 IL2 IL-2 Interleukin 2 
Q 5 IL20 IL-20 Interleukin 20 
1^5 IL21 IL-21 Homo sapiens Interleukin 21 
A 6 IL25 IL-25 Likely ortholog of mouse Interleukin 25 
B 6 IL2RA IL-2Ra Interleukin 2 receptor, alpha 
C6 IL2RB IL-2RP Interleukin 2 receptor, beta 
D6 丨L2RG 丨L-2RY ！nterleukin 2 receptor, gamma (severe combined 
immunodeficiency) 
IL4 IL-4 Interleukin 4 
p g IL5 IL-5 Interleukin 5 (colony-stimulating factor, eosinophil) 
G 6 IL5RA IL-5Ra Interleukin 5 receptor, alpha 
H6 IL6 IL-6 Interleukin 6 (Interferon, beta 2) 
A 7 IL6R IL-6Ra Interleukin 6 receptor 
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B 7 IL6ST Gp130 Interleukin 6 signal transducer (gp 130，oncostatin M 
receptor) 
C 7 IL9 lL9/p40 Interleukin 9 
D 7 IL9R IL-9Ra Interleukin 9 receptor 
E 7 LEP Leptin Leptin (murine obesity homolog) 
F7 LTA TNF-b/Lta Lymphotoxin-alpha (TNF superfamily, member 1) 
G 7 LTB Lt-b Lymphotoxin-beta 
H 7 LTBR LTbR Homo sapiens lymphotoxin beta receptor (TNFR 
superfamily) 
A 8 MIF MIF Macrophage migration inhibitory factor (glycosylation 
inhibiting factor) 
B 8 SCYA1 1-309 Small inducible cytokine A1 (1-309, homologous to mouse 
Tca-3) 
C 8 SCYA11 Eotaxin Small inducible cytokine subfamily A (Cys-Cys), member 
11 
D8 SCYA13 MCP-4 Small inducible cytokine subfamily A (Cys-Cys), member 
13 
E8 SCYA14 HCC-1 Small inducible cytokine subfamily A (Cys-Cys), member 
14 
F8 SCYA15 MIP-1 alpha Small inducible cytokine subfamily A (Cys-Cys), member 
15 
G 8 SCYA16 HCC-4 Small inducible cytokine subfamily A (Cys-Cys), member 
16 
H8 SCYA17 TARC Small inducible cytokine subfamily A (Cys-Cys), member 
17 
A 9 SCYA18 PARC Small inducible cytokine subfamily A (Cys-Cys), member 
18 
B 9 SCYA19 SCYA19 Small inducible cytokine subfamily A (Cys-Cys), member 
19 
C 9 SCYA2 MCP-1 Small inducible cytokine A2 
D9 SCYA20 MIP-3a Small inducible cytokine subfamily A (Cys-Cys), member 
20 
E9 SCYA21 MIP-2 Small inducible cytokine subfamily A (Cys-Cys), member 
21 
P9 SCYA22 MDC Small inducible cytokine subfamily A (Cys-Cys), member 
22 
Q 9 SCYA23 MPIF-1 Small inducible cytokine subfamily A (Cys-Cys), member 
23 
H9 SCYA24 MPIF-2 Small inducible cytokine subfamily A (Cys-Cys), member 
24 
A 1 0 SCYA25 TECK Human chemokine (TECK) 
B 1 0 SCYA3 MIP-1a Small inducible cytokine A3 (homologous to mouse 
Mip-1a) 
C 1 0 SCYA4 MIP-1b Small inducible cytokine A4 (homologous to mouse 
Mip-1b) 
D10 SCYA5 RANTES Small inducible cytokine A5 
E10 SCYA7 MCP-3 Homo sapiens mRNA for monocyte chemotactic protein-3 
F10 SCYA8 MCP-2 Small inducible cytokine subfamily A (Cys-Cys), member 8 
G 1 0 SCYB10 P10 (IP-10) Gamma-interferon inducible early response gene 
H10 SCYB11 l-TAC (IP9) Small inducible cytokine subfamily B (Cys-X-Cys), member 
11 
A 1 1 SCYB13 SCYB13 Small inducible cytokine subfamily B (Cys-X-Cys), member 
13 
B 1 1 SCYB5 ENA-78 Small inducible cytokine subfamily B (Cys-X-Cys), member 
5 
C 1 1 SCYB6 GCP-2 Human chemokine alpha 3 (CKA-3) mRNA 
D11 SCYC1 Lymphotacti Small inducible cytokine subfamily C, member 1 
门 
1 SCYC2 SCYC2 Small inducible cytokine subfamily C, member 2 
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F 1 1 SCYD1 Fractalkine Small inducible cytokine subfamily D, member 1 
G 1 1 SCYE1 SCYE1 Small inducible cytokine subfamily E, member 1 
H 1 1 SDF1 SDF1 Stromal cell-derived factor 1 
A 1 2 SDF2 SDF2 Homo sapiens mRNA for SDF2 
B 1 2 TGFA TFG-a Transforming growth factor, alpha 
C 1 2 TGFB1 TGF-(31 Transforming growth factor, beta 1 
D 1 2 TGFB2 TGF-P2 Transforming growth factor, beta 2 
E 1 2 TGFB3 TGF-pS Transforming growth factor, beta 3 
F 1 2 TNF TNFa Tumor necrosis factor (TNF superfamily, member 2) 
G 1 2 TNFRSF1A TNFR1 Tumor necrosis factor receptor superfamily, member 1A 
H 1 2 TNFRSF1B TNFR2 Human tumor necrosis factor receptor 2 
(TNFSF1B) 
A 1 3 PUC18 pUC18 PUC18Plasmid DNA 
B 1 3 PUC18 pUC18 PUC18 Plasmid DNA 
C 1 3 PUC18 pUC18 PUC18 Plasmid DNA 
D 1 3 BLANK BLANK 
E 1 3 BLANK BLANK 
F13 BLANK BLANK 
G 1 3 GAPD GAPDH Glyceraldehyde-3-phosphate dehydrogenase 
H 1 3 GAPD GAPDH Glyceraldehyde-3-phosphate dehydrogenase 
A 1 4 PPIA Cyclophilin Homo sapiens peptidylprolyl isomerase A 
A 
B 1 4 PPIA Cyclophilin Homo sapiens peptidylprolyl isomerase A 
A 
G 1 4 PPIA Cyclophilin Homo sapiens peptidylprolyl isomerase A 
A 
D 1 4 PPIA Cyclophilin Homo sapiens peptidylprolyl isomerase A 
A 
E 1 4 RPL13A RPL13A Ribosomal protein IL13a (23 Kda highly basic protein) 
F 1 4 RPL13A RPL13A Ribosomal protein IL13a (23 Kda highly basic protein) 
G 1 4 ACTB b-actin Beta Actin 
H 1 4 ACTB b-actin Beta Actin 
Table 10.1. List of genes shown in the GE Array Q Series Human 
Inflammatory Cytokine/Receptor Gene Array. 
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% Change of Expression 
Gene Coordinate 丄 
(MeantSD) 
IL2RA B6 -72.4 ±5.6 
M C P - 1 C 9 -15.1 ±23.2 
M D C F9 -20.9 ± 79.1 
M C P - 2 F10 -44.7 ±48.7 
Table 10.2. In vitro effects of Wheeze-Relief Formula on the the gene 
expression of PBMC. Percentage change of gene expression w a s 
calculated by comparing the Wheeze-Relief-Formula-treated Der p 
1-activated P B M C with the untreated Der p 1-activated P B M C . 
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10.3. Discussion 
Agents that are effective in reducing detrimental effects of eosinophils are of 
potential therapeutic value for asthma (O'Byrne et al, 2001; Justice et al, 
2003). The present results demonstrated that Wheeze-Relief Formula 
down-regulated the expression of chemokine receptor C C R 3 and adhesion 
molecule C D 4 9 d on the eosinophil surface. Analogously, the liberation of toxic 
protein E C P from eosinophils was also reduced profoundly. Wheeze-Relief 
Formula m a y be beneficial in treating asthma. 
Eosinophils are recruited to the lungs by locally released chemotactic agents 
(Menzies-Gow et al, 2001; Romagnani; 2002; Lloyd et al, 2000). The C C 
chemokines eotaxin are potent stimulators of eosinophil chemotaxis which 
bind exclusively to C C R 3 (Ponath e^ al, 1996; Kitaura et al, 1996; Forssmann 
et al, 1997). Compared to other C C R s , C C R 3 is expressed in high numbers 
on eosinophils (Daugherty et al, 1996; Ying et al, 1997). Blocking of C C R S 
has been shown to inhibit eosinophil response to eotaxin, R A N T E S , and 
monocyte chemotactic protein(MCP)-2, -3，and -4 by more than 9 5 % , 
indicating that C C R S is the most important eosinophil receptor for these 
chemokines (Heath et al, 1997). Down-regulation of C C R S expression by 
Wheeze-Relief Formula m a y inhibit chemotatic agents from binding 
eosinophils, which m a y subsequently reduce the eosinophil recruitment into 
the lungs. 
In the lungs, eosinophils firmly adhere to the endothelial cells by binding 
surface adhesion molecules such as integrin VLA-4 (CD29/CD49d) to their 
endothelial cell counterpart V C A M - 1 (Thomas and Warner, 1996). Binding of 
VLA-4 with V C A M - 1 promotes eosinophil cell superoxide production (Nagata 
et al, 1995), while adhesion of eosinophils to fibronectin via VLA-4 prolongs 
eosinophil survival possibly by Fas antigen signalling (Higashimoto et al, 
1996). Reduction of CD49d expression by Wheeze-Relief Formula m a y 
therefore inhibit the liberation of cyto-toxic superoxide from eosinophils. 
Synchronously, the decreased CD49d expression m a y also shorten 
eosinophil survival and subsequently relieve inflammatory responses. 
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In addition, eosinophils are degranulated below the respiratory epithelial cell 
layer of the asthmatic airway (Bousquet et al, 1990; T h o m a s and Warner, 
1996). Upon degranulation, eosinophils release eosinophil cationic protein 
(ECP), eosinophils derived neurotoxin (EDN), eosinophil peroxidase (EPO), 
eosinophil protein X (EPX) and major basic protein (MBP) (Thomas and 
Warner, 1996). These granular proteins m a y cause contraction of the airway 
smooth muscle and correlates with epithelium damage (White et al，1990; 
Gleich et al, 1988). Based on T C M principles, E C P in asthmatic patients also 
plays an important role in the development of "heat" manifestations (Hsu et al, 
2003). Inhibition of E C P liberation by Wheeze-Relief Formula thereby 
suggests the beneficial role of the concoction in relieving asthmatic 
symptoms. 
Furthermore, results showed that the Wheeze-Relief Formula did not possess 
mitogenicity on normal eosinophils, which implies Wheeze-Relief Formula as 
a detrimental agent to eosinophils. However, Wheeze-Relief Formula mildly 
antagonized the enhancement effect of IL-5 on eosinophils, suggesting a 
possible counteraction of Wheeze-Relief Formula on activated eosinophils 
which m a y relieve asthmatic symptoms. 
Atopic diseases are the result of Th2-dominated responses to single or 
multiple environmental allergens. Th2 cells produce interleukins that account 
for the joint involvement of IgE antibody producing B cells (IL-4, IL-13)，mast 
cells (IL-4, IL-10), and eosinophil granulocytes (IL-5) in allergic inflammation 
(Romagnani, 2002). Our in vitro system demonstrated that Der p 1 induced 
the liberation of Th2 cytokines T N F a , IL-10 and IL-5 from P B M C . Parronchi et 
al has depicted IL-5 production from Der p1 specific T cells but not T N F a and 
IL-10. However, evidence has shown that the level of IL-5 (Mueller ef al, 1996; 
Ishizuka et al, 2002)，IL-10 (Wong et al, 2001) and T N F a (Finotto et al, 1994; 
Mueller et al, 1996; Yoshida et al, 1996) are generally elevated in asthmatic 
patients. These reports validate our in vitro system mimicking asthmatic 
condition. The addition of Wheeze-Relief Formula into the Der p 1 activated 
P B M C subsequently reduced the liberation of the mentioned cytokines -
TNFa, IL-10 and IL-5. Specifically, TNFa is an important chemoattractant for 
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the recruitment of eosinophils into the lungs (Sabatini et al, 2002; Lampinen et 
a/, 2004). It is also a potent modulator of immune and inflammatory response. 
The down-regulation of T N F a by Wheeze-Relief Formula m a y therefore 
reduce the severity of allergic inflammation. IL-5 uniquely and specifically 
participate in the control of eosinophil production and differentiation. Although 
the down-regulation of IL-5 by Wheeze-Relief Formula did not reach statistical 
significance, the potential anti-allergic activities of Wheeze-Relief Formula is 
suggested. IL-10 is an anti-proinflammatory Th2 cytokines. Several reports 
have stated its heightening in allergic asthma (Wong et al, 2001; Koulis et al 
2000). The T C M concoction contains C. sinensis, which is a Yin-yang double 
invigorator. It is possible that C. sinensis modulate the over-production status 
of IL-10. Furthermore, such modulation was not statistically significant, 
implicating the down-regulation of Wheeze-Relief Formula on the 
anti-inflammatory cytokine IL-10 m a y be rather mild, and m a y not promote 
inflammation as a consequence. 
G e n e expression of cytokine receptor IL-2a (CD25) and chemokine MIP-1, 
MIP-2 and M D C in P B M C were enhanced by Der p1 but suppressed 
significantly in the presence of Wheeze-Relief Formula. The house dust mite 
antigen triggers allergic responses with Th2 cells as the major participant 
(Hamid et al, 1992). The activated-T-cell marker, CD25, was thereby 
promoted in the presence of Der p 1 with heightened expression at the gene 
transcriptional level (Table 10.2). The addition of Wheeze-Relief Formula 
down-regulated the T cell stimulation, implicating its anti-allergic effects. 
MIP-1 and MIP-2 are chemoattractant for T-cell mediated neutrophil 
recruitment (Appelberg, 1992; Norzila et al, 2000). The suppressed gene 
expression of MIP-1 and MIP-2 by Wheeze-Relief Formula suggested the 
reduction of neutrophil infiltration and subsequently airway inflammation 
(Ennis, 2003). O n the other hand, M D C is a potent attractant for C C R 4 
expressing polarized Th2 (Mantovani et al, 2000). It is also a chemoattractant 
for monocytes, monocyte-derived dentritic cells and natural killer cells 
(Godiska et al, 1997). Recent evidence has shown that level of M D C is 
elevated in the exhaled breath condensate and plasma from children with 
asthma (Leung et al, 2004). The suppression of M D C gene expression m a y 
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contribute to the down-regulation of inflammatory responses which 
consequently relieve asthmatic symptoms. 
W e found that the low affinity IgE receptor (FcsRII, C D 2 3 ) on P B M C w a s 
up-regulated in the presence of Der p 1 but down-regulated w h e n cultivated 
with Wheeze-Relief Formula in adjunction. C D 2 3 is the negative feedback 
component for IgE synthesis (Dugas et al, 1992; Yu et al, 1994; 
Riffo-Vasquez et al, 2000). Up-regulated C D 2 3 therefore correlates with an 
increased IgE synthesis (Inaoki et al, 2004) and thus m a y play an important 
role in maintaining immediate hypersensitivity and the chronic inflammatory 
state in asthma (Harkins et al, 2003). Wheeze-Relief Formula suppressed the 
Der p 1 activated C D 2 3 expression, which reduces the IgE synthesis and 
consequently allergic response. 
Together with the above results, w e m a y conclude that Wheeze-Relief 




The Clinical Trial: 
Analysis of Serological Markers 
11.1. Introduction 
Atopic asthma is characterized by episodic, recurrent and reversible airway 
obstruction due to airway inflammation. Asthma severity therefore relates to 
the inflammatory state of the airways (McFadden and Gilbert, 1992). 
Inflammatory mediators such as leukotrienes, cytokines, chemokines, allergic 
immunonoglobulin IgE and eosinophil granular proteins are important 
biological marker for predicting asthma severity. 
Cysteinyl leukotrienes(LTs) C4, D4 and E4 are the most powerful 
bronchoconstrictor agents involving in the control of the inherent tone of 
h u m a n isolated bronchi (Ellis and Undem, 1994; Watson et al, 1997; Devillier 
et al, 1999; Bisgaard, 2001). Leukotriene B4, however, is a chemoattractant 
for polynuclear neutrophils (Sampson et al, 1990; Martin et al, 1989) and IL-5 
primed eosinophils (Sehmi et al, 1992) into the inflamed airways. Increased 
levels of leukotrienes have been found in the bronchoalveolar lavage fluids of 
asthmatic patients (Lam et al, 1988)，their concentrations further heighten 
after bronchial allergen challenge (Chan-Yeung et al, 1989; Wenzel et al, 
1990，1991; Ketchell et al, 2002) or after bronchial aspirin challenge in 
patients with aspirin-induced asthma (Sladek et al, 1994; Szczeklik et al, 1996) 
and also after an isocapnic hyperventilation test (Pliss et al, 1990). 
IL-18, formerly called IFNy inducing factor, is a novel proinflammatory 
cytokine related to the IL-1 family that is produced by Kupffer cells, activated 
macrophages, keratinocytes, intestinal epithelial cells, osteoblasts and 
adrenal cortex cells (Wong et al, 2001). Murine model of allergic asthma has 
indicated that 丨L-18 can increase allergic sensitization, serum IgE, Th2 
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cytokines and airway eosinophilia (Kumano et al, 1999; Wild et al, 2000). 
Several reports have found that plasma or serum IL-18 level w a s significantly 
higher in patients with acute asthma when compared to control subjects 
(Wong et al, 2001 ； Tanaka et al, 2001). 
TNFa is a multifunctional proinflammatory cytokines regulating a number of 
inflammatory responses. Evidence showed that plasma TNFa and TNFa in 
bronchial biopsies were elevated in asthmatic patients (Mueller et al, 1996; 
Subratty and Hooloman, 1998). 
T h y m u s and activation-regulated chemokine (TARC) is a selective 
chemoattractant of Th2 cells. Studies have determined that T A R C is 
up-regulated in the airways of human subjects with asthma (Berin, 2002). The 
plasma level of T A R C was elevated in asthmatic patients when compared to 
the control (Leung et al, 2002，2003; Sugawara et al, 2002). Leung et al has 
suggested the possible role of T A R C as inflammatory marker. 
Ongoing degranulation of eosinophils in the asthmatic airway was evident 
(Broide et al, 1991). Eosinophil derived neurotoxin (EDN) is one of the 
eosinophil-derived proteins being degranulated upon eosinophil activation 
(Thomas and Warner, 1996). Reports showed that E D N in the peripheral 
blood, serum E D N and urinary E D N were elevated in asthmatic patients 
(Durham et al, 1989; Hoekstra et al, 1996). 
Synthesis of IgE is triggered by allergen. IgE bind to receptors on mast cells 
and basophils upon synthesis. This event subsequently leads to the liberation 
of histamines and other soluble mediators including the symptoms 
characteristic of allergies. Significantly elevated IgE levels are seen in most 
patients with allergic disorders including asthma (Johansson, 1967). The total 
IgE and specific IgE of asthmatic patients were elevated when compared to 
the control subjects (Sunyer et al, 1996). 
The purpose of this study was to determine whether Wheeze-Relief Formula 
would decrease asthma exacerbations compared with placebo treatment, 
judging from the plasma level of leuktrienes(LTs) B4 and C4/D4/E4, cytokines 
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IL-18 and T N F a , E D N and IgE (total and specific) of asthmatic patients before 
and after the placebo or Wheeze-Relief Formula treatment. 
11.2. Results 
11.2.1 • Demographic Data and Drop-out Cases 
A total of 90 patients were recruited in the study with stringent inclusion and 
exclusion criteria (Section 3.3.1-3.3.2). Table 11.1 shows the demographic 
data of this study. Respectively 1 and 4 subjects were withdrawn from the 
Wheeze-Relief Formula and placebo treatment. These five cases were 
excluded because w e could not contact them after the study had launched. 
The compliance rate of Wheeze-Relief Formula was more than 90 % . 
11.2.2. Lung Function Test 
The lung function test revealed that there was no statistical differences on the 
forced expiration volume expired in 1 second (FEV1), forced vital capacity 
(FVC) and peak expiration flow rate (PEFR) before and after the 
Wheeze-Relief Formula or placebo treatment (p > 0.05) (Table 11.2). 
11.2.3. Steroid Dosage 
As shown in Table 11.3, there was no statistical differences on the steroid 
dosage before and after Wheeze-Relief Formula and placebo treatment (p > 
0.05). However, it was observed that the steroid dosage was decreased after 
both Wheeze-Relief Formula and placebo treatments. Less than 30 % of the 
subjects require higher dosages of steroid after treatments. 
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Group TCM Placebo 
Items (n = 43) (n = 47) 
Age (Year) 10.4 (2.3) 10.0(2.3) 
Sex (%) 
Male 67.4 63.8 
Female 32.6 36.2 
Body height (cm) 142.9 (14.4) 138.6 (13.0) 
Body weight (kg) 39.4 (15.9) 32.6 (9.0) 
Severity of Asthma 13.2 (1.9) 13.0 (2.1) 
Scoring 10-15 (%) 86.0 89.4 
Scoring 16-20 (%) 14.0 10.6 
History of airway hyperactivity 
Months 84.1 (38.5) 73.8 (30.9) 
Year 3.8 (2.7) 4.2 (2.7) 
FEV1 % predicted 96.4 (15.2) 95.7 (18.6) 
FVC % predicted 105.4 (16.9) 103.9 (14.8) 
FEV/FVC % predicted 92.1 (11.0) 91.7 (10.3) 
PEFR (Spirometry) % predicted 91.8 (17.0) 87.2 (22.0) 
PEFR 25-75% (Spirometry) predicted 78.0 (23.2) 75.8 (24.8) 
PEFR (meter) L 310.8 (75.6) 293.6 (70.5) 
Dropout 1 4 
Table 11.1. Demographic and baseline information. F E V 1 = Forced 
expiration volume expired in 1 second; F V C = Forced vital capacity; P E F R 二 
Peak expiration flow rate; T C M = Wheeze-Relief Formula. Data are presented 
as m e a n (SD). 
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TCM Placebo Effect 
Mean(SD) Mean(SD) Difference P value 
(TCM-PIacebo) 
Pre Post Pre Post 
FEV1 96.4 (15.2) 88.4 (12.6) 95.7 (18.6) 87.2 (16.7) 1.2 (3.1) 0.698 
FVC 105.4 (16.9) 96.2 (13.8) 103.9 (14.9) 93.9 (12.8) 2.4 (2.8) 0.397 
FEV/FVC% 92.1 (11.0) 92.3 (10.0) 91.7 (10.3) 92.4 (10.1) -0.1 (2.1) 0.946 
PEFR 91.8 (17.0) 84.3 (17.7) 87.2 (22.0) 86.8 (18.8) -2.5 (3.9) 0.520 
(Spirometry) 
PEFR 25-75% 78.0 (23.3) 71.1 (22.2) 75.8 (24.8) 74.0 (31.4) -2.9 (5.8) 0.623 
(Spirometry) 
PEFR (Meter) 310.8 (75.6) 344.7 (81.9) 293.6 (70.5) 313.8 (68.6) 30.8 (15.9) 0.055 
Table 11.2. Lung function test. Statistical differences were calculated by 
using Student's t-test. F E V 1 = Forced expiration volume expired in 1 second; 
F V C = Forced vital capacity; P E F R = Peak expiration flow rate; T C M = 
Wheeze-Relief Formula. Data are presented as m e a n (SD). 
Frequency Chi-square P value 
TCM Placebo 
Decreased/Off 30 (69.8%) 37 (78.0%) � 
0.346 
Increased/No Change 13 (30.2%) 10 (21.3%) 
Table 11.3. Effects on the steroid dosage before and after Wheeze-Relief 
Formula or placebo treatment. TCM = Wheeze-Relief Formula. Data are 
presented as m e a n (SD). 
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11.2.4. Serological Markers 
Table 11.4 shows the median value of the examined biological markers 
before and after placebo or Wheeze-Relief Formula treatment. There were no 
statistical differences before and after treatments in all biological marker 
examined except T N F a . 
A s shown in Figure 11.1，median plasma concentration of LT B4 w a s 
suppressed in patients after both Wheeze-Relief Formula and placebo 
treatment (Day 168)，though statistical differences could not be reached (p > 
0.05). 
Figure 11.2 shows that median plasma LT C4/D4/E4 concentration w a s 
decreased in subjects after Wheeze-Relief Formula treatment (Day 168). 
There were observable differences between Wheeze-Relief Formula and 
placebo group in Day 168，though statistical differences could not be obtained 
(p > 0.05). 
Figure 11.3, 11.4, 11.7 and 11.8 respectively show the plasma level of E D N , 
IL-18，total IgE and house-dust-mite specific IgE in the influence of placebo 
and Wheeze-Relief Formula treatment. There were observable differences 
between the median level of E D N , IL-18 and IgE (total and specific) of 
placebo and Wheeze-Relief Formula treatment group on Day 1 and Day 168， 
though statistical differences could not be obtained (p > 0.05). 
A s shown in Figure 11.5, plasma T A R C concentration in patients did not 
change before and after treatment and a m o n g placebo and Wheeze-Relief 
Formula treated group. 
Figure 11.6 shows that the plasma concentration of T N F a w a s significantly 
decreased in patients before and after Wheeze-Relief Formula treatment (p < 
0.05). 
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Placebo Wheeze-Relief Formula 
Day 1 Day 168 p Day 1 Day 168 p 
LT B4 (pg/well) 1.27 0.88 0.185 1.197 0.70 0.169 
LTs C4/D4/E4 (pg/well) 17.10 17.80 0.385 17.12 16.53 0.615 
lL-18 (pg/mL) 228.40 225.30 0.591 151.90 174.20 0.731 
TARC (pg/mL) 77.69 90.77 0.539 72.31 87.69 0.402 
TNFa (pg/mL) 2.24 2.04 0.139 2.31 2.03 0.001 
Total IgE (lU/mL) 598.80 835.60 0.314 214.00 228.60 0.136 
House dust mite 
132.30 155.10 0.605 44.50 55.25 0.326 
specific IgE (kUA/l) 
Table 11.4. Median and p value of the biological marker before and after 
Wheeze-Relief Formula and placebo treatment. Statistical differences were 
calculated by using the Wilcoxon Signed Ranks Test. 
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Figure 11.1. Plasma concentration of Leukotriene B4 in asthmatic 
patients before and after the Wheeze-Relief Formula or placebo 
treatment. Plasma was obtained from the peripheral blood of asthmatic 
subjects. The plasma leukotriene B4 concentration was quantified by 
leukotriene B4 enzymimmunoassay (EIA) system (Amersham Pharmachia 
Biotech, NJ, U S A ) using recombinant leukotriene B4 as standard. Results 
were expressed by scattered-plots with lines denoting median. Statistical 
differences between the treatment groups were compared by Wilcoxon 
signed ranks test. N S = Not significant; T C M = Wheeze-Relief Formula. 
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Treatment Groups 
Figure 11.2. Plasma concentration of cysteinyl leukotriene C4/D4/E4 in 
asthmatic patients before and after the Wheeze-Relief Formula or 
placebo treatment. Plasma was obtained from the peripheral blood of 
asthmatic subjects. The plasma cysteinyl leukotriene C4/D4/E4 concentration 
w a s quantified by leukotriene C4/D4/E4 enzymimmunoassay (EIA) system 
(Amersham Pharmachia Biotech, NJ, U S A ) using recombinant leukotriene 
C4/D4/E4 as standard. Results were expressed by scattered-plots with lines 
denoting median. Statistical differences between the treatment groups were 
compared by Wilcoxon signed ranks test. N S = Not significant; T C M 二 
Wheeze-Relief Formula. 
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Figure 11.3. Plasma concentration of eosinophils derived neurotoxin 
(EDN) in asthmatic patients before and after the Wheeze-Relief Formula 
or placebo treatment. Plasma was obtained from the peripheral blood of 
asthmatic subjects. The plasma E D N concentration was quantified by E D N 
ELISA (MBL, Nagoya, Japan) using recombinant E D N as standard. Results 
were expressed by scattered-plots with lines denoting median. Statistical 
differences between the treatment groups were compared by Wilcoxon 
signed ranks test. N S - Not significant; T C M = Wheeze-Relief Formula. 
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Figure 11.4. Plasma concentration of IL-18 in asthmatic patients before 
and after the Wheeze-Relief Formula or placebo treatment. Plasma was 
obtained from the peripheral blood of asthmatic subjects. The plasma IL-18 
concentration was quantified by human IL-18 ELISA (MBL, Nagoya, Japan) 
using recombinant IL-18 as standard. Results were expressed by 
scattered-plots with lines denoting median. Statistical differences between the 
treatment groups were compared by Wilcoxon signed ranks test. N S = Not 
significant; T C M = Wheeze-Relief Formula. 
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Figure 11.5. Plasma concentration of TARC in asthmatic patients before 
and after the Wheeze-Relief Formula or placebo treatment. Plasma was 
obtained from the peripheral blood of asthmatic subjects. The plasma T A R C 
concentration was quantified by Quantikine® human T A R C ELISA ( R & D 
System Inc, M N , U S A ) using recombinant T A R C as standard. Results were 
expressed by scattered-plots with lines denoting median. Statistical 
differences between the treatment groups were compared by Wilcoxon 
signed ranks test. N S = Not significant; T C M = Wheeze-Relief Formula. 
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Figure 11.6. Plasma concentration of TNFa in asthmatic patients before 
and after the Wheeze-Relief Formula or placebo treatment. Plasma was 
obtained from the peripheral blood of asthmatic subjects. The plasma T N F a 
concentration was quantified by human T N F a high-sensitivity ELISA ( R & D 
System Inc, M N , U S A ) using recombinant T N F a as standard. Results were 
expressed by scattered-plots with lines denoting median. Statistical 
differences between the treatment groups were compared by Wilcoxon 
signed ranks test. N S = Not significant; T C M = Wheeze-Relief Formula; **，p < 
0.005 
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Figure 11.7. Plasma concentration of Total IgE in asthmatic patients 
before and after the Wheeze-Relief Formula or placebo treatment. 
Plasma was obtained from the peripheral blood of asthmatic subjects. The 
plasma total IgE concentration was quantified by I M X ® total IgE assay kit 
(Abbott Laboratories, Diagnostics Division, IL, USA). Results were expressed 
by scattered-plots with lines denoting median. Statistical differences between 
the treatment groups were compared by Wilcoxon signed ranks test. N S = Not 
significant; T C M = Wheeze-Relief Formula. 
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Figure 11.8. Plasma concentration of house dust mite specific IgE in 
asthmatic patients before and after the Wheeze-Relief Formula or 
placebo treatment. Plasma was obtained from the peripheral blood of 
asthmatic subjects. The plasma concentration of house dust mite IgE was 
quantified by Pharmacia C A P system™ specific IgE 
fluoroenzymimmunoassay (Pharmacia Diagnostics AB, Uppsala, Sweden). 
Results were expressed by scattered-plots with lines denoting median. 
Statistical differences between the treatment groups were compared by 
Wilcoxon signed ranks test. N S = Not significant; T C M = Wheeze-Relief 
Formula. 
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11.3. Discussion 
The current study is a randomized, double blind clinical trial aimed at 
elucidating the immunomodulatory activities of Wheeze-Relief Formula on 
asthmatic subjects. W e had expected the Wheeze-Relief Formula m a y 
reduce asthma severity in certain extent. However, w e found no significant 
clinical improvement in subjects treated with Wheeze-Relief Formula. The 
FEV1/FVC and P E R F of asthmatic patients did not ameliorate after treatment. 
Analogously, most of the serological markers for asthma did not reduce after 
the T C M treatment, though their concentrations in the local inflammatory sites 
are not yet ascertained. Plasma concentration of the Th1/Th2 cytokines, 
including IL-2, IL-4，IL-5，IL-10 and IFNy, was also undetectable before and 
after treatment (data not shown) by using H u m a n Th1/Th2 cytokine C B A (BD 
Biosciences, C A , USA). A possible explanation for our negative result is that 
the recruited subjects merely bear mild asthma, as judged from the lung 
function tests. Moreover, steroid was prescribed to the subjects in conjunction 
with Wheeze-Relief Formula. It is possible that the subject's airway is only 
mildly inflamed, which could be easily and efficiently suppressed by the 
steroid treatment. Subsequent application of Wheeze-Relief Formula could 
not profoundly affect the already normal immunity. Furthermore, the 
serological markers that w e investigated are released only at the acute phase 
during an asthmatic attack. Subjects in the cohort are mild chronic asthmatics 
with comparatively rare exacerbations, thereby making the levels of asthma 
serological markers low and the anti-asthmatic effects of Wheeze-Relief 
Formula less apparent. Therefore, w e could not accurately examine the 
therapeutic effects of Wheeze-Relief Formula in the present clinical trial. The 
best experimental design would be prescribing the moderate to acute 
asthmatic only with Wheeze-Relief Formula and without any steroid treatment. 
Moreover, the concentrations of the inflammatory markers and mediators in 
bronchoalveolar lavage or nasopharyngeal aspirate should also be examined. 
However, ethical issue should be addressed before the launch of this 
mentioned clinical trial design. O n the other hand, the Wheeze-Re lief Fomula 
m a y need certain adjustment. Despite their anti-tussive or bronchodilating 
effects, it is possible that certain components in the Wheeze-Relief Formula 
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m a y possess immuno-activation which subsequently counteracts the 
anti-allergic activity of C. sinensis. Either the herbal composition in the 
Wheeze-Relief Formula m a y require further revision, or certain herb(s) in the 
Formula m a y oblige removal, or s o m e new TCM(s) m a y need to be added for 
a more promising result. Ongoing experiments are examining the in vitro 
anti-allergic activities of each individual herb in the Wheeze-Relief Formula. 
Based on these new in vitro results, w e are expecting that a new and more 
effective anti-allergic T C M can be formulated. 
However, there was significant difference of the plasma serological marker 
T N F a before and after Wheeze-Relief Formula treatment, though observable 
changes are not prominent. T N F a is a multifunctional cytokine important in 
the modulation of m a n y inflammatory responses. T N F a also induces a 
hypercontractile phenotype by enhancing agonist-induced calcium signals, as 
well as agonist-induced force generation (Amrani and Panettieri, 1998). 
Changes in airway smooth muscle phenotype m a y play a role in the airway 
remodeling and bronchial hyper-responsiveness that is observed in asthma. 
Furthermore, T N F a elevates the expression of ICAM-1 and endothelial 
leukocyte adhesion molecule (ELAM)-1. Both molecules can facilitate the 
infiltration of neutrophils into the lungs (Aggarwa丨 et a/’ 2001). Therefore, the 
suppression of TNFa liberation by Wheeze-Relief Formula m a y 
down-regulate airway remodeling, neutrophil infiltration and subsequently 
allergic inflammatory responses. This result suggests that the Wheeze-Relief 
Formula is of potential therapeutic value in treating asthma, although the 
current experimental design cannot fully elucidate this hypothesis. 
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Concluding Remarks and Future 
Perspectives 
This study has investigated the immunomodulatory efficacy of the singly apply 
C. sinensis and H E R B S n S E N S E S ™ Cordyceps, and concocted C. sinensis, 
Wheeze-Relief Formula. 
W e demonstrated that H E R B S n S E N S E S ™ Cordyceps possessed 
immunomodulatory and anti-tumor activities as efficiently as that exerted by 
natural C. sinensis. The underlying immunomodulatory activities m a y involve 
various cellular components in a complex cascade that ultimately enhance the 
cell-mediated immunity. From the in vitro experiments, the specific effects 
m a y be the enhanced phagocytosis, R O S production and increased secretion 
of cytokines T N F a , IL-ip, IL-6 and IL-10 from monocytes and macrophages, 
and the heightened expression of IL-2 receptor a and generation of cytokines 
IL-6, IL-10 and T N F a from the lymphocytes. The in vivo model showed that 
increased numbers of CD3+ and CD4+ T cells are the chief promoter of the 
cell-mediated immunity. The escalated cellular functions suggested from the 
in vitro and in vivo assays m a y be contributed by the mitogenic activity 
possesses by C. sinensis and H E R B S n S E N S E S ™ Cordyceps (Chapter 5). 
A n increased number of immunologic effecter cells virtually elevated the 
amount of inflammatory mediators secreted and the level of inflammatory 
markers expressed. The up regulated cell-mediated immunity m a y be 
anti-tumorigenic (Burnet, 1957; Dunn et al, 2002) and this explains the 
anti-tumor potential of H E R B S n S E N S E S ™ Cordyceps. The markedly 
reduced tumor size in the BALB/c mice experiments m a y due to the enhanced 
macrophage phagocytosis (Blankenstein, 2004)，as supported from the in 
vitro human macrophage experiments (Chapter 7). Furthermore, this 
anti-tumor activity of H E R B S n S E N S E S ™ Cordyceps was not due to direct 
apoptosis or cytotoxicity, as suggested by the in vitro apoptosis assays on 
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SC-180 cell line (Chapter 8). However, the anti-tumor activity m a y still be 
contributed by inducing apoptosis, but will only be specific to certain tumor 
cells, such as EoL-1 and PU5-1.8 (Chapter 8). 
The clinical trial cannot fully validate the in vitro anti-asthmatic activities of 
Wheeze-Relief Formula. W e found that activated eosinophil was down 
regulated in terms of suppressed degranulation, proliferation and expression 
of adhesion molecules in vitro. Functions of house-dust-mite stimulated 
P B M C , including surface expression of low affinity IgE receptor FcsRII C D 2 3 , 
cytokine IL-5, IL-10 and T N F a release and gene expression of cytokines and 
cytokine receptors, were similarly suppressed in vitro. Significant reduction of 
plasma level of T N F a after Wheeze-Relief Formula treatment, however, m a y 
be due to the repressed activity of P B M C . Yet pro-inflammatory mediators 
secreted from activated eosinophils such as LT B4 and cysteinyl LTs (Aizawa 
et al, 1990)，and the cytokine 丨L-18 (Puren et al, 1999) liberated from 
stimulated P B M C did not reduced in blood level in asthmatic patients after 
taking Wheeze-Relief Formula. Analogously, w e could not observe any 
significant differences on the serological markers E D N , IgE (Total and specific) 
and T A R C of asthma patients after Wheeze-Relief Formula treatment. 
W e found that C. sinensis possesses different immune regulation when 
applied singly and in concoction. Furthermore, C. sinensis exerts immune 
activation on unstimulated cells but immunosuppression on stimulated cells. 
Our findings demonstrated the contrasting action of C. sinensis in different 
physiological conditions，which has virtually manifested the Yin-yang double 
invigorating concepts of the T C M . Yin and yang are two opposing doctrines in 
the human body for achieving general well-being. Yin portrays passive or 
negative, cold, hypofufictional，static, downward, descending, dull and 
retrogressive factors, while Yang represents active or positive, heat, 
hyperfunctional, dynamic, upward, ascending, brilliant and progressive factors 
(Chan, 1995). Therefore, the immunological activation of single herb C. 
sinensis in the unstimulated cells contributed to the Yang properties, while its 
immune suppressive action in concoction represents the Yin properties. This 
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m a y also implicate that the Yin properties of C. sinensis m a y be fully achieved 
only in concoction, which m a y be explained by the interaction between 
individual herbs in a T C M formula. Therefore, w e have shown that the T C M 
theories, although legendary, m a y be supported scientifically. The 
knowledge of T C M is based on centuries-old observation. T C M literature 
recorded that small-scale clinical trials had been carried out in the past. For 
example, the Atlas of Materia Medica reported that, 'In order to evaluate the 
efficacy of ginseng, find two people and let one eat ginseng and run, and the 
other run without eating ginseng. The one that did not eat ginseng will develop 
shortness of breath sooner； (World Health Organization, 2000) Thus, T C M is 
an important source of immunomodulatory agents intrinsically，which is 
worthy of further scientific-based research. The recent direction on the 
scientific evaluation of T C M has not merely relied on their pharmacological 
effects, but also the cultivation technology. The traditional preparation of T C M 
by boiling is tedious and time consuming. Much efforts has been m a d e in the 
past few decades for maximizing the production of T C M . Most precious T C M 
such as C. sinensis have now cultivated and eventually marketed. Evidence 
has shown that ethanol extracts of fruiting bodies of the tilled species of C. 
sinensis, Paecilomyces japonica, is efficiently immunomodulating (Shin et al, 
2003). W e also portrayed similar immunomodulatory functions in the fruiting 
bodies of cultivated C. sinensis, H E R B S n S E N S E S ™ Cordyceps. Because 
the commercially available cultivated products m a y be as efficient as the 
natural counterparts, the future T C M markets m a y be contributed much by 
cultivated commercial products，which are usually in capsular form and is 
therefore convenient for everyday's intake. In addition, herbs accumulate 
more pollutants than vegetables grown for food because of a longer growing 
period (sometimes several years). The cultivated C. sinensis is therefore 
advantageous to the natural form in that the growing conditions can be tightly 
monitored to avoid contamination and ensure yield. The present experiments 
have also elucidated the immunomodulatory activities of natural C. sinensis 
including the fungus and host larva. Further experiments separating the 
fungus and larva m a y be performed to regionize the differential 
pharmacological activities possessed and compared to the fruiting bodies 
(fungal part) of H E R B S N s E N S E S ™ Cordyceps. 
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Additional investigations of the three T C M preparations are necessary to 
depict their immunomodulatory mechanism. Aqueous extracts of 
H E R B S n S E N S E S ™ Cordyceps and C. sinensis m a y be further fractionated 
by gel filtration, ion-exchange chromatography, and high-performance liquid 
chromatography (HPLC) equipped with a multichannel ultraviolet (UV) 
absorption detector for the analysis of active ingredients. O n the other hand, 
as the active compounds should appear in urine with appropriate urinary 
excretion rates after the administration of Wheeze-Relief Formula, urine m a y 
be collected for extracting lipophillic components by rapid-flow fractionation 
(RFF) followed by H P L C ( H o m m a etal, 1992). These fractionated ingredients 
m a y then be subjected to immunomodulatory experiments previously 
depicted in this study. Furthermore, the amount of urine active ingredients 
m a y also suggest a more objective compliance rate on the consumption of 
Wheeze-Relief Formula in asthmatic patients, in contrast to the present 
compliance system which merely based on subjective reports from the 
patients themselves. 
W e found that H E R B S n S E N S E S ™ Cordyceps m a y possess 
immunomodulatory and anti-tumor activities both in vitro and in vivo. A 
multi-center and multi-phase clinical trial m a y be carried out to validate the 
therapeutic value of H E R B S n S E N S E S ™ Cordyceps. W e suggest a 
randomized, double-blinded, placebo-controlled clinical trial by using healthy 
people and cancer patients as the subjects. Serum and urine m a y be 
collected for the detection of biological markers, identification of active 
ingredients and the calculation of compliance rate. Ex vivo whole blood 
culture activated by T cell mitogen, P H A , and B cell and 
monocyte/macrophage mitogen, LPS, m a y also carried out for quantification 
of cytokines. 
Furthermore, although the immunomodulatory and anti-tumor activities of 
H E R B S n S E N S E S ™ Cordyceps is ascertained, the underlying mechanism is 
still insufficiently depicted. W e speculate that T N F a m a y be induced in prior 
for the triggering of IL-1 and IL-6 and subsequently IL-2. This postulation m a y 
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be substantiated by collecting cultured supernatant of peripheral blood 
mononuclear cells at different culture time interval. 
Possible improvements of individual experiment have been suggested in the 
previous chapters. 
W e m a y conclude that C. sinensis is an important immunomodulatory agent 
both as a single herb and in concoction. Commercially cultivated C. sinensis 
will be a n e w trend in the T C M market. T C M prescription as a formula m a y be 
beneficial and on scientific-basis. 
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Appendices 
Parent Information Sheet 
A randomized double-blind placebo-controlled study of the effect of traditional 
Chinese medicine in the treatment of childhood asthma 
Investigator: Dr. Fok Tai Fai, Dr. Sung Yn Tz，Dr. Cheung Kam Lau, 
Dr. Leung Ting Fan, Dr. Albert Li, Dr. Dorothy Chan, Dr. Leung Ping Chung 
Dr.KTSo, Dr. SYLam 
We would like you to allow us to include your child in this study. This study is 
conducted in this hospital to investigate the efficacy of a mixture of Huang qi 黃民， 
Dong Chong Cao 冬蟲草，Bai Bu 百部，Chuan Bei 川贝 and Huang Qin 黄零 as an 
adjunct therapy in the treatment of childhood asthma. The five ingredients of the 
herb mixture are commonly used for various diseases and known to be safe. It is 
known that Huang qi and Lingzhi have immunomodulatory effect and Dong Chong 
Cao can relax bronchial smooth muscle. We believe that the usage of this mixture 
could possibly improve the symptoms of asthmatic children and enable them to 
reduce their requirement for corticosteroids. We cannot find any report in the 
medical literature about the acute side effects of these three drugs taken orally and 
data about tolerability of long term usage are not available. 
If you agree your child to join this study, your child will be randomized to receive the 
mixture of Huang qi 黃民,Dong Chong Cao 冬蟲草,Bai Bu 百音口, Chuan Bei 川贝 
and Huang Qin 黄零 or no adjunctive therapy for the treatment of asthma. Your 
child will have detailed history review, lung function test and skin prick test before 
he/she is seen by the doctor on the first visit and 3 ml blood samples will be taken by 
the doctor after the consultation. All information about your child will be kept private 
and confidential. Your child will receive proper attention and treatment in case of 
any side effects or events arising from the treatment. You may refuse to have your 
child joining the study or withdraw your child from the study at any time. Your 


























Parent Consent Form 
A randomized double-blind placebo-controlled study of the effect of traditional 
Chinese medicine in the treatment of childhood asthma 
I, , parent / guardian of , hereby consent for 
my child, to receive traditional Chinese medicine as an adjunct therapy for bronchial asthma. I 
understand that the herbal medicines will be provided by the Clinical Trial Section of The Institute of 
Chinese Medicine , The Chinese University of Hong Kong. I acknowledge that the purpose and 
methods of the study have been fully explained to me. I have read the parent information sheet and 
understand the nature of the study. I also agree not to receive alternative medicine beyond this study. 
I acknowledge that I may refuse to have my child joining the study or withdraw my child from the 
study at any time. My child will receive the same quality of care at the hospital whether or not 
he/she joins the study. 
家長同意 
中藥對兒童哮喘之療效一雙肓隨機對照硏究 






Father / Mother / Guardian Signature Father / Mother / Guardian Name 
父/母/監護人簽署 父/母濫護人姓名 
(A ) 
Patient Signature Patient Name 
病人簽署 病人姓名 
Witness Signature Witness Name 
見證人簽署 見證人姓名 
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LEE Ka-wai , Sharon 
Depar tment of Chemical Pathology 
The Chinese Universi ty of Hong Kong 
Dear S i r /Madam, 
Animals (Control of Exper iments) Ordinance  
Chapter 340 
1 refer to your application/letter dated 21.7.2003 and forward herewith the 
fol lowing licence(s) issued/duly renewed under the above Ordinance :-
Form 2 : Licence to Conduct Exper iments 
Your attention is drawn to regulations 4 and 5 of the Animals (Control of 
Exper iments) Regulat ions, copies of these regulations together with copies of Forms 6 
——and 7 are enclosed for your convenience. Failure to comply with either regulation 4 or 
regulation 5 is an offence, each offence punishable by a f ine of HK$500 and to 
imprisonment for 3 months . Conviction of an offence against either regulation 4 or 
regulation 5 or failure to comply with either regulation may result in your licenece being 
cancelled. 
Please also be reminded that if you wish to cont inue your experiments after 
the specified periods as stated on the above licence / endorsements / teaching permit, you 
should renew them at least one-month before the end-dates. On the other hand, if you 
have completed or stopped your experiments before the specified periods, you should 
inform this Off ice immediately. 
We are committed to providing quality client-oriented service 




Licence to Conduc t Exper iments 
N a m e LEH Ka-wai . Sharon 
Address Depar tmen t of Chemica l Pathology 
The Ch inese Univers i ty 0 � 1 long Kong 
By vir tue of sect ion 7 o f l h e Animals (Control of Expe r imen t s ) Ord inance . Chapter 340. 
Uie above -named is hereby l icensed to conduct the type of exper imen t ( s ) . a I the place(s) and upon 
the c o n d i t i o n s � h e r e i n a f t e r ment ioned . 
Type o r cxper imenl ( s ) 
About 150 B A L B / c mice a I the age of 6-8 weeks will be used in this study. At Day 0, vvc shall 
inoculate the t u m o r subcutaneous ly at the back of the mice af ter anaes the t ize by ether. Starting 
tVoni Day 7, Tradi t ional Chinese Medic ine was orally admin is te red consecut ive ly for total 14 
days. At Day 21, each study mouse will be killed, blood will be col lec ted and the spleen will 
be dissected and reserved for spleenocytes isolation. The col lected sp leenocytes will then be 
used for fur ther prol i fera t ion assay. 
Place(s) where exper iment ( s ) may be conducted 
Shanghai Fralernity Associa te Research Services Centre . The Chinese I Iniversity o t � H o n g 
Kong . 
Condi t ions 
(1) Such exper iment (s ) may only be conducted for the fo l lowing purposes :-
To invest igate the an t i - tumor and immunomodula to ry activity of Ch inese herbal medicine. 
(2) This licence is valid until. 12.8.2005 
. • • ^ - — 
Dated The Thir teen of August 2003 / f 渗 、 
納、厂——广輪 
We are committed to providing qiicility client-oriented service 
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